Modelling Hepatitis C viral host interaction and co‐infection by Lissauer, Samantha Mary

















This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 




	   ii	  
Abstract	  	   Hepatitis	  C	  Virus	  (HCV)	  is	  a	  clinically	  important	  infection	  that	  leads	  to	  chronic	  liver	  disease	  and	  Human	  Immunodeficiency	  Virus	  (HIV)	  co-­‐infected	  patients	  have	  more	  rapid	  progression	  to	  severe	  liver	  disease	  and	  show	  higher	  rates	  of	  HCV	  vertical	  transmission.	  	  Hepatocytes	  are	  a	  highly	  differentiated	  cell	  type	  and	  support	  low	  level	  HCV	  replication.	  Most	  studies	  of	  the	  viral	  life	  cycle	  use	  de-­‐differentiated	  hepatoma	  cell	  lines,	  which	  are	  highly	  permissive.	  The	  mechanism	  behind	  this	  difference	  is	  poorly	  understood.	  We	  show	  that	  dimethylsulfoxide	  (DMSO)	  differentiated	  Huh-­‐7	  cells	  have	  a	  100-­‐fold	  reduction	  in	  permissivity	  to	  HCV	  infection.	  We	  confirm	  that	  these	  cells	  are	  differentiated	  and	  upregulate	  key	  liver	  specific	  markers	  including	  miR122.	  They	  are	  metabolically	  active	  and	  have	  intact	  innate	  signaling	  pathways	  in	  response	  to	  infection.	  We	  observed	  a	  10-­‐fold	  reduction	  in	  the	  initiation	  of	  replication	  and	  a	  10-­‐fold	  loss	  in	  extra-­‐cellular	  particle	  infectivity.	  In	  contrast	  cell-­‐to-­‐cell	  dissemination	  rates	  were	  comparable	  and	  cell-­‐contact	  dependent	  infection	  of	  differentiated	  cells	  can	  overcome	  the	  restrictions	  seen	  in	  cell-­‐free	  infection.	  	  HCV	  cell-­‐to-­‐cell	  transmission	  can	  also	  be	  mediated	  by	  other	  cell	  types.	  T	  cells	  are	  the	  primary	  cell	  supporting	  HIV-­‐1	  infection.	  We	  have	  shown	  that	  HCV	  can	  bind	  primary	  and	  immortalized	  T	  cells	  and	  trans-­‐infect	  hepatoma	  cells.	  This	  requires	  replicating	  HIV	  but	  is	  independent	  of	  co-­‐receptor	  engagement.	  HIV-­‐1	  infection	  of	  CD4+	  T	  cells	  induces	  a	  significant	  increase	  in	  HCV	  trans-­‐infection	  by	  increased	  viral	  binding.	  T	  cells	  provide	  a	  vehicle	  for	  HIV-­‐1	  to	  promote	  HCV	  infectivity,	  transmission	  and	  persistence.	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1.1 :	  Hepatitis	  C	  –	  the	  clinical	  picture	  	  	  
1.1.1	  Epidemiology	  	   	  Hepatitis	  C	  virus	  is	  a	  significant	  global	  health	  problem.	  Acute	  HCV	  infection	  is	  often	  asymptomatic	  and	  between	  15-­‐45%	  of	  people	  can	  spontaneously	  clear	  the	  infection	  (WHO,	  2017).	  Thus	  much	  HCV	  burden	  remains	  undiagnosed.	  The	  remaining	  60-­‐80%	  of	  people	  develop	  chronic	  infection;	  there	  are	  currently	  thought	  to	  be	  around	  71	  million	  people	  with	  chronic	  HCV	  infection	  worldwide.	  It	  is	  likely	  that	  only	  about	  20%	  of	  these	  individuals	  know	  they	  are	  infected.	  Over	  time,	  chronic	  HCV	  infection	  causes	  ongoing	  liver	  inflammation,	  fibrosis	  and	  cirrhosis.	  The	  risk	  of	  liver	  cirrhosis	  is	  15-­‐30%	  within	  20	  years	  (WHO,	  2017).	  A	  significant	  proportion	  of	  chronically	  infected	  patients	  develop	  hepatocellular	  carcinoma	  (1-­‐5%).	  Liver	  disease	  resulting	  from	  infection	  with	  HCV	  is	  the	  seventh	  most	  common	  cause	  of	  mortality	  worldwide	  (Stanaway	  et	  al,	  2016).	  Figure	  1.1	  shows	  the	  leading	  causes	  of	  mortality	  worldwide	  from	  1990-­‐2013.	  Notably,	  unlike	  other	  communicable	  disease,	  mortality	  rankings	  for	  viral	  hepatitis	  (A,	  B,	  C	  and	  E)	  have	  increased	  over	  time.	  Figure	  1.2	  shows	  a	  map	  of	  viral-­‐related	  hepatitis	  mortality	  rates	  by	  country	  and	  relative	  contributions	  of	  the	  hepatitis	  virus	  to	  mortality	  rates.	  Most	  deaths	  were	  due	  to	  liver	  cirrhosis	  and	  carcinoma	  secondary	  to	  infection	  with	  HBV	  and	  HCV	  (Stanaway,	  et	  al,	  2016).	  	  	   	  
	   3	  
	  	  	  	  	  	  	  	  	  	  	  	  
	  
Figure	  1.1	  Leading	  causes	  of	  global	  mortality	  and	  trends	  1990-­‐2013	  	  	  From	  Stanaway	  et	  al	  (2016)	  Reproduced	  with	  permission	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Figure	  1.2	  Viral	  hepatitis-­‐related,	  age-­‐standardised	  mortality	  rates	  by	  
region.	  	  
	  Pie	  charts	  indicate	  the	  proportion	  of	  deaths	  attributable	  to	  each	  virus.	  From	  Stanaway	  et	  al	  (2016),	  reproduced	  with	  permission.	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   Despite	  concerning	  global	  statistics,	  it	  is	  likely	  that	  these	  figures	  will	  improve,	  as	  recent	  developments	  in	  treating	  HCV	  with	  direct	  acting	  antivirals	  have	  transformed	  outcomes	  for	  patient	  with	  chronic	  HCV.	  However,	  the	  challenge	  remains	  to	  identify	  these	  individuals	  globally	  and	  provide	  access	  to	  treatment	  and	  adequate	  follow	  up	  (WHO,	  2017).	  The	  World	  Health	  Organisation	  has	  set	  ambitious	  targets	  to	  treat	  80%	  of	  eligible	  patients	  with	  chronic	  HCV	  by	  2030.	  If	  this	  target	  is	  achieved	  it	  will	  change	  the	  landscape	  of	  global	  HCV,	  however	  the	  burden	  of	  liver	  damage	  will	  remain.	  Liver	  transplants	  secondary	  to	  chronic	  HCV	  and	  associated	  liver	  damage	  remain	  as	  the	  second	  most	  common	  cause	  for	  transplantation	  in	  the	  UK	  (Neuberger,	  2016).	  	  	  
1.1.2	  Genotypes	  and	  geographical	  distribution	  	   	  To	  date	  there	  have	  been	  seven	  genotypes	  of	  HCV	  classified	  (Simmonds,	  Holmes	  et	  al,	  1993;	  Simmonds,	  McOrmish	  et	  al,	  1993;	  reviewed	  in	  Simmonds,	  2004)	  with	  significant	  differences	  in	  geographical	  prevalence.	  There	  is	  about	  30%	  sequence	  divergence	  in	  the	  genotypes,	  however	  despite	  this	  they	  remain	  very	  similar	  in	  transmission,	  viral	  kinetics	  and	  pathogenesis	  (reviewed	  in	  Simmonds,	  2004).	  Genotype	  1	  is	  the	  most	  commonly	  found	  in	  America	  (70%),	  Japan	  (75%)	  and	  Europe	  (50-­‐75%),	  although	  genotype	  2	  and	  3	  are	  also	  found	  in	  these	  regions.	  Genotype	  3	  and	  6	  are	  found	  predominantly	  in	  Asia	  and	  South	  Asia	  and	  genotypes	  4	  and	  5	  predominate	  in	  Africa.	  A	  recently	  identified	  genotype	  7	  (Murphy	  et	  al,	  2014)	  was	  identified	  in	  the	  democratic	  republic	  of	  Congo,	  in	  central	  Africa,	  but	  does	  not	  appear	  to	  have	  large	  clinical	  significance	  to	  date.	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HCV	  genotypes	  were	  predictive	  of	  response	  to	  traditional	  interferon	  based	  treatment	  regimes,	  with	  genotypes	  2	  and	  3	  consistently	  showing	  higher	  rates	  of	  viral	  clearance	  than	  genotypes	  1	  and	  4	  (Manns	  et	  al,	  2006).	  In	  contrast,	  most	  direct	  acting	  antivirals	  (DAAs)	  show	  pan-­‐genotypic	  efficacy	  to	  cure	  infection.	  In	  fact,	  the	  first	  DAA	  were	  used	  to	  treat	  those	  with	  genotype	  1	  infection	  with	  very	  promising	  rates	  of	  viral	  response.	  	  	  
1.1.3	  Co-­‐infection	  	   	  There	  are	  some	  populations	  who	  are	  at	  increased	  risk	  of	  HCV	  infection	  and	  complications.	  Patients	  co-­‐infected	  with	  HIV	  have	  significantly	  accelerated	  progression	  of	  liver	  cirrhosis,	  decompensated	  liver	  disease	  and	  hepatocellular	  carcinoma	  (Chew	  and	  Bhattacharya,	  2016).	  In	  some	  areas,	  HCV	  related	  liver	  disease	  is	  the	  leading	  cause	  of	  death	  in	  co-­‐infected	  patients	  (Mandorfer	  et	  al,	  2016;	  Peters	  et	  al,	  2014).	  HIV	  co-­‐infection	  increases	  perinatal	  transmission	  risk	  of	  HCV	  (reviewed	  in	  Sulkowski,	  2008).	  It	  is	  estimated	  that	  there	  are	  around	  2.3	  million	  people	  co-­‐infected	  with	  HIV	  and	  HCV	  (Platt	  et	  al,	  2016).	  Pockets	  of	  high	  levels	  of	  co-­‐infection	  exist,	  such	  as	  in	  Eastern	  Europe,	  where	  80%	  of	  HIV	  infected	  patients	  are	  seropositive	  for	  HCV	  (Peters	  et	  al,	  2014).	  In	  these	  areas	  intravenous	  drug	  use	  is	  the	  most	  common	  transmission	  route	  and	  co-­‐infected	  subjects	  are	  a	  high	  risk	  group	  to	  develop	  HCV	  related	  complications.	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1.1.4	  Treatment	  of	  chronic	  HCV	  	   	  Significant	  advances	  have	  been	  made	  in	  the	  treatment	  of	  HCV	  in	  the	  last	  5	  years.	  The	  first-­‐generation	  direct	  acting	  antiviral	  drugs	  were	  the	  protease	  inhibitors	  Telapravir	  and	  Bocepravir,	  that	  were	  administered	  alongside	  interferon	  and	  ribavirin.	  They	  were	  only	  effective	  in	  genotype	  1	  infection,	  were	  associated	  with	  significant	  side	  effects	  and	  the	  virus	  rapidly	  developed	  resistance	  (Kieffer	  et	  al,	  2007).	  Since	  then,	  the	  rapid	  development	  of	  next	  generation	  DAA’s	  have	  revolutionized	  treatment	  options	  and	  outcomes	  for	  patients	  with	  chronic	  HCV,	  even	  with	  advanced	  liver	  disease	  or	  co-­‐infection	  with	  HIV.	  Treatment	  algorithms	  are	  available	  (European	  Association	  for	  the	  Study	  of	  the	  Liver,	  2017),	  but	  broadly,	  interferon	  free	  oral	  treatment	  regimens	  are	  now	  available	  for	  all	  genotypes	  (1-­‐6)	  achieving	  high	  viral	  response	  rates.	  Sofosbuvir,	  a	  NS5B	  protease	  inhibitor	  was	  the	  first	  drug	  approved	  by	  the	  FDA	  for	  treatment	  of	  HCV.	  Initial	  studies	  including	  Sofosbuvir	  for	  the	  treatment	  of	  chronic	  HCV	  in	  genotype	  1patients	  (alongside	  PEG-­‐Interferon	  and	  ribavirin)	  were	  successful	  in	  achieving	  sustained	  virological	  response	  rate	  (SVR)	  of	  more	  than	  90%	  versus	  60%	  for	  standard	  treatment	  (Lawitz	  et	  al,	  2013).	  A	  further	  significant	  step	  forward	  was	  the	  development	  of	  ‘Harvoni’	  a	  combination	  of	  Sofosbuvir	  and	  Ledipasvir,	  an	  NS5A	  inhibitor.	  Genotype	  1	  infections,	  with	  or	  without	  cirrhosis	  can	  be	  treated	  with	  8-­‐12	  weeks	  of	  an	  interferon	  free,	  oral	  fixed	  drug	  combination	  regimen,	  achieving	  a	  SVR	  of	  over	  90%	  (NICE	  guidance,	  UK).	  Furthermore,	  a	  host	  of	  new	  drugs	  continue	  to	  become	  available,	  acting	  on	  various	  targets	  in	  the	  HCV	  viral	  lifecycle	  (European	  Association	  for	  the	  Study	  of	  the	  Liver,	  2017).	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Remarkably,	  treatment	  response	  rates	  are	  comparable	  between	  HIV/HCV	  co-­‐infected	  patients	  and	  mono-­‐infected	  patients.	  	  	  Despite	  significant	  advances	  in	  HCV	  treatment	  there	  remains	  some	  challenges.	  Drug	  combinations	  are	  very	  expensive,	  and	  despite	  tiered	  pricing	  strategies	  and	  some	  generic	  drugs	  becoming	  available	  there	  is	  still	  significant	  difficulties	  in	  making	  these	  drugs	  widely	  available	  (WHO	  Guidelines,	  2016).	  	  Furthermore,	  there	  are	  problems	  identifying	  those	  with	  chronic	  HCV,	  and	  organisational	  barriers	  exist	  to	  implementing	  drug	  treatment.	  In	  addition	  there	  are	  some	  patient	  groups	  that	  do	  not	  have	  access	  to	  these	  drugs,	  including	  pregnant	  women,	  despite	  significant	  clinical	  need.	  The	  residual	  burden	  of	  liver	  disease	  post	  HCV	  cure	  is	  also	  challenging	  and	  patients	  require	  ongoing	  monitoring	  for	  development	  of	  HCC	  (Ringelhahn	  et	  al,	  2017).	  	  	  HCV	  has	  a	  high	  genetic	  diversity	  through	  it’s	  high	  replicative	  activity,	  producing	  an	  estimated	  1012	  new	  virions	  each	  day	  (Neumann	  et	  al,	  1998)	  and	  the	  lack	  of	  proof	  reading	  ability	  of	  the	  RNA-­‐dependent	  RNA	  polymerase	  (RdRp).	  	  Consequently,	  it	  is	  possible	  that	  quasi-­‐species	  exist	  that	  already	  harbour	  resistance	  mutations	  against	  DAA	  in	  drug	  treatment	  naïve	  individuals	  (Rong	  et	  al,	  2010).	  Raj	  et	  al	  recently	  described	  the	  pre-­‐existence	  of	  mutations	  present	  in	  the	  liver	  of	  patients	  with	  chronic	  HCV	  that	  conferred	  resistance	  to	  NS5B	  inhibitors	  (Raj	  et	  al,	  2017).	  Although	  this	  has	  not	  been	  seen	  as	  clinically	  relevant	  yet,	  the	  pre-­‐existence	  of	  resistance	  mutations	  raises	  the	  possibility	  that	  suppression	  of	  wild	  type	  virus	  may	  function	  as	  selection	  pressure	  allowing	  growth	  of	  resistant	  virus	  (Sarazzin	  et	  al,	  2007).	  It	  is	  therefore	  crucially	  important	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that	  we	  continue	  to	  study	  the	  virus	  and	  pathogen/host	  interactions,	  even	  in	  the	  new	  DAA	  era.	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1.2.1	  The	  virion	  
	  	   The	  single	  RNA	  HCV	  strand	  is	  surrounded	  by	  an	  icosahedral	  capsid	  and	  envelope	  derived	  from	  a	  host	  cell	  lipid	  bilayer	  (Bartosch	  et	  al,	  2006).	  E1	  and	  E2	  glycoproteins	  form	  heterodimers	  that	  are	  embedded	  in	  the	  lipid	  bilayer	  (Gastaminza	  et	  al,	  2008).	  The	  virion	  associates	  with	  low	  density	  (LDL)	  and	  very	  low	  density	  lipoproteins	  (VLDL),	  resulting	  in	  heterogeneity	  of	  the	  viral	  particle	  in	  culture	  and	  a	  low	  buoyant	  density	  (Popescu	  et	  al,	  2014;	  Merz	  et	  al,	  2011,	  Lindenbach	  and	  Rice,	  2013).	  Human	  lipoprotein	  Apolipoprotein	  E	  and	  C	  (ApoE/C)	  associate	  with	  the	  viral	  particle	  in	  vitro	  and	  in	  vivo	  and	  are	  essential	  for	  viral	  replication	  (Chang	  et	  al,	  2007).	  The	  heterogeneity	  of	  HCV	  particles	  makes	  recognition	  by	  E1E2-­‐specific	  neutralizing	  antibodies	  challenging	  (Scheel	  and	  Rice,	  2013).	  	  
	  
1.2.2	  Viral	  entry	  	  	   The	  initial	  stage	  of	  the	  HCV	  life	  cycle	  starts	  with	  the	  virus	  binding	  to	  hepatocytes,	  which	  are	  the	  primary	  target	  cell.	  HCV	  entry	  is	  a	  multi-­‐step	  process	  and	  an	  overview	  of	  the	  important	  virus-­‐cellular	  interactions	  are	  shown	  in	  Figure	  
1.4.	  The	  two	  surface	  glycoproteins	  E1	  and	  E2	  play	  an	  important	  role	  in	  receptor	  recognition	  and	  binding.	  Due	  to	  the	  association	  of	  the	  virion	  with	  VLDL	  (André	  et	  al,	  2002)	  the	  LDL	  receptor,	  alongside	  glycosaminoglycans,	  are	  thought	  to	  be	  an	  important	  capture	  molecule	  for	  initial	  low	  affinity	  binding	  to	  hepatocytes	  (Barth	  et	  al,	  2003;	  Agnello	  et	  al,	  1999).	  Scavenger	  receptor	  BI	  (SRBI),	  expressed	  on	  hepatocytes,	  interacts	  with	  HCV	  proteins	  E1	  and	  E2	  on	  the	  surface	  of	  the	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lipoviral	  particle.	  It	  is	  likely	  that	  this	  acts	  as	  the	  primary	  attachment	  factor	  for	  HCV	  (Scarselli	  et	  al,	  2002;	  Grove	  et	  al,	  2007;	  Catanese	  et	  al,	  2010;	  Syder	  et	  al,	  2010).	  The	  CD81	  tetraspanin	  interacts	  with	  E1	  and	  E2	  and	  most	  likely	  acts	  as	  a	  post	  attachment	  co-­‐receptor	  (Pileri	  et	  al,	  1998,	  Bartosch	  et	  al,	  2003;	  Flint	  et	  al,	  2006,	  Meuleman	  et	  al,	  2008).	  There	  is	  evidence	  to	  suggest	  that	  CD81	  forms	  complexes	  with	  the	  tight	  junction	  protein	  Claudin-­‐1	  (Harris	  et	  al,	  2008;	  Harris	  et	  al,	  2010).	  Trafficking	  of	  CD81	  and	  Claudin-­‐1	  to	  tight	  junctions	  is	  promoted	  by	  the	  virion	  itself	  (Farquhar	  et	  al,	  2012)	  and	  both	  receptors	  are	  endocytosed	  with	  the	  viral	  particle.	  Hepatocellular	  polarisation	  limits	  CD81	  trafficking	  and	  may	  explain	  the	  limited	  infection	  of	  these	  primary	  cells	  in	  vivo	  (Harris	  et	  al,	  2013;	  Mee	  et	  al,	  2009).	  The	  tight	  junction	  proteins	  Claudin	  1	  (Evan	  et	  al,	  2007;	  Meertens	  et	  al,	  2008)	  and	  Occludin	  (Ploss	  et	  al,	  2009)	  are	  essential	  factors	  defining	  HCV	  entry.	  Claudin	  6	  and	  9	  have	  been	  reported	  to	  replace	  Claudin	  1	  as	  an	  entry	  factor,	  however	  they	  are	  expressed	  at	  very	  low	  levels	  in	  the	  human	  liver	  (Zheng	  et	  al,	  2007).	  The	  tyrosine	  kinases,	  epidermal	  growth	  factor	  receptor	  (EGFR)	  and	  ephrin	  receptor	  A2	  (EphA2)	  are	  also	  important	  for	  entry	  as	  they	  regulate	  CD81-­‐claudin-­‐1	  associations	  (Lupberger	  et	  al,	  2011).	  More	  recently	  the	  transferrin	  receptor	  (TfR1)	  has	  been	  identified	  as	  an	  HCV	  entry	  factor	  (Martin	  and	  Uprichard,	  2013).	  TfR1	  is	  thought	  to	  act	  after	  the	  CD81	  binding	  step	  and	  is	  likely	  to	  be	  involved	  in	  particle	  internalisation.	  Late	  in	  the	  entry	  process	  the	  Niemann-­‐Pick	  C1-­‐like	  1	  cholesterol	  absorption	  receptor	  mediates	  virion-­‐cell	  membrane	  fusion	  via	  a	  cholesterol	  dependent	  step	  (Sainz	  et	  al,	  2012).	  	  	  Final	  uptake	  of	  the	  viral	  particle	  occurs	  through	  a	  clarithrin-­‐mediated	  pH	  dependant	  process	  of	  internalisation,	  probably	  in	  endosomes	  (Tscherne	  et	  al,	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2006;	  Farquhar	  et	  al,	  2012).	  	  Acidification	  of	  the	  endosome	  induces	  HCV	  glycoprotein	  membrane	  fusion.	  It	  is	  not	  clear	  which	  protein	  mediates	  the	  process	  of	  membrane	  fusion,	  with	  recent	  evidence	  that	  E1	  is	  important	  for	  this	  final	  step	  in	  HCV	  entry	  (Omari	  et	  al,	  2013;	  Li	  et	  al,	  2014).	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Figure	  1.4	  An	  overview	  of	  the	  steps	  involved	  in	  hepatitis	  C	  viral	  entry	  	  
	  (from	  Lindenbach	  and	  Rice,	  2013,	  reproduced	  with	  permission)	  Step	  1	  involves	  HCV	  lipoviral	  particle	  interacting	  with	  heparin	  sulphate	  proteoglycans	  (HSPGs),	  low	  density	  lipoprotein	  receptor	  (LDLR)	  and	  SRB1.	  	  Step	  2	  involves	  interaction	  of	  E2	  and	  CD81	  which	  activates	  signal	  transduction	  through	  epidermal	  growth	  factors,	  RAS	  and	  RHO	  GTP-­‐ases	  Step	  3	  There	  is	  lateral	  movement	  of	  the	  CD81/HCV	  complex	  to	  tight	  junctions	  Step	  4	  Interaction	  of	  virus	  with	  tight	  junction	  proteins	  mediate	  endocytosis	  Step	  5	  Low	  pH	  inside	  the	  endosomes	  induces	  membrane	  fusion	  and	  uncoating	  of	  the	  viral	  particle,	  possibly	  mediated	  by	  E1.	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1.2.3	  Translation	  and	  Replication	  	   	  Once	  internalised,	  the	  genome	  is	  trafficked	  to	  the	  endoplasmic	  reticulum	  where	  translation	  of	  the	  genome	  is	  initiated	  by	  an	  IRES	  located	  in	  the	  5’UTR	  (reviewed	  in	  Hoffman	  and	  Liu,	  2011).	  Translation	  initiation	  begins	  with	  recruitment	  of	  the	  40S	  ribosomal	  subunit	  to	  the	  HCV	  IRES	  (Pestova	  et	  al,	  1998).	  Correct	  positioning	  of	  the	  ribosomal	  subunit	  is	  required	  for	  translation	  (Wang,	  et	  al,	  1995).	  Following	  ribosomal	  binding	  the	  cellular	  initiation	  factors	  eIF2	  (eukaryotic	  initiation	  factor),	  eIF3	  and	  eIF5	  interact	  with	  the	  IRES/40S	  complex	  to	  form	  a	  translationally	  competent	  ribosomal	  unit	  that	  progresses	  with	  elongation	  and	  termination	  resulting	  in	  viral	  protein	  translation	  (Hellen	  et	  al,	  2009;	  Hoffman	  and	  Liu,	  2011;	  Fraser	  et	  al,	  2007).	  In	  addition	  to	  eIF	  there	  are	  a	  number	  of	  other	  cellular	  factors	  identified	  that	  interact	  with	  the	  IRES	  or	  3’UTR	  that	  can	  modulate	  translation.	  These	  are	  reviewed	  in	  Hoffman	  and	  Liu	  (2011)	  however	  include	  the	  micro-­‐RNA’s	  miR122	  and	  miR196a	  (see	  section	  1.3.6).	  Following	  translation	  the	  resulting	  polyprotein	  is	  cleaved	  by	  cellular	  and	  viral	  encoded	  proteases	  to	  produced	  10	  HCV	  proteins	  (see	  Figure	  1.3).	  	  	  	   Replication	  of	  the	  virus	  is	  accompanied	  by	  cellular	  ER	  membrane	  rearrangement	  to	  form	  the	  ‘membranous	  web’	  mediated	  by	  NS4B	  (Gretton	  et	  al,	  2005;	  Bartenschlager	  et	  al,	  2004),	  which	  forms	  the	  membrane	  anchor	  for	  the	  replication	  complex.	  The	  replication	  stage	  of	  the	  HCV	  life	  cycle	  is	  closely	  related	  to	  host	  lipid	  metabolism.	  RNA	  replication	  occurs	  in	  membranes	  rich	  in	  cholesterol	  and	  sphingolipids,	  which	  are	  likely	  transported	  as	  part	  of	  the	  replication	  complex	  to	  the	  ER	  (Grassi	  et	  al,	  2016).	  HCV	  also	  induces	  de	  novo	  lipid	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metabolism	  within	  hepatocytes,	  likely	  mediated	  by	  the	  sterol	  regulatory	  membrane	  binding	  protein	  (SREBP)	  (Waris	  et	  al,	  2007).	  Positive	  and	  negative	  strand	  RNA	  is	  transcribed	  and	  initiated	  by	  the	  NS5B	  RNA	  dependent	  RNA	  Polymerase	  (RdRp)	  (Zhong	  et	  al,	  2000).	  The	  NS5A	  is	  important	  to	  HCV	  replication	  (Scheel	  and	  Rice,	  2013),	  although	  it’s	  exact	  mechanisms	  are	  not	  completely	  understood.	  NS5A	  associates	  with	  lipid	  rafts,	  which	  is	  essential	  for	  the	  HCV	  replication	  complex	  (Gao	  et	  al,	  2004).	  NS5A	  phosphorylation	  state	  is	  important	  in	  regulating	  viral	  assembly	  (Appel	  et	  al,	  	  2005),	  and	  regulates	  the	  balance	  between	  downstream	  processing	  and	  RNA	  replication	  (Neddermann	  et	  al,	  2004).	  NS5A	  is	  also	  shown	  to	  bind	  Cyclophilin	  A,	  a	  cellular	  based	  peptidyl-­‐prolyl	  cis-­‐trans	  peptidase,	  that	  catalyses	  a	  conformational	  change	  in	  NS5A	  that	  is	  necessary	  for	  replication	  to	  occur	  (Yang,	  2008).	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finally fulfilled. Classical virological techniques can 
now be applied to the study of previously unexplored 
lifecycle steps, including viral entry, genome packag-
ing, virion assembly, maturation and release. Although 
low levels of infectious virus have been obtained from a 
genotype 1a isolate with five adaptive mutations29, the 
challenge remains to develop robust systems for all HCV 
genotypes.
The virus and its lifecycle
The lifecycle of HCV is illustrated in FIG. 1.
Virion structure. Although exciting progress has been 
made towards determining virion structures of some of 
the related alphaviruses and flaviviruses, for example, 
dengue virus30, HCV has not been definitively visualized 
and its structure remains to be elucidated. Based on filtra-
tion and electron microscopic studies, HCV particles are 
40–70 nm in diameter (REF. 11 and references therein). It is 
thought that the core protein and the envelope glycopro-
teins E1 and E2 are the principal protein components of 
the virion. E1 and E2 are presumably anchored to a host 
cell-derived double-layer lipid envelope that surrounds 
a nucleocapsid composed of multiple copies of the core 
protein and the genomic RNA.
HCV circulates in various forms in the infected host 
and can be associated with low-density lipoproteins 
(LDL) and very-low-density lipoproteins (VLDL), both 
of which seem to represent the infectious fraction, and 
also circulates as virions bound to immunoglobulins 
and free virions (reviewed in REF. 31). This feature may 
explain its unusually heterogenous and low buoyant 
density (peak infectivity near 1.10 g per ml).
Viral entry. HCV only infects humans and chimpanzees. 
Hepatocytes are the main target cells but infection of 
B cells, dendritic cells and other cell types has also been 
reported. CD81, a tetraspanin protein that is found on 
the surface of many cell types, including hepatocytes32, 
the LDL receptor (LDLR)33, scavenger receptor class B 
type I (SR-BI)34 and, most recently, claudin-1 (REF. 35) 
have, among others, been proposed as HCV receptors 
(REFS 36,37; FIG. 2).
The LDLR is an attractive candidate receptor because 
of the association of HCV with LDL and VLDL. However, 
its precise role remains to be determined. Together with 
glycosaminoglycans, the LDLR and other cell surface 
proteins involved in serum lipoprotein binding and 
metabolism might serve as primary collectors of HCV 
particles for further targeting to CD81 and additional 
receptor components (FIG. 2). HCV E2 also binds to 
DC-SIGN (dendritic cell-specific intercellular adhesion 
molecule-3-grabbing non-integrin) and L-SIGN (liver/
lymph node-specific intercellular adhesion molecule-
3-grabbing integrin). L-SIGN is a calcium-dependent 
lectin expressed on liver sinusoidal endothelial cells that 
may facilitate the infection process by trapping the virus 
for subsequent interaction with hepatocytes.
Both CD81 and SR-BI bind E2 and are necessary but 
not sufficient for HCV entry. Expression of CD81 in 
CD81-negative hepatocyte-derived cell lines confers sus-
ceptibility to HCV pseudoparticles (HCVpp) and HCVcc. 
Blocking antibodies against CD81 or SR-BI, recombinant 
soluble CD81, oxidized LDL or siRNA-mediated down-
regulation of CD81 expression reduce infectivity. However, 
expression of CD81 and SR-BI in non-hepatocyte-derived 
cell lines does not confer susceptibility to HCV infection, 
indicating that additional hepatocyte-specific factors must 
be required for HCV entry.
Using an iterative expression cloning approach the 
tight junction component claudin-1 was recently identi-
fied as an HCV co-receptor35. Claudin-1 was found to be 
essential for HCV entry into hepatic cells and rendered 
non-hepatic cells permissive to HCV infection. However, 
certain cell types were found to be non-permissive despite 
expression of CD81, SR-BI and claudin-1, indicating that 
one or more additional HCV entry factor(s) remain to 
be discovered. Claudin-1 acts at a late stage of the entry 
process, after virus binding and interaction with CD81. 
Interestingly, other tight junction-associated molecules 
have been shown to serve as viral (co-)receptors. In this 
context, coxsackievirus B entry requires initial binding 
to a primary receptor (decay-accelerating factor) on the 
lumenal cell surface, followed by lateral migration of 
the virus–receptor complex to the tight junction, where 
interaction with the co-receptor CAR (coxsackievirus 
and adenovirus receptor) and uptake into the host cell 
occur38. Future studies should clarify if HCV follows a 
similar pathway for cell entry.
HCV enters by clathrin-mediated endocytosis39, 
with transit through an endosomal, low pH compart-
ment40,41 and presumably endosomal membrane fusion. 
The structural basis for low pH-induced membrane 
fusion has been elucidated for related flaviviruses and 
alphaviruses, including dengue virus and Semliki Forest 
Figure 1 | Lifecycle of hepatitis C virus (HCV). Virus binding and internalization (a); 
cytoplasmic release and uncoating (b); IRES-mediated translation and polyprotein 
processing (c); RNA replication (d); packaging and assembly (e); virion maturation 
and release (f). The topology of HCV structural and non-structural proteins at the 
endoplasmic reticulum membrane is shown schematically. HCV RNA replication occurs 
in a specific membrane alteration, the membranous web. Note that IRES-mediated 
translation and polyprotein processing, as well as membranous web formation and 
RNA replication, which are illustrated here as separate steps for simplicity, might occur 
in a tightly coupled fashion. IRES, internal ribosome entry site.
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1.2.5	  Viral	  dissemination	  and	  spread	  	   	  Once	  a	  virion	  is	  released	  from	  an	  infected	  cell	  it	  can	  infect	  other	  naive	  cells	  as	  described.	  In	  addition	  to	  cell-­‐free	  virus	  transmission	  HCV	  can	  transmit	  directly	  cell-­‐to-­‐cell	  between	  hepatocytes	  (Timpe	  et	  al,	  2008;	  Brimacombe	  et	  al,	  2011;	  Witteveld	  et	  al,	  2009).	  This	  allows	  the	  virus	  to	  evade	  host	  immune	  responses	  including	  neutralizing	  antibody	  (Timpe	  et	  al,	  2008)	  and	  is	  an	  efficient	  route	  of	  dissemination	  route	  (Meredith	  et	  al,	  2013).	  Although	  the	  exact	  mechanisms	  of	  cell-­‐to-­‐cell	  transmission	  have	  not	  been	  fully	  elucidated	  it	  is	  thought	  that	  the	  entry	  molecules:	  CD81,	  SR-­‐BI,	  Claudin1	  and	  Occludin	  are	  important	  (Grove	  et	  al,	  2008;	  Ciesek	  et	  al,	  2011;	  Brimacombe	  et	  al,	  2011).	  The	  visualization	  of	  infected	  cells	  in	  foci	  within	  liver	  biopsy	  samples	  also	  suggests	  that	  this	  is	  an	  important	  route	  of	  viral	  dissemination	  in	  vivo	  (Liang	  et	  al,	  2009).	  Furthermore,	  cell-­‐to-­‐cell	  dissemination	  can	  spread	  virus	  harboring	  resistance	  mutations	  to	  DAAs	  efficiently	  throughout	  the	  liver	  (Xiao	  et	  al,	  2015).	  In	  addition	  to	  direct	  cell	  delivery	  between	  two	  hepatocytes	  there	  is	  increasing	  evidence	  that	  HCV	  can	  associate	  with	  other	  cells,	  such	  as	  B	  cells	  (Stamataki	  et	  al,	  2009),	  which	  allow	  the	  possibility	  of	  cell-­‐to-­‐cell	  delivery	  of	  virus	  to	  distant	  sites	  in	  the	  liver.	  	  	  
1.2.6	  Studying	  the	  HCV	  life	  cycle	  	   	  10	  years	  after	  the	  discovery	  of	  HCV	  a	  successful	  replicon	  system	  was	  developed	  allowing	  study	  of	  subgenomic	  viral	  replication	  in	  hepatoma	  cell	  lines	  (Lohman	  et	  al,	  1999)	  (Figure	  1.6).	  Since	  then	  many	  more	  full	  length	  and	  subgenomic	  replicons,	  of	  differing	  genotypes	  have	  been	  constructed.	  This	  has	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possible by the isolation of a full-length genotype
2a genome from a Japanese patient with fulminant
hepatitis C (JFH-1).53 For reasons still unknown,
this unique strain is able to replicate in cultured
hepatoma cells without acquiring mutations.51–53 It
also retains the ability to infect chimpanzees after
passage through cultured cells.53 54 Importantly,
delivery of the JFH-1 genome into hepatoma cells
resulted in the production of progeny virions that
could infect naı¨ve hepatoma cells.51–53 The high
efficiency of replication permitted the detection of
viral proteins by antibody-based assays such as
immunohistochemistry and flow cytometry.
Studies with HCVcc confirmed and extended
many of the observations reported with HCVpp,
including the role of low pH in particle internalisa-
tion. Fusion of viral and cell membranes com-
mences when a ‘‘trigger’’ initiates a conformational
change in the gp that exposes a hydrophobic
peptide(s) which inserts into the host cell mem-
brane (reviewed in Kielian and Rey55). The trigger
or activation signal differs among enveloped
viruses, and generally falls into two categories
based upon the requirement for low pH. Fusion of
pH-independent viruses, such as HIV, is activated
by receptor binding at the plasma membrane. In
contrast, the fusion of pH-dependent viruses, such
as influenza or alphaviruses/flaviviruses, is trig-
gered by low pH in the endosome. Lavillette and
colleagues reported pH- and cholesterol-dependent
fusion of HCVpp with liposomes in the absence of
receptors.56 However, recent studies suggest that
HCVcc particle-48 and E1E2 gp-mediated cell–cell
fusion57 58 are dependent on receptor expression
and low pH activation, supporting a model where
multiple triggers may be required to promote
HCV–cell membrane fusion.
CD81 AS HCV RECEPTOR
Together, sE2, HCVpp and HCVcc model systems
permitted the discovery of many aspects of HCV
attachment and internalisation, including the
identification and characterisation of cellular
receptors required for viral entry. Using sE2 as a
probe for interactions with cell surface proteins,
Pileri and colleagues identified the first putative
HCV receptor as the tetraspanin CD81, a widely
expressed cell surface protein with various func-
tions such as tissue differentiation, cell adhesion,
gametogenesis and immune cell maturation.59 60
CD81 contains four TMDs separated by short
intracellular domains, a short extracellular loop
(SEL) and a long extracellular loop (LEL) (fig 3). E2
binding was mapped to the LEL of CD81 and was
shown to be inhibited by E2-specific antibo-
dies.35 39 61 Subsequent studies demonstrated that
HCVpp and HCVcc infection are sensitive to
neutralisation by anti-CD81 antibodies or soluble
CD81 LEL (sCD81).54 62 63 Neutralisation occurred
after viral attachment to the host cell, suggesting
that CD81 functions as a co-receptor for inter-
nalisation rather than the primary receptor.64–66 In
confirmation of the critical role of CD81 in HCV
entry, HepG2 and HH29 CD81-negative hepatoma
cells were able to support HCVpp entry after
transduction to express exogenous CD81.52 62–64 67
Additionally, silencing CD81 expression in hepa-
toma cells with small interfering RNAs (siRNAs)
inhibited HCV infection.52 62 63 While the studies
listed above utilised immortalised hepatoma cell
lines, HCV infection of primary hepatocytes was
shown to be CD81 dependent.68 The ubiquitous
expression of CD81 is inconsistent with the
tropism of the virus for the liver and suggests that
other molecules are likely to coordinate with CD81
to define the specific targeting of the virus to the
liver.
SR-BI AND LIPOPROTEIN METABOLISM
In contrast to the ubiquitous expression of CD81,
SR-BI is relatively restricted, with the highest levels
found in the liver and adrenal glands. Scavenger
Figure 2 Model systems to study hepatitis C virus (HCV). Replicons are self-replicating viral RNAs, incorporating the
complete or subgenome, allowing studies to address host cell and viral components regulating viral RNA replication.
Recombinant soluble versions of E2 and E1E2 glycoproteins permitted the identification of CD81 and scavenger receptor
BI (SR-BI) as receptors for HCV but may not accurately mimic native proteins. HCV pseudoparticles (HCVpp) facilitate
studies on E1E2-mediated entry in a single cycle model. Cell culture-grown HCV (HCVcc) models the complete viral life
cycle including the assembly and release of infectious virus particles.
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1.3	  The	  host	  	  HCV	  is	  a	  natural	  human	  pathogen	  and	  hepatocytes	  are	  the	  host	  cell.	  This	  narrow	  cellular	  tropism	  is	  due	  to	  a	  number	  of	  specific	  factors	  including	  proteins	  required	  for	  viral	  entry,	  lipid	  pathways	  important	  for	  viral	  assembly	  and	  molecules	  needed	  for	  replication,	  such	  as	  miR122	  (Jopling	  et	  al,	  2005).	  It	  is	  estimated	  that	  up	  to	  30-­‐50%	  of	  hepatocytes	  are	  infected	  in	  patients	  with	  hepatitis	  C	  (Wieland	  et	  al,	  2014)	  and	  HCV	  infects	  in	  clusters	  with	  differential	  innate	  immune	  response	  to	  the	  virus	  between	  infected	  and	  uninfected	  cells	  (Wieland	  et	  al,	  2014;	  Kandathil	  et	  al,	  2013).	  Key	  viral/host	  interactions	  are	  important	  to	  study	  as	  these	  are	  likely	  to	  affect	  viral	  pathogenicity	  and	  outcome	  from	  infection.	  	  	  
1.3.1	  The	  Liver	  
	   	  The	  liver	  is	  a	  large	  organ	  with	  a	  broad	  range	  of	  functions.	  It	  is	  made	  up	  largely	  of	  hepatocytes	  (75-­‐80%),	  which	  support	  the	  main	  roles	  of	  the	  liver	  in	  secretory,	  metabolic	  and	  endocrine	  functions.	  The	  liver	  also	  has	  many	  other	  cell	  types;	  Kupffer	  cells	  are	  specialist	  macrophages,	  which	  line	  the	  sinusoids,	  hepatic	  stellate	  cells	  (HSC)	  are	  contractile	  cells	  within	  the	  space	  of	  Disse,	  and	  liver	  sinusoidal	  endothelial	  cells	  (LSECs)	  line	  the	  sinusoid.	  There	  are	  also	  intrahepatic	  lymphocytes	  present	  within	  the	  sinusoidal	  space	  (Krishna,	  2013).	  	  	   The	  cells	  are	  arranged	  within	  lobules:	  hexagonal	  structures	  with	  plates	  of	  hepatocytes	  radiating	  from	  a	  central	  vein.	  The	  portal	  triad,	  which	  has	  a	  branch	  of	  the	  hepatic	  artery	  and	  portal	  vein,	  supplies	  oxygenated	  blood	  to	  the	  lobule.	  Blood	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from	  the	  portal	  vein/hepatic	  artery	  drains	  to	  the	  central	  vein	  via	  the	  liver	  sinusoids.	  The	  triad	  also	  contains	  a	  bile	  duct,	  which	  collects	  bile	  generated	  by	  hepatocytes	  and	  drains	  via	  the	  common	  bile	  duct	  to	  the	  gall	  bladder	  (Krishna,	  2013).	  Figure	  1.7	  and	  1.8	  show	  the	  macroscopic	  view	  of	  the	  liver	  and	  a	  detailed	  view	  of	  the	  portal	  triad.	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   The	  liver	  has	  a	  range	  of	  known	  physiological	  functions,	  including	  the	  formation	  and	  secretion	  of	  bile	  and	  the	  metabolism	  of	  protein,	  lipid	  and	  carbohydrate.	  Some	  of	  the	  main	  functions	  of	  the	  liver	  are	  detailed	  below	  (Sendenburg	  and	  Dufour,	  2011):	  -­‐ Glucose	  homeostasis	  and	  glycogen	  storage	  -­‐ De	  novo	  synthesis	  of	  proteins	  such	  as	  albumin	  and	  clotting	  factors	  -­‐ Hematopoiesis,	  particularly	  in	  the	  fetal	  period	  -­‐ Lipid	  metabolism	  including	  cholesterol	  synthesis,	  lipogenesis	  and	  triglyceride	  formation	  	  -­‐ Production	  of	  IGF-­‐1,	  an	  important	  anabolic	  hormone,	  particularly	  in	  childhood.	  	  -­‐ Breakdown	  of	  insulin	  and	  other	  hormones	  -­‐ Detoxification	  and	  excretion	  of	  metabolites,	  such	  as	  ammonia	  -­‐ Drug	  metabolism	  via	  the	  cytochrome	  P450	  system	  	  -­‐ Iron	  metabolism	  	  	  
1.3.2	  Hepatic	  Polarity	  	  	   	  Hepatocytes,	  like	  many	  other	  epithelial	  cells,	  are	  polarized.	  This	  contributes	  to	  their	  function,	  and	  also	  their	  ability	  to	  maintain	  a	  barrier	  between	  two	  interfaces	  or	  body	  compartments,	  such	  as	  air/blood	  in	  lung	  epithelium	  or	  blood/bile	  in	  hepatocytes.	  Epithelial	  cells	  maintain	  distinct	  apical	  and	  basolateral	  domains	  that	  are	  mediated	  by	  tight	  junctions	  (Treyer	  et	  al,	  2013;	  Shin	  et	  al,	  2006).	  Most	  polarized	  epithelial	  cells	  in	  the	  body	  such	  as	  gut	  or	  lung	  epithelium	  maintain	  simple	  polarity,	  where	  there	  are	  single	  opposing	  apical	  and	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basal	  layers	  (Mee	  et	  al,	  2009).	  Lateral	  cell	  walls	  associate	  with	  other	  cells	  (Figure	  1.9)	  and	  mediate	  cell:cell	  interactions.	  Hepatocytes,	  however,	  show	  a	  more	  complex	  polarity	  and	  have	  several	  apical	  and	  basal	  poles.	  The	  apical	  poles	  of	  adjacent	  hepatocytes	  form	  a	  continuous	  system	  of	  bile	  cannuliculi,	  into	  which	  bile	  is	  secreted.	  The	  basal	  poles	  are	  in	  contact	  with	  the	  sinusoids,	  and	  are	  important	  in	  uptake	  of	  nutrients	  and	  secretion	  of	  metabolized	  proteins	  and	  drugs	  (Decaens	  et	  al,	  2008;	  Shinn	  et	  al,	  2006).	  Tight	  junctions	  form	  the	  border	  between	  apical	  and	  basal	  domains	  in	  polarized	  cells	  (see	  Figure	  1.9).	  	  	  	   Tight	  junctions	  consist	  of	  transmembrane	  proteins	  and	  peripheral	  membrane	  proteins	  that	  interact	  with	  one	  another	  to	  form	  a	  complex	  network	  (Shin	  et	  al,	  2006).	  Transmembrane	  proteins	  include	  Occludin	  (Feldman	  et	  al,	  2005),	  Claudin	  (Tsukita	  et	  al,	  2001)	  and	  Junctional	  Adhesion	  Molecules	  (JAM)	  (Mandell	  et	  al,	  2005).	  They	  reach	  across	  the	  junction,	  connecting	  adjacent	  cell	  membranes	  to	  make	  a	  seal	  between	  cells.	  Transmembrane	  proteins	  bind	  intracellularly	  to	  peripheral	  proteins	  allowing	  cellular	  cytoskeleton	  arrangement	  and	  downstream	  signaling.	  Peripheral	  proteins	  include	  Zona	  Occludens	  (ZO	  proteins),	  Cingulin	  and	  Rab	  13,	  amongst	  others	  (reviewed	  in	  Decaens	  et	  al,	  2008).	  Adherens	  junctions	  containing	  proteins	  such	  as	  cadherin,	  nectin	  and	  catenin	  act	  to	  initiate	  and	  maintain	  cell:cell	  contact	  (Hartsock	  et	  al,	  2008).	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1.3.4 Oxygen	  levels	  and	  hepatocytes	  	   	  	   Hepatocytes	  in	  the	  liver	  are	  exposed	  to	  varying	  amount	  of	  nutrients	  and	  oxygen;	  cells	  in	  the	  periportal	  region	  are	  exposed	  to	  nutrient	  rich,	  oxygenated	  blood,	  whereas	  cells	  in	  the	  peri-­‐venous	  region	  are	  exposed	  to	  relative	  hypoxia	  (see	  Figure	  1.8).	  This	  oxygen	  gradient	  across	  the	  liver	  results	  in	  liver	  zonation,	  where	  hepatocytes	  have	  distinct	  structural	  and	  functional	  properties	  (Braeuning	  et	  al,	  2006;	  Jungermann	  et	  al,	  2000).	  Modest	  changes	  to	  oxygen	  levels	  during	  viral	  hepatitis	  can	  induce	  a	  hypoxic	  response	  in	  hepatocytes	  via	  hypoxia	  inducible	  factors	  (HiFs).	  Hypoxia	  indubible	  factors	  in	  turn	  regulate	  transcription	  of	  a	  large	  number	  of	  genes	  involved	  in	  cellular	  functioning	  including	  cell	  metabolism	  and	  inflammation	  (reviewed	  in	  Wilson	  et	  al,	  2014).	  Hifs	  have	  been	  implicated	  in	  altering	  the	  liver	  microenvironment	  contributing	  to	  liver	  damage	  and	  promoting	  oncogenesis	  (Wilson	  et	  al,	  2014).	  	  	   Hepatitis	  C	  virus	  can	  also	  directly	  stabilize	  Hifα,	  causing	  a	  ‘pseudohypoxic’	  response	  in	  the	  liver,	  even	  under	  normal	  oxygen	  tension,	  which	  is	  mediated	  by	  the	  oxidative	  stress	  induced	  by	  HCV	  gene	  expression	  (Nasimuzzaman	  et	  al,	  2007).	  Hifα	  is	  a	  transcriptional	  activator	  of	  VEGF,	  which	  can	  alter	  hepatocyte	  polarity	  and	  promote	  HCV	  entry	  (Mee	  et	  al,	  2010).	  Additionally,	  exposing	  cells	  to	  low	  oxygen	  levels	  has	  been	  shown	  to	  increase	  HCV	  replication	  (Vassilaki	  et	  al,	  2013)	  and	  inhibiting	  Hif	  can,	  in	  turn,	  reduce	  HCV	  replication	  (Wilson	  et	  al,	  2012).	  There	  may	  be	  a	  number	  of	  pathways	  involved	  in	  hypoxia	  and	  HCV	  replication,	  as	  Vassilaki	  et	  al	  (2013)	  reported	  that	  exposing	  cells	  to	  low	  oxygen	  tension	  increased	  HCV	  replication,	  but	  this	  was	  independent	  of	  Hif.	  In	  this	  study	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replication	  directly	  correlated	  with	  an	  increase	  in	  anaerobic	  glycolysis,	  suggesting	  that	  metabolic	  pathways	  affected	  by	  hypoxia	  are	  likely	  to	  alter	  viral/host	  interactions	  (Ripoli	  et	  al,	  2010).	  	  
1.3.5 Hepatocyte	  metabolism	  	  	   	  The	  liver	  is	  crucial	  to	  maintaining	  normal	  glucose	  homeostasis	  by	  balancing	  hepatic	  glucose	  production	  (gluconeogenesis)	  and	  utilization	  (glycolysis).	  These	  pathways	  are	  coordinated	  so	  that	  one	  is	  always	  more	  active	  in	  the	  cells	  than	  the	  other	  at	  any	  point	  in	  time	  (Shoji	  et	  al,	  2012).	  Figure	  1.10	  gives	  an	  overview	  of	  the	  main	  enzymes	  involved	  in	  glucose	  metabolism	  within	  hepatocytes.	  There	  is	  much	  clinical	  evidence	  that	  HCV	  infection	  leads	  to	  aberrant	  glucose	  metabolism	  and	  there	  is	  association	  between	  chronic	  HCV	  and	  Type	  2	  Diabetes	  (Mason	  et	  al,	  1999;	  Negro	  et	  al,	  2009;	  Negro	  et	  al,	  2011).	  Although	  the	  precise	  mechanisms	  behind	  this	  are	  not	  known,	  it	  is	  likely	  that	  there	  is	  a	  combination	  of	  altered	  metabolism	  of	  glucose	  (Ripoli	  et	  al,	  2010),	  reduced	  hepatic	  glucose	  uptake	  (Kasai	  et	  al,	  2009)	  and	  the	  development	  of	  insulin	  resistance	  (Koike	  et	  al,	  2007;	  Miyamato	  et	  al,	  2007;	  Pazienza	  et	  al,	  2007).	  There	  are	  conflicting	  data	  on	  whether	  HCV	  causes	  cells	  to	  switch	  to	  gluconeogenesis	  (Shoji	  et	  al,	  2012)	  or	  glycolysis	  (Ripoli	  et	  al,	  2010)	  when	  acutely	  infected.	  However,	  long-­‐term	  HCV	  infection	  damages	  oxidative	  phosphorylation	  causing	  cells	  to	  switch	  to	  glycolysis	  as	  a	  means	  of	  maintaining	  cell	  survival	  and	  this	  is	  mediated	  by	  Hif1α	  (Cuninghame	  et	  al,	  2014).	  Cells	  then	  utilize	  pyruvate	  as	  a	  main	  form	  of	  energy	  and	  produce	  lactate	  as	  a	  by-­‐product.	  This	  phenomenon,	  termed	  the	  ‘Warburg	  effect’	  is	  the	  metabolic	  process	  that	  de-­‐differentiated	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1.3.6 Liver	  Micro-­‐RNAs	  and	  HCV	  	   	  
	   Hepatocytes	  express	  a	  huge	  number	  of	  micro-­‐RNAs,	  many	  of	  which	  have	  been	  shown	  to	  interact	  with	  HCV.	  Micro-­‐RNAs	  (miR)	  are	  endogenous	  short	  (about	  22	  nucleotides)	  non-­‐coding	  RNAs	  that	  play	  a	  key	  role	  in	  regulating	  gene	  expression,	  by	  sequence	  specific	  binding	  to	  nucleic	  acids	  (reviewed	  in	  Filipowicz	  et	  al,	  2008).	  There	  is	  increasing	  evidence	  that	  miRs	  are	  important	  in	  liver	  development,	  regeneration	  and	  metabolism,	  and	  some	  host	  miRs	  are	  known	  to	  directly	  impact	  the	  HCV	  lifecycle.	  Interestingly,	  miRs	  require	  a	  minimum	  of	  just	  7	  nucleotides	  to	  pair,	  meaning	  a	  single	  miR	  may	  target	  a	  number	  of	  different	  mRNA.	  Up	  to	  60%	  of	  all	  human	  protein	  coding	  genes	  are	  predicted	  to	  be	  subject	  to	  miR	  modification	  (Friedman	  et	  al,	  2009)	  and	  several	  miRs	  can	  act	  together	  along	  a	  pathway	  (Tsang	  et	  al,	  2010).	  Consequently,	  there	  is	  a	  complex	  interaction	  between	  a	  huge	  range	  of	  miRs	  and	  the	  liver	  (Chen	  et	  al,	  2014;	  Yang	  et	  al,	  2015;	  Chen	  et	  al,	  2016;	  Wei	  et	  al,,	  2016;	  Vienberg	  et	  al,	  2017).	  	  	   Despite	  this	  complex	  interaction	  there	  are	  some	  important	  miRs	  that	  are	  known	  to	  interact	  with	  HCV;	  miR122	  is	  the	  most	  studied	  of	  these	  and	  is	  the	  most	  abundantly	  expressed	  miR	  in	  the	  human	  liver	  (Lagos-­‐Quintana	  et	  al,	  2002;	  Girard	  et	  al,	  2008).	  It’s	  expression	  is	  driven	  by	  liver-­‐specific	  transcription	  factors,	  including	  HNF4α	  and	  is	  very	  closely	  linked	  to	  hepatocyte	  differentiation	  (Deng	  et	  al,	  2014).	  miR122	  is	  unusual	  amongst	  miRs	  as	  being	  shown	  to	  positively	  regulate	  HCV	  (Jopling	  et	  al,	  2005),	  by	  binding	  to	  a	  highly	  conserved	  region	  in	  the	  5’UTR	  (Jopling	  et	  al,,	  2008;	  Jangra	  et	  al,	  2010;	  Machlin	  et	  al,	  2011).	  This	  enhances	  viral	  translation	  and	  stabilizes	  the	  genome	  by	  a	  number	  of	  mechanisms.	  miR122	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1.3.7 Iron	  	  	  The	  human	  liver	  is	  important	  in	  maintaining	  homeostasis	  for	  a	  number	  of	  micronutrients	  and	  metabolites,	  including	  iron.	  Cellular	  iron	  is	  crucial	  for	  many	  processes,	  such	  as	  DNA	  generation	  and	  ATP	  synthesis.	  Given	  that	  HCV	  replication	  is	  dependent	  on	  intracellular	  machinery,	  it	  is	  feasible	  that	  altering	  cellular	  iron,	  may	  affect	  viral	  replication.	  Furthermore,	  there	  is	  a	  clinical	  correlation	  between	  diseases	  in	  which	  iron	  metabolism	  is	  altered,	  such	  as	  haemachromatosis	  or	  β-­‐thalassaemia,	  and	  increased	  morbidity	  and	  mortality	  from	  HCV	  infection	  probably	  secondary	  to	  generation	  of	  free	  radicals	  and	  potentiating	  oxidative	  stress	  	  (reviewed	  in	  Drakesmith,	  Nature	  Reviews	  Microbiology,	  2008).	  	  	  Cellular	  iron	  has	  been	  shown	  to	  directly	  impact	  viral	  replication;	  increasing	  cellular	  iron	  is	  associated	  with	  an	  increase	  in	  HCV	  replication	  via	  stimulation	  of	  translation	  initiation	  factor	  eIF3	  (Kakizaki	  et	  al,	  2000;	  Theurl	  et	  al,	  2004).	  However,	  other	  authors	  have	  shown	  that	  cellular	  iron	  can	  inhibit	  HCV	  replication	  by	  specifically	  binding	  to	  the	  Mg2+	  binding	  pocket	  of	  the	  RNA	  polymerase	  and	  inhibiting	  enzymatic	  activity	  (Fillebeen	  et	  al,	  2005).	  Furthermore,	  Huh-­‐7	  cells	  supporting	  HCV	  subgenomic	  replicon	  show	  an	  altered	  iron	  metabolism	  with	  reduced	  uptake	  and	  increased	  release	  (Fillebeen	  et	  al,	  2007),	  possibly	  allowing	  viral	  escape	  from	  the	  effect	  of	  iron	  on	  established	  replication.	  Although	  the	  molecular	  interactions	  between	  cellular	  iron	  in	  the	  liver	  and	  HCV	  replication	  require	  further	  clarification,	  there	  is	  good	  evidence	  that	  there	  is	  interplay	  between	  virus	  and	  host.	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1.4 :	  Innate	  and	  Adaptive	  Immunity	  	  
1.4.1	  Innate	  signaling	  	   	  The	  human	  innate	  immune	  response	  is	  the	  first	  line	  of	  defence	  against	  pathogens	  and	  interferons	  are	  a	  key	  feature	  of	  the	  chronic	  HCV	  infected	  liver.	  Hepatocytes	  can	  produce	  and	  respond	  to	  Type	  1	  and	  Type	  3	  interferons.	  Pathogen	  associated	  molecular	  patterns	  (PAMPS),	  such	  as	  double	  stranded	  RNA,	  are	  recognized	  by	  extra	  or	  intracellular	  pattern	  recognition	  receptors	  (PRRs),	  such	  as	  Toll-­‐like	  receptors	  or	  RIG-­‐I.	  Table	  1	  gives	  an	  overview	  of	  PAMPS	  and	  PRRs	  involved	  in	  innate	  signalling.	  	  	   	  




Table	  1.1	  An	  overview	  of	  human	  innate	  signalling	  molecules	  important	  in	  
pathogen	  recognition.	  	  
	  Those	  in	  bold	  are	  important	  in	  HCV	  infection	  (adapted	  from	  Satoh	  and	  Akira,	  2016).	  	  	  	  	   	  
	   Receptor	   Localisation	   Pathogen	  Associated	  Molecular	  Patterns	  
(PAMPS)	  TLR	   TLR1	   Cell	  surface	   Triacyl	  lipopeptides	  	   TLR2	   Cell	  surface	   Lipopeptides,	  Peptidoglycan	  	   TLR3	   Endosomes	   Double	  stranded	  RNA	  (Viruses)	  	   TLR4	   Cell	  surface	   Lipopolysaccharide	  	   TLR5	   Cell	  Surface	   Flagelin	  	   TLR6	   Cell	  surface	   Diacyl	  lipopeptides,	  Lipoteichoic	  acid	  	   TLR7	   Endosomes	   Single	  Stranded	  RNA	  (Viruses)	  	   TLR8	   Endosomes	   Single	  Stranded	  RNA	  (Viruses)	  	   TLR9	   Endosomes	   CpG	  containing	  DNA	  (Viruses)	  	   TLR10	   Endosomes	   Profilin-­‐like	  proteins	  RLR	   RIGI	   Cytosol	   RNA	  (double	  stranded	  regions	  and	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Figure	  1.12	  An	  overview	  of	  hepatocellular	  innate	  signalling	  HCV	  	  Human	  hepatocytes	  express	  TLR3	  on	  endosomes	  that	  can	  recognize	  dsRNA.	  Extracellular	  dsRNA	  can	  be	  taken	  up	  into	  uninfected	  cells	  by	  scavenger	  receptors	  (Dansako	  et	  al,	  2013)	  and	  brought	  to	  endosomes,	  where	  it	  is	  bound	  by	  TLR3.	  HCV	  infected	  cells	  can	  also	  generate	  dsRNA.	  This	  activates	  the	  TIR	  domain-­‐containing	  adapter-­‐inducing	  IFN-­‐β	  (TRIF).	  Additionally	  dsRNA	  intermediates	  intracellularly	  are	  recognized	  by	  retinoic	  acid-­‐induced	  gene	  I	  (RIG-­‐I)	  (Sumpter	  et	  al,	  2005)	  and	  melanoma	  differentiation-­‐associated	  gene	  5	  (MDA-­‐5)	  (Israelow	  et	  al,	  2014;	  Du	  et	  al,	  2016).	  In	  addition	  LGP2	  (laboratory	  of	  genetics	  and	  physiology	  2),	  present	  in	  the	  cytoplasm	  is	  likely	  to	  predominantly	  synergise	  with	  MDA5	  to	  promote	  efficient	  signal	  downstream	  (Satoh	  et	  al,	  2010).	  LGP2	  may	  also	  have	  a	  negative	  regulatory	  effect,	  by	  mopping	  up	  excess	  ds	  RNA	  in	  the	  cytoplasm	  (Komuro	  et	  al,	  2006).	  MAVS	  and	  TRIF	  trigger	  a	  signaling	  cascade	  that	  results	  in	  IκB	  kinases	  (IKK)	  and	  TANK-­‐binding	  kinase	  1	  (TBK1)	  activation	  leading	  ultimately	  to	  activation	  of	  NF-­‐κB	  and	  IRF3	  (Fitzgerald	  et	  al,	  2003;	  Seth	  et	  al,	  2005).	  These	  proteins	  bind	  to	  the	  promoter	  elements	  of	  IFNI	  and	  IFNIII	  in	  the	  nucleus	  leading	  to	  interferon	  and	  cytokine	  production.	  Interferons	  can	  act	  locally	  or	  at	  a	  more	  distant	  sites	  via	  binding	  cell	  surface	  receptors	  (Bruening	  et	  al,	  2017).	  IFN	  receptors	  activate	  the	  JAK-­‐STAT	  pathway	  that	  regulates	  a	  wide	  number	  of	  interferon	  stimulated	  genes	  (ISG)	  that	  can	  limit	  HCV	  replication.	  In	  chronic	  infection,	  HCV	  is	  able	  to	  persist	  and	  replicate	  within	  cells,	  due	  to	  the	  ability	  of	  the	  viral	  encoded	  NS3/4A	  protease	  to	  cleave	  the	  adaptor	  proteins	  MAVS	  (Li	  XD	  et	  al,	  2005)	  and	  TRIF	  (Li	  K	  et	  al.	  2005),	  that	  blunts	  the	  interferon	  response	  (Bellecave	  et	  al,	  2010).	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1.4.2	  Interferon	  production	  and	  Interferon	  Stimulating	  Genes	  (ISGs)	  	  	   Prior	  to	  the	  advent	  of	  novel	  direct	  acting	  antiviral	  drugs	  (DAAs)	  for	  treating	  HCV,	  exogenous	  interferon-­‐α	  was	  the	  only	  treatment	  option	  available.	  This	  binds	  the	  interferon	  receptor	  leading	  to	  JAK-­‐STAT	  activation	  and	  ISG	  upregulation	  within	  the	  cell.	  ISGs	  interfere	  with	  different	  stages	  of	  the	  viral	  lifecycle	  (reviewed	  in	  Schneider	  et	  al,	  2014).	  Table	  1.2	  provides	  an	  overview	  of	  ISGs	  produced	  in	  response	  to	  viral	  infection	  and	  their	  broad	  mechanism	  of	  action.	  The	  specific	  pattern	  and	  level	  of	  ISGs	  upregulated	  in	  response	  to	  interferon	  can	  predict	  outcome	  from	  acute	  infection	  and	  treatment	  response	  to	  interferons,	  independent	  of	  other	  factors.	  In	  chronic	  HCV	  infection	  the	  endogenous	  interferon	  response	  fails	  to	  clear	  the	  infection;	  the	  robust	  ISG	  upregulation	  in	  response	  to	  infection	  is	  thought	  to	  reflect	  a	  refractory	  state	  within	  the	  liver	  (Sarasin-­‐Filipowicz	  et	  al,	  2008;	  Chen,	  et	  al	  2005;	  Asselah	  et	  al,	  2008).	  Specific	  patterns	  of	  ISG	  upregulation	  can	  predict	  outcome	  to	  HCV	  infection,	  with	  a	  4-­‐gene	  classifier	  (IFI27,	  ISG15,	  RSAD2	  and	  the	  tumour	  marker	  HTATIP2)	  showing	  accurate	  correlation	  with	  treatment	  response	  (Dill	  et	  al,	  ,	  2011).	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Antiviral	  
effectors	  	  Exert	  an	  antiviral	  effect	  
Viral	  Entry	   Myxovirus	  resistance:	  Mx1	   -­‐	  Traps	  viral	  components	  e.g.	  nucleocapsid	  when	  entering	  cell	  	  Cholesterol-­‐25-­‐Hydoxylase:	  
CH25H	   -­‐	  Probable	  interference	  with	  viral	  host	  membrane	  fusion	  	  -­‐	  Can	  also	  directly	  inhibit	  HCV	  replication	  by	  altering	  protein	  synthesis	  	  Interferon	  Inducible	  Transmembrane:	  IFITM	   -­‐	  Inhibit	  viral	  entry	  in	  endosomal	  compartment	  Viral	  Translation	  and	  	  Replication	  
Tripartite	  motif:	  TRIM	   Large	  family	  that	  exert	  multiple	  effects	  -­‐	  TRIM14	  degrades	  NS5A	  -­‐	  TRIM22	  ubiquitinates	  NS5A	  
ISG15	   Complex	  signaling	  via	  covalently	  attaching	  to	  target	  proteins	  (ISGylation)	  -­‐	  ISGylation	  of	  host	  protein	  4EHP	  blocks	  translation	  of	  HCV	  Virus	  inhibitory	  protein,	  endoplasmic	  reticulum-­‐associated,	  IFN	  inducible:	  
Viperin	  (RSAD2)	  
Inhibits	  RNA	  replication	  by	  disrupting	  host	  (VAP-­‐1)	  and	  virus	  (NS5A)	  interaction	  within	  lipid	  droplets	  
IFI27	   Inhibits	  HCV	  replication	  in	  replicon	  system	  Viral	  egress	   Tetherin	  (BST2)	   Inhibits	  viral	  budding.	  Probably	  not	  a	  major	  player	  in	  HCV	  infection.	  
IFN	  desensitization	   SOCS	  proteins	   Inhibit	  JAK-­‐STAT	  signaling	  	  
USP18	   Interacts	  with	  IFNAR	  protein	  preventing	  JAK	  binding	  and	  downstream	  signaling.	  Only	  inhibits	  Type	  1	  IFN	  (not	  Type	  III)	  	  	  
Table	  1.2	  Important	  Interferon	  Stimulated	  Genes	  modulating	  HCV	  
infection.	  	  Adapted	  from	  Schneider	  et	  al	  (2014)	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   Another	  important	  correlate	  of	  outcome	  in	  HCV	  infection	  is	  IFNλ	  gene	  polymorphisms.	  These	  were	  identified	  by	  genome	  wide	  association	  studies	  investigating	  the	  differences	  in	  response	  rate	  to	  interferon	  treatment	  between	  those	  of	  African	  and	  European	  descent	  (Thomas	  et	  al,	  2009;	  Ge	  et	  al,	  2009).	  Further	  work	  identified	  three	  major	  SNPs	  near	  the	  INFλ3	  and	  IFNλ4	  genes,	  which	  correlate	  with	  HCV	  treatment	  response	  (Rauch	  et	  al,	  2010;	  Duggal	  et	  al,	  2013)	  and	  raised	  the	  importance	  of	  IFNλ	  in	  treatment	  and	  innate	  response	  to	  HCV	  infection	  in	  hepatocytes.	  IFNλ	  levels	  are	  increased	  in	  humans	  infected	  with	  HCV	  (Dolganiuc	  et	  al,	  2012),	  leading	  to	  increased	  ISG	  levels	  (Thomas	  et	  al,	  2012;	  Duong	  et	  al,	  2012),	  and	  hepatocytes	  infected	  with	  HCV	  express	  abundant	  IFNλR	  (Dolganuic	  et	  al,	  2012).	  Primary	  human	  liver	  cultures	  also	  express	  IFNλ	  (predominantly	  IL29	  IFNλ1)	  and	  HCV	  infection	  induces	  ISGs	  (Marukian	  et	  al,	  2011),	  that	  can	  inhibit	  viral	  replication.	  Indeed,	  IL29	  is	  the	  major	  Type	  III	  interferon	  produced	  by	  hepatocytes	  during	  acute	  HCV	  infection	  (Park	  et	  al,	  2012),	  and	  there	  is	  very	  little	  Type	  I	  interferon	  expressed.	  	  Although	  Type	  I	  interferons	  were	  initially	  thought	  to	  provide	  the	  first	  line	  of	  defence	  against	  HCV,	  there	  is	  very	  little	  IFN	  α/β	  production	  in	  chronic	  HCV	  infection.	  HCV	  has	  been	  reported	  to	  interfere	  with	  TLR-­‐3,	  RIG-­‐I	  and	  JAK-­‐STAT	  signalling	  (see	  Figure	  
1.12)	  downstream	  of	  the	  α/β	  receptor	  (Horner	  et	  al,	  2009.	  In	  contrast,	  Type	  III	  interferon	  signaling	  pathways	  remain	  functional	  and	  intact	  (Park	  et	  al,	  2012).	  	  	  There	  is	  likely	  to	  be	  variable	  response	  across	  the	  liver	  to	  infection	  with	  HCV.	  Kandathil	  et	  al	  (2013)	  showed,	  using	  laser	  capture	  micro-­‐dissection,	  that	  HCV	  clusters	  in	  cells,	  away	  from	  areas	  of	  high	  IFITM	  expression.	  Similarly	  
	   44	  
Sheahan	  et	  al	  (2014),	  using	  the	  same	  method,	  was	  able	  to	  show	  that	  infected	  cells	  expressed	  a	  unique	  innate	  antiviral	  signature,	  which	  differed	  from	  uninfected	  cells	  and	  was	  variable,	  depending	  on	  IFNλ	  genotype.	  These	  data	  suggest	  that	  early	  viral	  host	  interactions,	  particularly	  innate	  responses,	  determine	  the	  outcome	  of	  HCV	  infection.	  	  	  	  
1.4.3	  The	  cellular	  innate	  response	  
	  	   In	  addition	  to	  interferon	  production,	  cells	  of	  the	  innate	  immune	  system	  are	  also	  important	  in	  controlling	  HCV	  infection.	  The	  human	  liver	  contains	  many	  cells	  in	  addition	  to	  hepatocytes,	  such	  as	  NK	  cells	  and	  dendritic	  cells	  that	  can	  augment	  the	  response	  to	  acute	  infection.	  However,	  this	  is	  difficult	  to	  recapitulate	  in	  vitro	  and	  therefore	  studying	  innate	  signalling	  in	  hepatocytes	  is	  not	  a	  true	  reflection	  of	  the	  whole	  physiological	  innate	  response.	  	  	  Intrahepatic	  NK	  cells	  and	  NK	  T	  cells	  are	  activated	  in	  response	  to	  acute	  HCV	  infection	  and	  produce	  IFNγ,	  which	  leads	  to	  cytotoxic	  killing	  of	  infected	  hepatocytes	  (Amadei	  et	  al,	  2010).	  The	  production	  of	  IFNγ	  leads	  to	  activation	  of	  intra-­‐hepatic	  Kupffer	  cells	  and	  the	  release	  of	  pro-­‐inflammatory	  molecules	  including	  TNFα,	  galectin-­‐9	  and	  IL-­‐18	  (Mengshol	  et	  al,	  2010;	  Chattergoon	  et	  al,	  2011).	  The	  role	  of	  these	  molecules	  is	  not	  wholly	  defined	  but	  they	  promote	  inflammation	  and	  enhance	  maturation	  of	  dendritic	  cells	  (Mengshol	  et	  al,	  2010)	  that	  can	  express	  IFNα	  (Takahashi	  et	  al,	  2012;	  Zhang	  et	  al,,2013).	  Dendritic	  cells	  produce	  IFN	  in	  response	  to	  HCV	  infection	  in	  hepatocytes,	  a	  response	  that	  requires	  replicating	  HCV	  and	  direct	  cell	  contact	  (Takahashi	  et	  al,	  2012).	  Myeloid	  
	   45	  
derived	  dendritic	  cells	  are	  also	  involved	  with	  the	  adaptive	  response	  by	  activating	  naïve	  T	  cells	  present	  in	  lymphoid	  tissues	  (Terilli	  and	  Cox,	  2013).	  	  	  When	  the	  innate	  and	  adaptive	  response	  to	  infection	  fails	  to	  clear	  the	  virus,	  ongoing	  inflammation	  and	  cell	  activation	  in	  the	  liver	  leads	  to	  a	  gradual	  loss	  of	  NK	  cell	  number	  and	  function	  (Amadei	  et	  al,	  2010;	  Ahlenstiel	  et	  al,	  2010).	  The	  presence	  of	  pro-­‐inflammatory	  molecules	  is	  detrimental	  over	  time	  resulting	  in	  hepatocyte	  damage,	  inflammation	  and	  cirrhosis.	  	  	  
1.4.4 HIV/HCV	  Co-­‐infection	  and	  the	  innate	  response	  	   	  There	  is	  evidence	  that	  the	  innate	  response	  to	  HCV	  is	  altered	  when	  a	  patient	  is	  co-­‐infected	  with	  HIV	  (Hou	  et	  al,	  2009;	  Parczewski	  et	  al,	  2012;	  Chen	  et	  al,	  2016;	  Hullegie	  et	  al.	  2012).	  Interestingly,	  the	  polymorphisms	  in	  the	  IL28B	  gene	  that	  are	  associated	  with	  improved	  outcome	  and	  response	  to	  treatment	  in	  HCV,	  are	  associated	  with	  increase	  in	  all-­‐cause	  mortality	  in	  HIV	  infected	  patients	  on	  antiretroviral	  treatment.	  This	  suggests	  that	  HIV	  infection	  alters	  interferon	  λ	  expression,	  altering	  the	  ability	  of	  the	  innate	  system	  to	  respond	  to	  HCV	  (Parczewski	  et	  al,	  2012).	  Furthermore	  interferon	  λ	  induced	  by	  HCV	  infection	  reduces	  macrophage	  infection	  by	  HIV	  by	  activating	  the	  JAK-­‐STAT	  pathway	  (Hou	  at	  al,	  2009;	  Liu	  et	  al,	  2012).	  These	  studies	  suggest	  there	  is	  significant	  interplay	  between	  Type	  III	  interferon	  responses	  in	  HIV	  and	  HCV	  infection.	  	  	  HIV	  can	  also	  affect	  cellular	  responses	  to	  HCV.	  HIV	  can	  infect	  dendritic	  cells,	  thereby	  altering	  their	  numbers	  and	  response	  to	  HCV	  (reviewed	  by	  
	   46	  
Lambotin	  et	  al,	  2010).	  Similarly,	  chronic	  HIV	  can	  alter	  NK	  cell	  functioning	  (reviewed	  by	  Iannello	  et	  al,	  2008).	  There	  is	  evidence	  for	  significant	  interplay	  between	  HIV	  and	  HCV	  and	  innate	  signalling	  in	  co-­‐infection,	  which	  may	  limit	  the	  host’s	  ability	  to	  respond	  to	  infection.	  	  	  
1.4.5 Adaptive	  immune	  response	  to	  HCV	  	  	   	  The	  adaptive	  immune	  response	  to	  HCV	  shows	  a	  delayed	  antibody	  and	  T	  cell	  response	  that	  appear	  no	  earlier	  than	  8-­‐12	  weeks	  following	  acute	  self-­‐limiting	  or	  chronic	  infection	  (Chen	  et	  al,	  1999;	  Park	  and	  Rehermann,	  2014).	  There	  is	  limited	  evidence	  that	  the	  humoral	  antibody	  response	  is	  important,	  and	  in	  chronically	  infected	  patients	  there	  is	  generally	  low	  titre	  and	  late	  evolving	  antibody	  (Logvinoff	  et	  al,	  2004).	  	   By	  contrast,	  T	  cell	  responses	  to	  HCV	  infection	  are	  crucially	  related	  to	  outcome;	  the	  development	  of	  a	  robust	  CD4+	  and	  CD8+	  T	  cell	  response	  is	  associated	  with	  viral	  clearance,	  with	  both	  cells	  being	  important	  (reviewed	  by	  Neumann-­‐Haefelin	  and	  Thimme,	  2011;	  Klenerman	  et	  al,	  2012).	  The	  CD8	  repertoire	  is	  developed	  early	  in	  the	  disease	  and	  requires	  CD4+	  T	  cell	  help	  to	  maintain	  the	  response	  (Cox	  et	  al,	  2005).	  Despite	  this	  early	  response,	  the	  majority	  of	  patients	  go	  on	  to	  develop	  chronic	  HCV.	  CD4+	  T	  cells	  and	  CD8+	  T	  cells	  show	  rapid	  exhaustion	  and	  deletion	  in	  the	  context	  of	  persistent	  HCV	  infection	  (Bengsch	  et	  al,	  2010).	  Viral	  mutations	  can	  lead	  to	  escape,	  meaning	  viral	  epitopes	  are	  not	  recognized	  by	  T	  cells.	  Furthermore,	  upregulation	  of	  markers	  of	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exhaustion	  inhibit	  T	  cell	  function	  in	  chronic	  HCV	  infection	  (Rutebemberwa	  et	  al,	  2008).	  	  
1.4.6 Co-­‐infection	  and	  the	  adaptive	  immune	  response	  	  	   	  	   HIV	  also	  alters	  the	  adaptive	  response	  to	  HCV.	  CD4	  T	  cell	  depletion	  in	  HIV,	  alongside	  B	  cell	  exhaustion,	  reduced	  number	  of	  memory	  B	  cells	  and	  increased	  B	  cell	  turnover	  leads	  to	  a	  reduction	  of	  HCV	  specific	  antibodies	  (Lambotin	  et	  al,	  2012;	  Netski	  et	  al,	  2007).	  Patients	  can	  lose	  previously	  generated	  immunity	  against	  HCV	  when	  co-­‐infected	  with	  HIV.	  The	  immune	  dysregulation	  that	  occurs	  with	  HIV	  therefore	  leads	  to	  lower	  rates	  of	  HCV	  clearance	  and	  increased	  rates	  of	  disease	  progression	  (Terili,and	  Cox,	  2013).	  	  	  There	  is	  a	  complex	  interplay	  of	  innate,	  cellular	  and	  adaptive	  cellular	  response	  to	  HCV	  infection	  that	  is	  altered	  by	  the	  presence	  of	  other	  viruses,	  such	  as	  HIV.	  HCV	  has	  evolved	  mechanisms	  of	  subverting	  the	  immune	  response,	  allowing	  the	  virus	  to	  establish	  chronic	  infection	  in	  the	  majority	  of	  cases.	  It	  is	  likely	  that	  innate	  responses,	  particularly	  IFNλ	  signalling	  and	  downstream	  effects	  are	  predominant	  in	  early	  acute	  infection.	  Studying	  the	  host/viral	  response	  requires	  a	  system	  that	  in	  vitro	  is	  able	  to	  produce	  Type	  III	  interferon	  and	  associated	  ISGs.	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1.5 :	  Models	  for	  studying	  Hepatitis	  C	  virus-­‐host	  interactions	  	   	  There	  exist	  a	  number	  of	  model	  systems	  for	  studying	  HCV,	  the	  viral	  life	  cycle	  and	  viral-­‐host	  interactions.	  The	  ideal	  system	  is	  one	  that	  is	  physiological,	  accessible,	  easy	  to	  use	  and	  supports	  the	  replication	  of	  primary	  patient	  derived	  viral	  strains.	  However,	  this	  does	  not	  currently	  exist.	  There	  are	  a	  number	  of	  advantages	  and	  disadvantages	  to	  the	  current	  model	  systems	  available	  which	  will	  be	  considered	  below.	  
1.5.1	  Hepatoma	  cell	  lines	  	  	  	   	  Huh-­‐7	  cells,	  derived	  from	  a	  patient	  with	  hepatocellular	  carcinoma,	  are	  a	  permissive	  immortalized	  cell	  line.	  This	  cell	  line	  supports	  high	  level	  HCV	  replication	  in	  vitro	  and	  has	  revolutionized	  HCV	  research.	  Blight	  et	  al	  (2002)	  were	  able	  to	  identify	  a	  clone	  of	  Huh-­‐7	  that	  supported	  high	  levels	  of	  HCV	  replication.	  They	  transfected	  cells	  with	  a	  HCV	  subgenomic	  replicon,	  then	  cured	  the	  cells	  with	  prolonged	  interferon	  α	  treatment.	  Cured	  cells	  were	  transfected	  with	  the	  replicon	  and	  screened	  for	  clones	  that	  were	  able	  to	  support	  increased	  replication	  (Blight	  et	  al,	  2002).	  The	  Huh-­‐7.5	  clone	  was	  identified	  and	  has	  been	  key	  in	  HCV	  research	  since	  then,	  allowing	  study	  into	  viral	  entry	  pathways,	  replication	  and	  viral	  egress.	  Huh-­‐7.5	  clones	  have	  a	  defective	  RIG-­‐I,	  which	  is	  thought	  to	  be	  central	  to	  their	  increased	  permissivity	  (Sumpter	  et	  al,	  2005).	  Recently,	  Huh-­‐7.5	  were	  reported	  to	  support	  replication	  of	  patient	  derived	  virus,	  something	  that	  has	  long	  evaded	  HCV	  researchers.	  Saeed	  et	  al	  (2015)	  was	  able	  to	  show	  that	  expressing	  SEC14L2,	  a	  cytosolic	  lipid	  binding	  protein	  involved	  in	  cholesterol	  biosynthesis,	  allowed	  Huh-­‐7.5	  to	  support	  HCV	  replication	  after	  inoculation	  with	  patient	  sera.	  This	  is	  likely	  to	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lead	  to	  advances	  in	  understanding	  the	  biology	  of	  patient	  derived	  virus.	  Despite	  these	  advances,	  Huh-­‐7	  and	  derivatives	  are	  carcinoma	  derived	  cells	  and	  suboptimal	  for	  the	  study	  of	  viral-­‐host	  interaction,	  particularly	  studies	  investigating	  viral/cell	  interactions	  leading	  to	  cell	  damage	  and	  oncogenesis.	  	  	  	   Sainz	  et	  al	  described	  a	  method	  to	  differentiate	  Huh-­‐7	  cells	  towards	  a	  more	  ‘liver-­‐like’	  state,	  using	  dimethylsulfoxide	  (DMSO),	  which	  is	  commonly	  used	  to	  enhance	  cellular	  differentiation	  (Sainz	  and	  Chisari,	  2006).	  Huh-­‐7	  upregulated	  key	  markers	  of	  differentiation	  and	  supported	  HCV	  replication.	  Given	  their	  ease	  of	  use	  and	  ability	  to	  support	  HCV	  infection	  in	  vitro	  these	  cells	  offer	  great	  promise	  in	  providing	  a	  differentiated	  cell	  model	  for	  understanding	  virus/host	  interactions.	  	  	  	   Huh-­‐7.5	  have	  also	  been	  differentiated	  by	  propagation	  in	  human	  serum,	  showing	  increased	  expression	  of	  cellular	  differentiation	  markers	  and	  HCV	  replication	  	  (Steenbergen	  et	  al,	  2013).	  Although	  they	  do	  not	  appear	  to	  be	  a	  physiological	  system	  that	  recapitulates	  the	  viral	  lifecycle	  in	  vivo,	  given	  the	  high	  titre	  virus	  that	  is	  produced	  from	  these	  cells,	  the	  use	  of	  human	  serum	  in	  combination	  with	  other	  model	  systems	  may	  offer	  advantages.	  	  	  	   Other	  hepatoma	  cell	  lines,	  such	  as	  Hep3B,	  Huh-­‐6	  and	  PLC/PRF/5	  are	  derived	  from	  immortalized	  liver	  cancers,	  and	  support	  some	  aspects	  of	  the	  HCV	  viral	  lifecycle.	  However,	  none	  support	  the	  entire	  lifecycle,	  and	  their	  use	  is	  limited	  (reviewed	  in	  Wilson	  and	  Stamataki,	  2012).	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1.5.2	  Polarised	  models	  	  	   Hepatocytes	  exhibit	  a	  complex	  polarity	  in	  vivo	  (see	  figure	  1.9).	  Cell	  systems	  that	  are	  able	  to	  polarize	  in	  vitro	  are	  important	  in	  order	  to	  understand	  the	  impact	  this	  has	  on	  HCV	  entry	  and	  replication.	  	  Huh-­‐7	  cells	  fail	  to	  polarize	  and	  even	  primary	  human	  hepatocytes	  fail	  to	  form	  hepatic	  polarization	  when	  cultured,	  and	  rapidly	  de-­‐differentiate	  (Wilson	  et	  al,	  2012).	  There	  have	  been	  attempts	  to	  grow	  hepatoma	  cell	  lines	  on	  scaffolding	  to	  allow	  a	  3-­‐D	  differentiated	  polarized	  structure	  to	  develop,	  however	  these	  are	  difficult	  to	  establish	  and	  are	  not	  commonly	  used	  (Molina-­‐Jimenez	  et	  al,	  2012;	  Sainz	  et	  al,	  2009;	  Tran	  et	  al,	  2013).	  	  	  	   HepG2	  cells	  are	  derived	  from	  a	  human	  hepatoblastoma	  and	  over	  time	  in	  culture,	  with	  the	  development	  of	  pseudo	  bile	  cannaliculi.	  When	  engineered	  to	  express	  CD81	  and	  miR122,	  these	  cells	  can	  support	  low	  level	  HCV	  infection	  (Narbus	  et	  al,	  2011).	  Despite	  this,	  studies	  using	  HepG2	  cells	  have	  allowed	  us	  to	  understand	  the	  consequences	  of	  polarization	  on	  HCV	  entry	  (Mee	  et	  al,2009).	  Additionally,	  when	  HepG2	  cells	  are	  infected	  with	  HCV	  they	  lose	  polarity	  and	  undergo	  cellular	  differentiation,	  allowing	  study	  of	  the	  effects	  of	  the	  virus	  on	  aspects	  of	  carcinogenesis	  (Wilson	  et	  al,	  2012).	  	  	  HepaRG	  cells	  are	  an	  interesting	  cell	  line	  derived	  from	  a	  patient	  with	  HCV	  associated	  hepatocellular	  carcinoma.	  They	  are	  a	  bi-­‐potent	  progenitor	  cell	  that	  once	  plated	  and	  differentiated	  over	  time	  will	  form	  two	  cell	  types;	  hepatocyte	  like	  cells,	  which	  are	  surrounded	  by	  biliary	  like	  epithelial	  cells	  (Gripon	  et	  al,	  2002).	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1.5.3	  Primary	  cell	  culture	  	  
Primary	  Human	  Hepatocytes	  	  The	  gold	  standard	  for	  in	  vitro	  HCV	  studies	  are	  primary	  human	  hepatocytes.	  These	  support	  HCV	  entry	  and	  replication	  although	  this	  is	  at	  a	  low	  level	  and	  there	  is	  significant	  donor	  variability	  (Wilson	  et	  al,	  2015).	  Furthermore,	  these	  cells	  are	  well	  known	  to	  de-­‐differentiate	  rapidly	  ex-­‐vivo	  and	  are	  difficult	  to	  maintain	  in	  culture.	  This	  limits	  their	  ability	  to	  be	  used	  as	  a	  long-­‐term	  model	  for	  HCV	  or	  other	  hepatotropic	  pathogens.	  	  	  Recent	  studies	  have	  attempted	  to	  adapt	  primary	  human	  hepatocytes	  in	  culture	  in	  order	  to	  increase	  their	  utility	  in	  vitro.	  Micropatterned	  co-­‐cultures	  have	  been	  developed	  where	  primary	  human	  hepatocytes	  are	  grown	  in	  micro-­‐cultures	  supported	  by	  surrounding	  stroma	  and	  fibroblasts,	  in	  a	  model	  similar	  to	  HepaRG	  cells	  (March	  et	  al,	  2015;	  Ploss	  et	  al,	  2010).	  These	  can	  be	  maintained	  for	  weeks	  in	  culture	  and	  support	  the	  entire	  HCV	  life	  cycle	  in	  vitro.	  	  	  Primary	  human	  hepatocytes	  can	  also	  be	  immortalized	  by	  transfection	  of	  HCV	  core	  protein	  (Ray	  et	  al,	  2000;	  Basu	  et	  al,	  2002).	  HCV	  core	  protein	  in	  these	  cells	  transcriptionally	  alters	  cellular	  genes	  involved	  in	  growth,	  apoptosis	  and	  innate	  signaling	  and	  may	  provide	  a	  useful	  model	  for	  understanding	  viral	  replication	  and	  assembly	  (Kanda	  et	  al,	  2006).	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Human	  Fetal	  Liver	  Cells	  	  	  	   Human	  fetal	  liver	  derived	  cells	  have	  been	  used	  as	  a	  robust	  model	  system,	  particularly	  to	  study	  innate	  signalling	  responses	  to	  HCV	  (Marukian	  et	  al,	  2011;	  Laidlaw	  et	  al,	  2017;	  Andrus	  et	  al,	  2011;	  Lázaro	  et	  al,	  2007).	  They	  are	  derived	  from	  pools	  of	  human	  fetal	  livers	  at	  16-­‐22	  weeks	  gestation.	  They	  support	  HCV	  infection	  with	  laboratory	  viral	  strains,	  however	  levels	  of	  viral	  replication	  differ	  significantly	  between	  cultures.	  Furthermore	  the	  robust	  innate	  response	  clears	  infection	  quickly	  if	  measures	  to	  dampen	  this	  response	  are	  not	  used	  (Andrus	  et	  al,	  2011).	  Recently	  Guo	  et	  al	  described	  the	  development	  of	  a	  cell	  culture	  system	  based	  on	  human	  fetal	  liver	  stem	  cells	  that	  are	  able	  to	  support	  the	  entire	  viral	  lifecycle	  of	  patient	  derived	  virus	  (Guo	  et	  al,	  2017).	  	  	  
Induced	  pluripotent	  stem	  cells	  	  	   	   Hepatocyte	  like	  cells	  have	  also	  been	  generated	  from	  human	  induced	  pluripotent	  stem	  cells	  (methodology	  in	  Si-­‐Tayeb	  et	  al,	  2010).	  As	  these	  cells	  differentiate	  into	  hepatocyte	  like	  cells	  they	  produce	  albumin	  and	  express	  miR122	  and	  HCV	  entry	  factors.	  They	  simultaneously	  lose	  foetal-­‐specific	  markers	  suggesting	  they	  are	  differentiating	  towards	  adult	  hepatocytes,	  although	  culture	  methods	  have	  not	  yet	  driven	  these	  cells	  to	  terminal	  differentiation	  (Si-­‐Taybe,	  et	  al	  2009;	  Schwartz	  et	  al,	  2011).	  These	  cells	  support	  the	  entire	  HCV	  lifecycle,	  including	  replication	  and	  production	  of	  infectious	  virus	  (Schwartz	  et	  al,	  2011)	  and	  have	  been	  used	  to	  study	  HCV	  and	  host	  response.	  The	  particular	  benefit	  of	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these	  cells	  is	  allowing	  a	  personalized	  approach	  to	  studying	  host	  genetics	  and	  response	  to	  virus	  infection.	  	  
1.5.4 Animal	  Models	  	  	  	  
	   Until	  recently,	  animal	  models	  to	  study	  HCV,	  which	  are	  the	  ‘holy	  grail’	  in	  studying	  biological	  systems	  and	  viral	  infection,	  have	  eluded	  HCV	  researchers.	  Chimpanzees,	  which	  are	  the	  only	  known	  animal	  host	  for	  hepatitis	  C	  are	  not	  amenable	  to	  research,	  due	  to	  heavy	  ethical	  restrictions,	  however	  small	  primate	  models,	  based	  on	  GB-­‐virus	  infection	  do	  exist	  (Marnata	  et	  al,	  2015;Li	  et	  al,	  2014).	  Mouse	  models	  using	  chimeric	  humanised	  mouse	  models	  and	  grafted	  humanised	  immune	  systems	  also	  exist	  and	  have	  allowed	  the	  study	  of	  HCV	  pathophysiology	  and	  therapeutic	  targets	  (reviewed	  in	  Kremsdorf	  and	  Strick-­‐Marchland,	  2017).	  Billerbeck	  et	  al	  (2017)	  have	  developed	  a	  small	  animal	  model	  system	  using	  rats	  that	  are	  natural	  hosts	  for	  Norway	  rat	  hepacivirus	  (NrHV)	  which	  is	  a	  flavivirus	  very	  closely	  related	  to	  HCV.	  This	  is	  a	  very	  exciting	  development	  in	  the	  field	  of	  HCV	  research	  and	  will	  allow	  study	  of	  viral	  host	  interaction,	  particularly	  host	  immune	  response	  and	  allow	  significant	  steps	  forward	  with	  regard	  to	  vaccine	  development.	  	  	  	   There	  has	  been	  significant	  advancement	  in	  the	  development	  of	  model	  systems	  to	  study	  HCV,	  each	  with	  their	  own	  advantages.	  However,	  most	  of	  our	  understanding	  about	  the	  viral	  lifecycle	  has	  come	  from	  using	  the	  easily	  available	  and	  robust	  systems	  of	  hepatoma	  cells,	  particularly	  Huh-­‐7	  and	  Huh-­‐7.5.	  Using	  a	  more	  differentiated	  version	  of	  these	  cells	  is	  likely	  to	  represent	  a	  ‘middle	  ground’	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and	  allow	  significant	  strides	  forward	  understanding	  how	  the	  virus	  replicates	  in	  
vivo	  and	  host	  cellular	  response.	  	  	   	  
1.6:	  Co-­‐infection	  	   	  HCV	  can	  co-­‐infect	  alongside	  other	  viruses,	  particularly	  other	  hepatitis	  virus,	  and	  HIV.	  Globally,	  HIV	  and	  HCV	  co-­‐infection	  is	  a	  major	  concern,	  with	  overlapping	  modes	  of	  transmission	  and	  at-­‐risk	  populations.	  The	  following	  section	  briefly	  considers	  the	  HIV	  lifecycle	  and	  models	  to	  study	  the	  interplay	  between	  HIV	  and	  HCV	  infections.	  	  
1.6.1	  HIV	  virus	  	  	  	   Human	  Immune	  deficiency	  virus,	  a	  single	  stranded	  RNA	  virus,	  is	  a	  lentivirus,	  a	  subgroup	  of	  retroviridae.	  There	  are	  two	  subtypes	  of	  HIV;	  HIV-­‐1	  and	  HIV-­‐2.	  HIV-­‐1	  is	  the	  most	  virulent	  and	  geographically	  widespread	  and	  consequently	  is	  responsible	  for	  most	  of	  the	  HIV	  infections	  worldwide	  (Gilbert	  et	  al,	  2003	  Reeves	  and	  Doms,	  2002).	  The	  virus	  causes	  HIV	  infection	  in	  humans	  and,	  if	  left	  untreated,	  develops	  into	  the	  acquired	  immune	  deficiency	  syndrome	  (AIDS)	  (Levy,1993).	  	  	  Figure	  1.14	  gives	  an	  overview	  of	  the	  HIV	  viral	  lifecycle	  and	  major	  host	  cell	  factors	  that	  interact	  with	  the	  virus	  (Barré-­‐Sinoussi	  et	  al,	  2013).	  Briefly,	  the	  HIV	  virion	  contains	  two	  copies	  of	  single	  stranded	  RNA,	  surrounded	  by	  a	  lipid-­‐bilayer	  envelope.	  The	  surface	  glycoproteins,	  gp120	  and	  gp41,	  which	  are	  products	  of	  the	  ‘env’	  gene	  are	  embedded	  within	  this	  layer,	  and	  form	  the	  outermost	  surface	  of	  the	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response, resistance development and 
disease progression. The variations in the 
immunological and virological outcomes 
depend on a complex balance of viral and 
host factors, including human leukocyte 
antigen (HLA) variants, which can modu-
late both innate and adaptive immune 
responses. Several HLA-B alleles (includ-
ing HLA-B*57, HLA-B*27 and HLA-B*13) 
have been consistently associated with viral 
control, including in interaction with KIR 
genotypes40–42.
The treatment revolution. From a clinical 
perspective, the outcome of HIV infec-
tion over the past three decades has been 
revolutionized by considerable progress in 
the therapeutic options available, which has 
transformed HIV infection from a fatal to 
a manageable chronic disease that has little 
effect on life expectancy.
At the time of the first reports of AIDS, 
clinicians could only treat the opportunistic 
infections associated with the disease with 
limited success. Only when HIV was identi-
fied as the virus responsible for the disease, 
and its life cycle was characterized, were the 
medical and scientific communities able to 
start investigating antiretroviral approaches.
The first step in HIV therapy was made 
in 1987, when a clinical trial showed that 
azidothymidine (AZT; also known as zido-
vudine) decreased mortality and opportun-
istic infections in patients with AIDS43. AZT, 
which had been originally synthesized as 
an anticancer treatment, was found to also 
block the reverse transcription step of the 
HIV-1 life cycle44. However, viral resistance 
quickly developed, and so new drugs had to 
be developed on the basis of insights into the 
HIV replication cycle and how to target it.
Indeed, almost a decade later, a major 
breakthrough was made with the introduc-
tion of a therapy that combined several 
drugs to limit the development of resistance. 
Studies showed that the introduction of a 
protease inhibitor alongside two nucleoside 
reverse transcriptase inhibitors (NRTIs) 
in combination antiretroviral therapy 
(ART) markedly reduced morbidity and 
mortality45–47.
Clinical research continues to improve 
the therapeutic options available, with the 
aim of successfully controlling viral replica-
tion with minimal side effects and manage-
able treatment regimens. Several studies 




































NATURE REVIEWS | 90:;<=0<><?@)  VOLUME 11 | DECEMBER 2013 | 483
© 2013 Macmillan Publishers Limited. All rights reserved
	   59	  
During	  the	  process	  of	  viral	  replication	  HIV	  produces	  a	  number	  of	  regulatory	  proteins,	  other	  than	  vpu,	  vif	  and	  vpx	  (described	  in	  Figure	  1.14).	  Tat	  accelerates	  the	  availability	  of	  the	  viral	  RNA	  for	  virus	  production	  (Fields	  Virology,	  2013).	  Rev	  controls	  the	  splicing	  length	  of	  the	  mRNA,	  allowing	  regulatory	  proteins	  to	  be	  available	  early	  in	  replication,	  boosting	  the	  production	  of	  virus	  (Li	  and	  De	  Clercq,	  2016).	  Nef	  downregulates	  CD4	  expression	  on	  the	  cell	  surface,	  thereby	  reducing	  the	  immune	  response	  to	  an	  infected	  cell	  (Malim	  and	  Emerman,	  2008).	  HIV	  has	  devised	  a	  huge	  number	  of	  mechanisms	  to	  evade	  host	  mechanisms	  of	  viral	  control	  and	  allow	  viral	  persistence	  and	  pathogenicity.	  	   Human	  cells	  that	  support	  HIV	  entry	  and	  replication	  include	  CD4+	  T	  cells,	  monocytes,	  macrophages	  and	  dendritic	  cells	  (Fields	  Virology,	  2013).	  Following	  initial	  infection	  the	  majority	  of	  CD4	  positive	  T	  cells	  that	  are	  infected	  immediately	  start	  producing	  new	  virus.	  Dendritic	  cells	  are	  particularly	  important	  at	  mucosal	  surfaces	  where	  they	  can	  capture	  virus	  and	  become	  infected	  using	  the	  C-­‐type	  lectin	  DC-­‐SIGN	  for	  attachment	  (reviewed	  in	  Wu	  and	  KewalRemani,	  2006).	  HIV,	  like	  many	  other	  viruses	  can	  be	  transmitted	  cell	  free	  or	  directly	  cell-­‐to-­‐cell.	  Cell–to-­‐cell	  transmission	  in	  HIV	  between	  and	  within	  cell	  types	  at	  the	  ‘virological	  synapse’	  is	  highly	  efficient	  and	  contributes	  significantly	  to	  its	  virulence	  (reviewed	  in	  Costiniuk	  and	  Janabian,	  2014;	  Sattentau,	  2008	  ).	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1.6.2	  Viral	  Interplay	  	  	   	  The	  interaction	  between	  HIV	  and	  HCV	  affects	  the	  transmission	  and	  natural	  history	  of	  HCV	  infection,	  although	  the	  impact	  on	  HIV	  progression	  is	  much	  less	  clear.	  	  	  
Impact	  of	  HIV	  on	  HCV	  transmission	  	   The	  largest	  burden	  of	  HIV/HCV	  co-­‐infection	  currently	  exists	  within	  high-­‐risk	  groups,	  such	  as	  intravenous	  drug	  users	  (IVDU)	  and	  men	  who	  have	  sex	  with	  men	  (MSM)	  (Nishijima	  et	  al,	  2014).	  There	  is	  little	  evidence	  to	  suggest	  that	  HIV	  infection	  per	  se	  alters	  HCV	  transmission	  in	  IVDU,	  although	  these	  individuals	  are	  more	  likely	  to	  develop	  chronic	  HCV	  than	  non-­‐HIV	  infected	  IVDU	  (Chew	  and	  Bhattacharya,	  2016).	  There	  have	  also	  been	  reports	  of	  epidemics	  of	  HCV	  transmission	  in	  HIV-­‐infected	  MSM,	  suggesting	  that	  the	  risk	  of	  sexually	  transmitted	  HCV	  is	  altered	  in	  the	  presence	  of	  HIV	  infection	  (Nishijima	  et	  al,	  2014;	  Sánchez	  et	  al,	  2013,	  Wandeler	  et	  al,	  2012).	  There	  is	  inconclusive	  evidence	  as	  to	  why	  there	  is	  increased	  transmission	  risk	  in	  these	  individuals.	  HCV	  RNA	  levels	  are	  higher	  in	  the	  semen	  and	  blood	  of	  men	  co-­‐infected	  with	  HIV	  and	  this	  may	  increase	  the	  likelihood	  that	  co-­‐infected	  subjects	  will	  transmit	  infection	  (Briat	  et	  al,	  2005;	  Hsieh	  et	  al,	  2014).	  	  	  HIV	  infection	  also	  significantly	  impacts	  HCV	  perinatal	  transmission.	  In	  developed	  countries	  the	  majority	  of	  children	  with	  HCV	  are	  vertically	  infected	  	  (Mohan	  et	  al,	  2010).	  Children	  infected	  with	  HCV	  represents	  a	  small	  group	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compared	  to	  adults	  infected	  with	  HCV;	  it	  is	  estimated	  that	  between	  0.05	  and	  5%	  of	  children	  worldwide	  are	  infected	  with	  HCV	  (Arshad	  et	  al,	  2011).	  They	  are	  an	  important	  group	  in	  whom	  infection	  is	  potentially	  preventable,	  but	  understanding	  of	  vertical	  transmission	  is	  limited.	  Interestingly,	  children	  infected	  vertically	  with	  HCV	  are	  less	  likely	  to	  clear	  infection,	  suggesting	  that	  pathways	  of	  viral	  persistence	  are	  altered	  by	  the	  route	  of	  HCV	  transmission	  (Abdel-­‐Hady	  et	  al,	  2011).	  	  Mother	  to	  child	  HCV	  transmission	  rates	  are	  around	  5-­‐10%	  (Yeung	  et	  al,	  2010)	  and	  this	  increases	  fourfold	  when	  mothers	  are	  co-­‐infected	  with	  HIV	  (Gibb	  et	  al,	  2000;	  European	  Paediatric	  Hepatitis	  C	  virus	  network,	  2001;	  Marine-­‐Barjoan	  et	  al,	  2007).	  This	  was	  thought	  to	  be	  related	  to	  the	  higher	  HCV	  viral	  load	  in	  co-­‐infected	  mothers	  who	  transmitted	  virus,	  although	  this	  has	  not	  been	  consistently	  reported	  (Conte	  et	  al,	  2000;	  Zanetti	  et	  al,	  1995).	  Furthermore,	  it	  is	  feasible	  that	  altered	  immunity	  caused	  by	  HIV	  infection	  may	  alter	  innate	  or	  cellular	  responses	  at	  the	  fetal/maternal	  interface	  (Le	  Campion	  et	  al,	  2012).	  As	  HIV	  infects	  trophoblasts	  (Vidricaire	  et	  al,	  2007)	  it	  is	  also	  possible	  that	  the	  placental	  barrier	  function	  is	  affected	  by	  co-­‐infection	  leading	  to	  increased	  HCV	  transmission	  (Kwiek	  et	  al,	  2006).	  Interestingly,	  Azzari	  et	  al	  reported	  that	  vertical	  transmission	  of	  HCV	  is	  related	  to	  maternal	  peripheral	  blood	  mononuclear	  cell	  (PBMC)	  infection	  (Azzari	  et	  al,	  2009),	  therefore	  raising	  the	  hypothesis	  that	  PBMC	  could	  act	  as	  a	  viral	  vector	  for	  HCV	  in	  the	  new	  host	  (Le	  Campion	  et	  al,	  2012).	  Virus	  associated	  with	  cells	  that	  are	  permissive	  to	  HIV,	  such	  as	  T	  cells,	  raises	  an	  important	  hypothesis	  for	  altered	  HCV	  transmission	  in	  the	  presence	  of	  HIV.	  
Figure	  1.15	  outlines	  potential	  pathways	  of	  HCV	  transmission	  to	  the	  foetus.	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Figure	  1.15	  Models	  of	  HCV	  vertical	  transmission	  	  From	  Le	  Campion,	  2012	  and	  reproduced	  with	  permission.	  	  The	  placenta	  consists	  of	  fetally	  derived	  chorionic	  villi	  bathed	  in	  maternal	  blood.	  These	  have	  a	  stromal	  core	  with	  blood	  vessels	  and	  an	  outer	  layer	  of	  cytotrophoblasts.	  The	  fetal/maternal	  interface	  is	  formed	  by	  syncytiotrophoblasts	  and	  these	  mediate	  exchange	  between	  the	  mother	  and	  foetus.	  HCV	  infection	  could	  occur	  via;	  direct	  trancytosis	  through	  the	  cytotrophoblast	  layer,	  or	  mediated	  by	  HCV	  surface	  receptors,	  or	  blood	  mixing	  by	  micro-­‐transfusions.	  Given	  that	  there	  is	  no	  HCV	  RNA	  found	  in	  amniotic	  fluid	  (Delorme-­‐Axford	  et	  al,	  2013),	  it	  is	  likely	  that	  HCV	  is	  transferred	  across	  the	  placenta,	  rather	  than	  infecting	  it	  directly.	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Impact	  of	  HIV	  on	  HCV	  disease	  	  	  	   HIV	  is	  also	  known	  to	  influence	  the	  progression	  of	  HCV	  disease,	  particularly	  liver	  disease,	  which	  prior	  to	  the	  DAA-­‐era,	  was	  the	  leading	  cause	  of	  death	  in	  HIV	  infected	  individuals	  (Chew	  and	  Bhattacharya,	  2016).	  It	  has	  been	  shown	  that	  HIV	  co-­‐infection	  is	  associated	  with	  higher	  levels	  of	  HCV	  viraemia	  (Ghany	  et	  al,	  1996;	  Thomas	  et	  al,	  2000;	  Matthews-­‐Greer	  et	  al,	  2001),	  which	  is	  associated	  with	  lowered	  CD4+	  T	  cells	  (Thomas	  et	  al,	  1996,	  Martinez-­‐Sierra	  et	  al,	  2003)	  suggesting	  cellular	  responses	  are	  important	  in	  controlling	  HCV	  replication	  during	  chronic	  HCV	  infection.	  Furthermore,	  co-­‐infection	  has	  been	  associated	  with	  reduced	  ability	  for	  spontaneous	  HCV	  clearance	  (Seal	  et	  al,	  2007)	  resulting	  from	  impaired	  innate	  and	  cellular	  immune	  responses	  (reviewed	  in	  Chew	  and	  Bhattacharya,	  2016).	  Furthermore	  there	  is	  accelerated	  hepatic	  fibrosis	  in	  co-­‐infected,	  as	  compared	  to	  mono-­‐infected	  patients.	  This	  is	  as	  a	  result	  of	  complex	  interplay	  between	  immune	  dysregulation,	  microbial	  translocation	  and	  infection	  and	  interaction	  of	  HIV	  with	  intra-­‐hepatic	  cells	  (Chew	  and	  Bhattacharya,	  2006).	  	  	  
Impact	  of	  HCV	  on	  HIV	  disease	  	  	  	   The	  effect	  of	  HIV	  co-­‐infection	  on	  HCV	  transmission	  and	  disease	  is	  well	  studied	  and	  described.	  However,	  the	  impact	  of	  HCV	  on	  HIV-­‐related	  disease	  is	  much	  less	  clear.	  Much	  of	  the	  initial	  data	  on	  this,	  from	  the	  pre-­‐	  and	  post-­‐	  antiretroviral	  (ART)	  era	  is	  inconclusive	  in	  its	  findings.	  There	  is	  some	  evidence	  that	  HIV	  clinical	  progression	  is	  accelerated	  in	  co-­‐infected	  patients	  (Greub	  et	  al,	  2000;	  Piroth	  et	  al,	  1998),	  but	  this	  is	  not	  associated	  with	  immunological	  decline	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(CD4	  T	  cell	  count)	  (Piroth	  et	  al,	  1998).	  There	  may	  be	  some	  impact	  of	  HCV	  on	  CD4	  T	  cell	  recovery	  after	  initiation	  of	  ART	  (Law	  et	  al,	  2004;	  Greub	  et	  al,	  2000),	  possibly	  mediated	  by	  chronic	  immune	  activation	  driven	  by	  HCV	  (Sajadi	  et	  al,	  2012).	  	  	  	   The	  interplay	  between	  HIV	  and	  HCV	  is	  complex.	  Overall	  HIV	  has	  a	  significant	  effect	  on	  HCV	  transmission	  and	  clinical	  progression,	  particularly	  accelerated	  liver	  disease	  and	  immune	  dysregulation.	  Developing	  models	  of	  co-­‐infection	  will	  allow	  further	  studies	  into	  the	  mechanisms	  of	  viral	  interaction	  and	  provide	  areas	  for	  future	  investigation.	  	  	  
1.6.3	  Studying	  HIV/HCV	  co-­‐infection	  	  	  	  	   Many	  published	  studies	  have	  used	  clinical	  material	  derived	  from	  patients	  in	  order	  to	  study	  the	  effect	  of	  viral	  co-­‐infection	  on	  cellular	  immune	  response	  in	  
vivo.	  However,	  there	  are	  limited	  mechanistic	  studies	  investigating	  the	  interplay	  between	  these	  viruses	  and	  their	  respective	  life	  cycles.	  	  	   Studies	  of	  viral	  interplay	  in	  vitro	  are	  limited	  by	  the	  lack	  of	  cell	  systems	  that	  support	  both	  HIV	  and	  HCV.	  There	  are	  studies	  looking	  at	  HIV	  infection	  in	  hepatoma	  cells	  and	  the	  impact	  on	  HCV	  replication.	  Kong	  et	  al	  (2014)	  showed	  that	  HIV	  infection	  of	  hepatocytes	  is	  associated	  with	  an	  increase	  in	  HCV	  RNA.	  In	  addition	  Peng	  et	  al	  (2015)	  showed	  the	  HIV	  vpr	  can	  upregulate	  miR122	  and	  promote	  HCV	  replication	  by	  hepatocytes.	  These	  studies	  may	  provide	  insight	  into	  HCV	  associated	  liver	  disease	  in	  HIV	  infection.	  In	  addition	  to	  hepatoma	  cells,	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which	  appear	  to	  support	  very	  low	  level	  HIV	  replication	  (Xiao	  et	  al,	  2008),	  there	  has	  been	  much	  debate	  within	  HCV	  research	  whether	  PBMCs	  can	  support	  HCV	  infection.	  Early	  studies	  reported	  detectable	  negative	  strand	  HCV	  RNA	  (the	  replicative	  intermediate)	  in	  PMBC	  of	  infected	  patients	  (Qian	  et	  al,	  1992;	  Zignego	  et	  al,	  1992;	  Wang	  et	  al	  1992;	  Muller	  et	  al,	  1993)	  but	  the	  specificity	  of	  these	  assays	  have	  since	  been	  questioned	  (McGuinness	  et	  al,	  1994;	  Lanford	  et	  al,	  1995).	  Studies	  using	  highly	  sensitive	  assays	  detecting	  HCV	  RNA	  intermediates	  have	  failed	  to	  consistently	  show	  evidence	  of	  replicative	  HCV	  in	  PBMC	  in	  mono	  or	  co-­‐infected	  patients	  (Boisvert	  et	  al,	  2001;	  Lin,	  et	  al,	  2002;	  Laskus	  et	  al,	  2007,	  Blackard	  et	  al,	  2007).	  Marukian	  et	  al	  (2008)	  showed	  robustly,	  that	  PBMCs	  and	  specific	  cell	  subsets	  do	  not	  support	  ongoing	  HCV	  replication,	  are	  not	  permissive	  to	  HCVpp	  and	  that	  even	  if	  entry	  is	  bypassed	  are	  unable	  to	  translate	  virus.	  Azzari	  et	  al	  (2000)	  showed	  HCV	  positive	  and	  negative	  strand	  RNA	  detectable	  in	  PMBC	  in	  maternal	  blood	  associated	  with	  increased	  HCV	  maternal	  to	  child	  transmission	  and	  suggested	  that	  PBMC	  may	  act	  as	  a	  cell	  vector	  for	  virus	  as	  maternal	  cells	  cross	  into	  the	  fetal	  circulation	  (Petit	  et	  al	  1995).	  Taken	  together	  this	  would	  suggest	  that	  virus	  is	  able	  to	  associate	  with	  immune	  cells,	  but	  fails	  to	  replicate.	  	  	  Stamataki	  et	  al	  described	  an	  elegant	  model	  in	  which	  B	  cells	  can	  associate	  with	  and	  internalize	  HCV	  particles.	  These	  are	  transmitted	  to	  permissive	  cells	  in	  the	  liver	  allowing	  cell-­‐mediated	  trans-­‐infection	  of	  virus.	  Furthermore	  HCV	  infection	  increased	  the	  ability	  of	  B	  cells	  to	  adhere	  to	  hepatoma	  cells	  in	  vitro	  (Stamataki,	  Blood	  2009).	  This	  raises	  the	  possibility	  of	  interactions	  between	  HCV	  and	  cells	  that	  support	  HIV	  infection	  as	  a	  model	  system	  for	  investigating	  transmission	  in	  co-­‐infection.	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1.7 :	  Project	  Aims	  	  	  The	  overall	  aims	  of	  this	  project	  were	  to	  develop	  and	  characterize	  a	  differentiated	  model	  system	  to	  study	  the	  HCV	  lifecycle	  and	  key	  viral	  host	  interactions.	  Utilizing	  the	  methodology	  developed	  by	  Sainz	  (2006)	  to	  differentiate	  hepatoma	  cells	  into	  a	  more	  physiological	  cell	  system,	  we	  aimed	  to	  -­‐ Characterize	  differentiated	  cells	  with	  respect	  to	  important	  host	  factors	  that	  are	  known	  to	  interact	  with	  HCV	  -­‐ Study	  the	  viral	  lifecycle	  in	  these	  cells.	  Hepatoma	  cells	  support	  high	  levels	  of	  viral	  replication	  compared	  to	  primary	  cells,	  but	  the	  mechanism	  behind	  this	  is	  not	  fully	  known.	  	  -­‐ Study	  viral	  dissemination	  routes	  in	  differentiated	  cells	  given	  that	  HCV	  is	  known	  to	  infect	  hepatocytes	  efficiently	  via	  cell-­‐to-­‐cell	  transmission.	  	  	  Furthermore,	  we	  aimed	  to	  develop	  a	  model	  to	  study	  novel	  routes	  of	  viral	  dissemination	  that	  may	  occur	  in	  vivo	  including	  lymphocyte-­‐associated.	  We	  aimed	  to	  use	  this	  model	  to	  allow	  us	  to	  study	  HIV/HCV	  co-­‐infection	  and	  viral	  interplay.	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Chapter	  2:	  Materials	  and	  
Methods	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2.1:	  Cell	  lines	  and	  virus	  	  	  
2.1.1	  Cell	  lines	  and	  primary	  cells	  	   Huh-­‐7,	  Huh	  7.5,	  293T	  cells,	  HepG2	  cells	  and	  the	  H77	  subgenomic	  replicon	  (Blight,	  2002)	  were	  provided	  by	  C.	  Rice	  (Rockefeller	  University,	  New	  York,	  NY).	  H77	  replicon	  in	  Huh-­‐7	  cells	  (Ikeda	  et	  al,	  2002)	  were	  provided	  by	  S	  Lemon	  (University	  of	  Texas	  Medical	  Branch	  at	  Galveston,	  Texas).	  Huh-­‐7	  cells	  containing	  the	  replicating	  subgenomic	  JFH1	  HCV	  strain	  and	  expressing	  an	  HLA-­‐A2	  receptor	  and	  luciferase	  reporter	  (Jo	  et	  al,	  2009)	  were	  provided	  by	  R	  Thimme	  (University	  of	  Freiburg,	  Germany).	  JW	  cells	  were	  a	  gift	  from	  J	  Witteveld	  and	  P	  Simmonds	  (University	  of	  Edinburgh,	  UK).	  All	  cells	  were	  propagated	  in	  Dulbecco’s	  modified	  Eagle	  medium	  (DMEM)	  supplemented	  with	  10%	  foetal	  bovine	  serum	  (FBS),	  1%	  nonessential	  amino	  acids	  and	  1%	  penicillin/streptomycin	  (Invitrogen,	  Carlsbad,	  CA)	  at	  37°C	  in	  5%	  CO2.	  G418	  (Invivogen)	  at	  1mg/ml	  was	  added	  to	  the	  media	  of	  the	  replicon	  cell	  lines.	  The	  LucA2	  cells	  required	  additional	  Blasticidin	  (Invivogen)	  6	  micrograms/ml	  added	  to	  the	  media.	  	  	  1.5%	  (vol/vol)	  dimethylsulfoxide	  (DMSO)	  was	  added	  to	  the	  media	  of	  Huh	  7	  and	  Huh	  7.5	  cells	  for	  7	  days	  prior	  to	  use	  and	  replenished	  every	  3-­‐4	  days	  as	  previously	  described	  (Sainz	  and	  Chisari,	  2006).	  DMSO	  treated	  cells	  were	  seeded	  at	  3	  x	  104/cm2	  and	  non-­‐DMSO	  treated	  cells	  at	  6	  x	  104/cm2	  for	  all	  experiments	  other	  than	  the	  co-­‐culture.	  	  Primary	  human	  hepatocytes	  (PHH)	  used	  in	  this	  study	  were	  a	  kind	  gift	  from	  Dr	  Ragai	  Mitry	  (King’s	  College,	  London).	  They	  were	  isolated	  according	  to	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protocol	  (Mitry,	  2009)	  and	  RNA	  was	  extracted	  by	  G	  Wilson	  (University	  of	  Birmingham,	  UK).	  	  	  T	  cells	  lines	  Jurkat,	  SupT1	  and	  MOLT4	  (ATCC)	  were	  propogated	  in	  RPMI	  1640	  medium	  with	  10%	  Fetal	  Bovine	  Serum,	  1%	  penicillin/streptomycin,	  1%	  non-­‐essential	  amino	  acids	  and	  1%	  L-­‐Glutamine.	  	  	   Primary	  Blood	  Lymphocytes	  were	  isolated	  from	  whole	  blood	  from	  healthy	  anonymous	  donors	  using	  Lympholyte-­‐H	  as	  per	  manufacturers	  instructions	  (Cedarlane	  Laboratories,	  Ontaria,	  Canada).	  Briefly,	  whole	  blood	  was	  layered	  over	  Lympholyte-­‐H	  in	  a	  2:1	  ratio	  using	  a	  50ml	  centrifuge	  tube	  and	  then	  centrifuged	  at	  room	  temperature	  for	  20	  minutes	  at	  800g.	  Post	  centrifugation	  the	  lymphocyte	  layer	  was	  removed	  by	  pipette	  and	  transferred	  to	  a	  new	  50ml	  centrifuge	  tube.	  The	  cells	  were	  then	  pelleted	  and	  washed	  three	  times	  in	  serum	  free	  RPMI.	  The	  resultant	  cell	  pellet	  was	  then	  re-­‐suspended	  in	  RPMI/10%	  FCS	  and	  CD4+	  T	  cells	  were	  extracted.	  	  	  T	  cells	  were	  purified	  manually	  by	  negative	  selection	  using	  the	  Easysep	  CD4+	  T	  cell	  Enrichment	  Kit	  and	  “The	  Big	  Easy”	  Silver	  EasySep	  magnet	  according	  to	  manufacturer’s	  instructions	  (StemCell	  Technologies,	  Vancouver,	  Canada).	  Flow	  cytometry	  analysis	  showed	  99%	  of	  cells	  were	  CD4+	  T	  cells	  within	  the	  isolate.	  Isolated	  CD4+	  T	  cells	  were	  stimulated	  using	  anti-­‐CD3	  (OKT3)	  +	  anti-­‐CD28	  (Invitrogen)	  at	  1mcg/ml	  and	  cultured	  in	  complete	  RPMI	  1640	  medium	  in	  the	  presence	  of	  200	  IU/ml	  of	  IL-­‐2	  (resulting	  in	  “stimulated	  T	  cell	  blasts”).	  Cells	  were	  used	  5-­‐7	  days	  post	  isolation.	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  The	  HIV	  indicator	  cell	  line	  GHOST	  CXCR4+	  CCR5+	  cells	  were	  purchased	  from	  NIH	  AIDS	  Reagent	  programme	  and	  maintained	  in	  DMEM	  with	  10%	  foetal	  bovine	  serum	  and	  high	  glucose	  DMEM,	  90%	  and	  supplemented	  with	  500	  μg/ml	  G418,	  100	  μg/ml	  hygromycin,	  pen/strep,	  and	  1	  μg/ml	  puromycin.	  	  	  ACH2	  cells	  are	  an	  HIV-­‐1	  latent	  T	  cell	  clone	  and	  were	  obtained	  through	  the	  NIH	  AIDS	  Reagent	  Program,	  from	  Dr.	  Thomas	  Folks	  (Clouse,	  1989;	  Folks,	  1989).	  Cells	  were	  maintained	  in	  RPMI	  1640	  supplemented	  with	  10	  mM	  HEPES,	  2	  mM	  L-­‐glutamine,	  90%;	  heat	  inactivated	  fetal	  bovine	  serum,	  10%.	  	  
2.1.2	  Antibodies	  	  	   The	  primary	  antibodies	  were	  anti-­‐NS5A	  9E10	  (C.	  Rice,	  Rockefeller	  University),	  anti-­‐CD81	  (2.131),	  anti–claudin-­‐1	  (Abnova,	  Taipei,	  Taiwan	  and	  R&D,	  Minneapolis,	  MN),	  anti-­‐occludin	  (Invitrogen),	  anti–ZO-­‐1	  (Invitrogen)	  and	  anti-­‐MRP2	  (Sigma	  Aldrich).	  Intracellular	  p24	  staining	  used	  LIVE/DEAD	  fixable	  violet	  (Invitrogen),	  anti-CD4-APC antibody (BD Biosciences)	  and	  KC57-RD1 P24 
specific antibody (Beckman Coulter).	  Immunoglobulin	  (Ig),	  used	  in	  the	  cell-­‐to-­‐cell	  experiments	  was	  derived	  from	  healthy	  volunteers	  (HCV(-­‐)IgG)	  and	  chronically	  HCV-­‐infected	  donors.	  This	  was	  then	  purified	  by	  protein	  G	  affinity	  chromatography	  (HCV(+)IgG)	  as	  previously	  reported	  (Grove,	  2008).	  	  Fluorescent	  secondary	  antibodies	  Alexa-­‐Fluor	  488	  anti-­‐mouse,	  anti-­‐rat	  and	  anti-­‐rabbit	  IgG	  and	  RPE	  IgG2a	  anti-­‐mouse	  were	  obtained	  from	  Invitrogen.	  7	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aminoactinomycin	  (7AAD)	  for	  analysis	  of	  the	  cell	  cycle	  was	  obtained	  from	  Sigma	  Aldrich.	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Table	  2.1:	  Cell	  lines	  used,	  tissue	  type,	  growth	  media	  and	  source	  	  
Cell	  Type	  	   Tissue	  type	  	   Growth	  
media	  	  
Source	  	  Huh-­‐7	   Human	  Hepatoma	   DMEM	   C	  Rice,	  Rockefeller	  University,	  NY,	  USA	  Huh-­‐7.5	   Human	  Hepatoma	   DMEM	   C	  Rice,	  Rockefeller	  University,	  NY,	  USA	  Primary	  Human	  Hepatocytes	   Human	  Liver	  	   Williams	  E	   Ragai	  Mitry,	  Kings	  College	  London,	  UK	  HepG2-­‐CD81	   Human	  Hepatoblastoma	   DMEM	   In	  house	  HepG2-­‐NTCP-­‐IOV	   Human	  Hepatoblastoma	   DMEM	   U	  Protzer,	  TUM,	  München,	  Germany	  A2-­‐HCV	  replicon-­‐	  luciferase	  Huh-­‐7	  cells	   Human	  Hepatoma	   DMEM	   Robert	  Thimme,	  University	  of	  Freiburg	  H77	  replicon	  Huh-­‐7	  cells	   Human	  Hepatoma	   DMEM	   S	  Lemon,	  Texas	  University,	  USA	  	  JW	  cells	   Human	  Hepatoma	  stably	  expressing	  SEC14L2	   DMEM	   J	  Witteld,	  University	  of	  Edinburgh,	  UK	  Caco-­‐2	   Human	  Colonic	  Adenocarcinoma	   DMEM	   ATCC	  293T	  	   Human	  Embryonic	  Kidney	  	   DMEM	   ATCC	  Jurkat	   Human	  T	  cell	  leukaemia	  	   RPMI-­‐1640	   ATCC	  MOLT-­‐4	   Human	  T	  cell	  lymphoblastic	  leukaemia	  	   RPMI-­‐1640	   ATCC	  Sup-­‐T1	   Human	  T	  cell	  lymphoblastic	  lymphoma	   RPMI-­‐1640	   ATCC	  ACH2	  	  	   	  
Subclone	  A3.01	  of	  CEM,	  a	  human	  T	  cell	  lymphoblastic	  leukaemia	  line.	  Harbours	  a	  single	  copy	  HIV-­‐1	  proviral	  DNA	  	  
RPMI-­‐1640	   W	  Paxton,	  University	  of	  Liverpool,	  UK	  
Primary	  CD4+	  T	  cells	   PBMC	  from	  healthy	  anonymous	  donors	   RPMI-­‐1640	   Queen	  Elizabeth	  Hospital,	  Birmingham,	  UK	  GHOST	  CXCR4+	  CCR5+	   Human	  Osteosarcoma	  cells.	  Contains	  hGFP	  under	  transcriptional	  control	  of	  HIV-­‐2	  LTR	  promoter	  and	  expresses	  HIV-­‐1	  co-­‐receptors	  CXCR4	  and	  CCR5	  
	   NIH	  AIDS	  Reagant	  Programme,	  Germantown,	  US	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Table	  2.2:	  Primary	  Antibodies	  used	  	  	  
Antibody	  	   Antigen	   Type	  	   Specifi
city	  






Anti-­‐NS5A	  (NE10A)	   HCV	  NS5A	   Hybridoma	  Supernatant	   Mono	  clonal	   Mouse	  	   2	   IF,	  Flow	  	   Rockefeller	  University,	  NY,	  US	  Anti-­‐CD81	  (2s131)	   Human	  CD81	   Purified	  IgG	   Mono	  clonal	   Mouse	   1	   IF	   In	  house	  	  Anti-­‐Claudin1	   Human	  Claudin1	   Purified	  IgG	   Poly	  clonal	   Rabbit	  	   1	   IF	   Zymed,	  CA,	  US	  Anti-­‐ZO1	   Human	  ZO-­‐1	   Purified	  IgG	   Poly	  clonal	  	   Rabbit	  	   1	   IF	   Zymed,	  CA,	  US	  Anti-­‐MRP2	   Human	  MRP2	   Purified	   Mono	  clonal	  	   Mouse	  	   2	   IF	   Abcam,	  UK	  Anti-­‐Occludin	   Human	  Occludin	   Purified	  IgG	   Poly	  clonal	   Rabbit	  	   1	   IF	   Zymed,	  CA,	  US	  Anti-­‐CD4-­‐APC	   Human	  CD4	   Purified	  IgG	   Mono	  clonal	   Mouse	  	   3	   Flow	  	   BDBiosciences,	  	  Anti-­‐p24-­‐FITC	  (KC57	  RD1)	  
HIV-­‐1	  55,	  39,	  33	  and	  24	  kDa	  proteins	  	  
Purified	  IgG	   Mono	  clonal	   Mouse	  	   0.5	   Flow	  	   Beckman	  Coulter	  
	  
Table	  2.3	  Secondary	  Antibodies	  used	  	  
	  
Antibody	  	   Antigen	   Type	  	   Specificity	   Species	   Working	  
dilution	  	  
Application	   Source	  	  Mouse	  Alexa-­‐Fluor	  488	   Mouse	  IgG	   Purified	  IgG	  (H+L)	   Polyclonal	  	   Goat	  	   1:500	   IF,	  Flow	   Molecular	  Probes,	  Invitrogen,	  CA	  Rabbit	  Alexa-­‐Flour	  488	   Rabbit	  IgG	   Purified	  IgG	  (H+L)	   Polyclonal	  	   Goat	  	   1:500	   IF	   Molecular	  Probes,	  Invitrogen,	  CA	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2.1.3	  Virus	  
	  
HCVcc	  	   Plasmids	  encoding	  chimeric	  SA13/JFH	  (Jensen	  J	  Infect	  Dis	  2008)	  and	  J6/JFH	  were	  used	  to	  generate	  RNA	  as	  previously	  described	  (Lindenbach,	  2005).	  Briefly,	  RNA	  was	  electroporated	  into	  Huh-­‐7.5	  cells,	  and	  supernatants	  were	  collected	  at	  72	  and	  96	  hours	  and	  stored	  at	  −80°C.	  The	  SA13	  virus	  was	  then	  passaged	  serially	  in	  infected	  Huh	  7.5	  cells	  and	  the	  supernatant	  collected	  and	  stored	  at	  -­‐80°C.	  Infected	  cells	  were	  fixed	  with	  ice-­‐cold	  methanol	  and	  stained	  for	  NS5A	  with	  monoclonal	  antibody	  9E10	  and	  isotype-­‐matched	  Alexa	  488–conjugated	  anti-­‐mouse	  IgG	  (H+L).	  NS5A-­‐positive	  foci	  were	  counted,	  and	  infectivity	  was	  expressed	  as	  focus-­‐forming	  units	  per	  milliliter.	  The	  SA13	  used	  in	  all	  experiments	  had	  an	  infectivity	  of	  2.5	  million	  FFU/ml.	  For	  experiments	  using	  DMSO,	  the	  viral	  inoculum	  was	  added	  to	  cells	  without	  DMSO.	  Cells	  were	  incubated	  with	  virus	  for	  6-­‐8	  hours	  and	  normal	  media	  +/-­‐	  DMSO	  was	  added	  with	  no	  washing	  step.	  	  	  
HCV	  and	  HIV	  Pseudoparticles	  	  	  	   Luciferase	   reporter	   pseudoparticles	   expressing	   a	   panel	   of	   HCV	  envelope	   glycoproteins	   (HCVpp),	   vesicular	   stomatitis	   virus	   G	   glycoprotein	  (VSV-­‐Gpp),	  HIV	  envelopes	  BAL	  and	  LAI	   (gift	   from	  Bill	  Paxton,	  University	  of	  Liverpool,	   UK)	   or	   a	   no-­‐envelope	   control	   were	   generated	   as	   previously	  reported	  (Hsu	  M,	  2003).	  A	  panel	  of	  patient	  derived	  HCV	  pseudoparticles	  was	  gifted	   from	   Stuart	   Ray	   (Johns	   Hopkins	   University,	   Baltimore,	   USA).	  
	   75	  
Supernatants	  were	  harvested	  at	  48h	  post	  transfection,	  clarified,	  and	  filtered	  through	  a	  0.45-­‐μm	  membrane.	  Virus-­‐containing	  medium	  was	  added	  to	  target	  cells	  plated	  in	  96	  well	  plates	  seeded	  at	  7.5	  x	  103	  cells/cm2	  and	  incubated	  for	  72h.	  After	  72h,	  cells	  were	  lysed	  with	  cell	  lysis	  buffer	  (Promega,	  Madison,	  WI)	  and	  luciferase	  activity	  measured	  for	  10s	  in	  a	  luminometer	  (Lumat	  LB	  9507).	  Specific	   infectivity	  was	   calculated	   by	   expressing	   the	   HCV	   signal	   relative	   to	  the	  VSV-­‐G	  luciferase	  signal	  (relative	  light	  units,	  RLU).	  	  
	  
gLUC	  virus	  	  	  	   Huh-­‐7	  cells	  were	  electroporated	  with	  in	  vitro-­‐transcribed	  RNA	  of	  Jc1,	  containing	  the	  Gaussia	  luciferase	  reporter	  gene	  (Jc1gLuc)	  (Gottwein,	  2011)	  or	  replicase-­‐negative	  JC1gLuc-­‐GNN.	  For	  infection	  gLuc	  assays,	  HCVgLuc	  were	  added	  to	  Huh-­‐7	  cells	  seeded	  the	  day	  before	  in	  48-­‐well	  plates	  and	  incubated	  for	  2	  hours	  at	  37°C.	  The	  supernatants	  were	  then	  removed,	  and	  the	  cells	  were	  incubated	  in	  DMEM	  with	  10%	  FBS	  at	  37°C.	  At	  4,	  24,	  48,	  72	  or	  144	  h	  post	  infection	  Gaussia	  luciferase	  assays	  were	  performed	  as	  indicated	  by	  the	  manufacturer	  (Promega).	  Results	  plotted	  are	  the	  luciferase	  signal	  of	  the	  Jc1gLuc	  virus	  over	  the	  GNN	  control.	  	   	  
HIV	  	   The	  full-­‐length	  HIV	  plasmids	  HXb2,	  NL4.3,	  NL4.3	  GFP	  and	  BAL	  were	  gifted	  from	  W	  Paxman	  (University	  of	  Liverpool,	  UK).	  293	  T	  cells	  were	  plated	  on	  Poly-­‐L-­‐lysine	  (Sigma-­‐Aldrich)	  coated	  plates	  and	  the	  plasmids	  were	  transfected	  using	  Fugene-­‐6	  (Promega,	  Canada)	  and	  optimem.	  Cells	  were	  transfected	  for	  6	  hours	  at	  37°	  and	  the	  media	  replaced	  with	  3%	  FBS/DMEM	  without	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Penicillin/Streptomycin.	  Subsequently	  cells	  were	  incubated	  and	  virus	  collected	  at	  48-­‐72	  hours	  post-­‐transfection.	  Virus	  stocks	  were	  pooled,	  clarified	  by	  centrifugation	  at	  2000	  rpm	  for	  5	  minutes	  and	  stored	  in	  aliquots	  at	  -­‐80°C.	  HIV	  titers	  were	  determined	  using	  infection	  of	  Jurkat	  cells	  and	  analysis	  of	  p24	  in	  the	  media	  using	  ELISA,	  or	  using	  the	  HIV	  indicator	  cell	  line	  GHOST	  CXCR4+	  CCR5+.	  	  	  GHOST	  cells	  were	  seeded	  at	  1.5x104/cm2	  in	  a	  48	  well	  plate	  in	  DMEM	  supplemented	  with	  10%	  FCS,	  500	  μg/ml	  G418,	  100	  μg/ml	  hygromycin,	  pen/strep,	  and	  1	  μg/ml	  puromycin.	  HIV-­‐1	  virus	  was	  added	  in	  serial	  dilutions	  for	  48	  hours	  prior	  to	  being	  fixed	  with	  paraformaldehyde	  (PFA)	  (TAAB,	  UK)	  at	  1	  in	  10	  dilution	  for	  20	  minutes.	  GFP	  positive	  cells,	  as	  a	  marker	  of	  HIV	  infectivity,	  were	  visualized	  using	  a	  fluorescent	  UV	  microscope	  (Nikon	  eclipse	  TE2000-­‐5	  inverted)	  and	  imaged	  with	  a	  digital	  camera	  (Hammatsu,	  Japan)	  or	  quantified	  by	  flow	  cytometry.	  	  	  
Sendai	  and	  EMCV	  	  	   Infection	  of	  Huh-­‐7	  and	  Huh-­‐7diff	  with	  Sendai	  virus	  and	  encephalomyocarditis	  virus	  (EMCV)	  for	  the	  IL29	  experiments	  were	  kindly	  carried	  out	  by	  A	  Mayer,	  University	  of	  Oxford.	  Briefly,	  differentiated	  cells	  were	  infected	  on	  Day	  10	  post	  plating.	  Cells	  were	  infected	  with	  Sendai	  virus	  (from	  LGC	  standards)	  by	  the	  addition	  of	  virus	  to	  the	  culture	  medium	  at	  5.3x104	  pfu/well	  in	  a	  24	  well	  plate.	  EMCV	  (Rehwinkel,	  University	  of	  Oxford)	  was	  added	  to	  the	  media	  at	  5.3x104	  pfu/well	  in	  a	  24	  well	  plate.	  4	  hours	  post	  infection	  virus	  was	  removed	  and	  normal	  media	  (+/-­‐)	  DMSO	  was	  added	  to	  the	  cells	  with	  no	  washing	  step.	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Supernatants	  were	  then	  collected	  24	  hours	  post	  infection.	  Cell	  numbers	  per	  well	  were	  enumerated	  on	  the	  day	  of	  infection	  and	  cell	  viability	  was	  assessed	  visually	  by	  light	  microscopy	  24	  hours	  post	  infection.	  Cells	  were	  also	  lysed	  in	  1%	  NP40	  lysis	  buffer	  and	  stored	  at	  -­‐80°C.	  Supernatants	  and	  cell	  lysates	  were	  then	  sent	  from	  Oxford	  and	  IL-­‐29	  in	  the	  supernatant	  was	  quantified	  using	  ELISA	  as	  described.	  Results	  were	  normalized	  for	  cell	  count.	  	  	  
2.1.4	  Drugs	  and	  cytokines	  	  	   Huh-­‐7	  and	  Huh-­‐7diff	  were	  plated	  and	  infected	  with	  HCVcc	  SA13	  as	  described.	  24	  hours	  post	  infection	  VX950	  or	  2CMC	  was	  added	  to	  the	  media	  at	  varying	  concentrations.	  VX950	  and	  2CMC	  were	  given	  as	  gifts	  from	  J	  Neyts	  (Rega	  Institute,	  Belgium).	  72	  hours	  post	  infection	  cells	  were	  pelleted,	  stained	  for	  NS5A	  and	  the	  number	  of	  NS5A	  positive	  cells	  quantified	  using	  flow	  cytometry.	  	  	  For	  experiments	  with	  exogenously	  added	  nucleotides,	  the	  nucleotides	  were	  added	  at	  day	  0,	  which	  is	  the	  day	  when	  the	  cells	  first	  became	  confluent	  (1	  day	  after	  cell	  seeding).	  Uridine,	  and	  Cytidine	  were	  purchased	  from	  Sigma	  and	  used	  as	  previously	  described	  (Nelson,	  HV	  2008).	  	  	  TNF-­‐α	  was	  used	  to	  disrupt	  tight	  junctions	  prior	  to	  infecting	  with	  HCVpp.	  Cells	  were	  treated	  with	  TNF-­‐	  α	  (Sigma	  Aldrich)	  at	  100ng/ml-­‐1	  for	  15	  minutes	  prior	  to	  infecting	  with	  HCVpp	  as	  decribed	  (Fletcher,	  2017).	  TNF-­‐	  α	  was	  also	  used	  to	  activate	  ACH2	  cells.	  Cells	  were	  treated	  with	  10ng/ml	  (Duh,	  1989;	  Gallastegui,	  2012)	  of	  TNF-­‐α	  added	  directly	  to	  the	  media	  for	  12	  hours.	  PMA	  (Sigma	  Aldrich)	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was	  also	  used	  to	  activate	  ACH2	  cells	  at	  10nM	  (Folks	  et	  al,	  1989)	  added	  to	  the	  media	  for	  12	  hours.	  	  	  Zidovudine	  (AZT	  from	  NIH	  Aids	  Reagant)	  was	  used	  to	  treat	  HIV	  infected	  T	  cells.	  AZT	  was	  added	  at	  10mM	  to	  HIV	  infected	  T	  cells	  for	  48	  hours	  prior	  to	  use	  in	  a	  trans-­‐infection.	  HIV	  cure	  was	  confirmed	  by	  quantifying	  p24	  in	  the	  supernatant	  by	  ELISA.	  	  	  2.2:	  Routine	  techniques	   	  	  
2.2.1	  Cell	  differentiation	  	   For	  differentiation	  of	  Huh-­‐7	  and	  Huh-­‐7.5	  with	  dimethylsulfoxide,	  cells	  were	  plated	  at	  5x104/ml	  in	  a	  48	  well	  plate,	  unless	  otherwise	  stated.	  DMSO	  (1.5%	  vol/vol)	  was	  added	  directly	  to	  the	  media	  and	  maintained	  throughout	  the	  cell	  culture,	  except	  for	  during	  viral	  inoculation,	  where	  DMSO	  was	  removed	  for	  up	  to	  8	  hours	  and	  them	  immediately	  replaced.	  Cells	  could	  be	  maintained	  for	  up	  to	  6	  weeks	  using	  this	  method	  of	  differentiation,	  but	  used	  7-­‐10	  days	  post	  differentiation	  for	  all	  experiments	  unless	  otherwise	  stated.	  DMSO	  was	  stored	  at	  -­‐20°C	  in	  1	  ml	  aliquots	  in	  order	  to	  prevent	  loss	  of	  efficacy	  if	  stored	  at	  room	  temperature	  for	  long	  periods	  of	  time	  (verbal	  communication,	  David	  Durantel).	  	  	  Huh-­‐7	  were	  also	  differentiated	  using	  2%	  human	  serum	  (to	  replace	  FBS)	  in	  DMEM	  supplemented	  with	  1%	  nonessential	  amino	  acids	  and	  1%	  penicillin/streptomycin	  (Invitrogen,	  Carlsbad,	  CA)	  as	  described	  (Steenbergen,	  2013).	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To	  compare	  cells	  using	  alternative	  methods	  of	  differentiation	  Huh-­‐7	  were	  propogated	  for	  4	  weeks	  (by	  N	  Frampton)	  in	  Williams	  E	  media	  (Gibco)	  supplemented	  with	  5%	  FCS,	  40	  IU/ml	  Insulin,	  1μl/ml	  Iosine,	  22μl/ml	  Hydrocortisone,	  1%	  nonessential	  amino	  acids	  and	  1%	  penicillin/streptomycin	  (Invitrogen,	  Carlsbad,	  CA)	  (J	  Graf,	  University	  Munich,	  Germany).	  	  	  
2.2.2	  Indirect	  Immunofluorescence	  	  	  
 	   HCV	  infection	  was	  detected	  by	  immunofluorescence.	  Infected	  cells	  were	  fixed	  using	  either	  ice-­‐cold	  methanol	  (Fisher	  Scientific,	  UK)	  for	  5	  minutes	  or	  3.6%	  paraformaldehyde	  (PFA)	  (TAAB,	  UK)	  for	  20	  minutes,	  at	  room	  temperature.	  Cells	  were	  blocked	  and	  permeabilised	  in	  PBS	  containing	  1%	  BSA	  and	  0.1%	  saponin	  for	  30	  minutes	  at	  room	  temperature.	  Cells	  were	  washed	  x2	  (PBS)	  prior	  to	  the	  addition	  of	  primary	  antibody	  (anti-­‐NS5A	  9E10)	  for	  60	  minutes	  at	  room	  temperature.	  Cells	  were	  then	  washed	  (PBS)	  and	  the	  secondary	  fluorescent	  conjugated	  antibody	  was	  added.	  Cells	  were	  incubated	  in	  the	  dark	  for	  60	  minutes	  at	  room	  temperature.	  Staining	  was	  visualized	  using	  fluorescent	  UV	  microscope	  (Nikon	  eclipse	  TE2000-­‐5	  inverted)	  and	  imaged	  with	  a	  digital	  camera	  (Hammatsu,	  Japan)	  at	  magnification	  x10,	  unless	  otherwise	  stated.	  	  	  
2.2.3	  Flow	  cytometry	  	  	  	   For	  detecting	  HCV	  infection	  cells	  were	  fixed	  using	  PFA	  (TAAB,	  UK)	  for	  20	  minutes,	  at	  room	  temperature.	  Primary	  and	  secondary	  antibodies	  were	  added	  as	  above.	  Cells	  were	  then	  acquired	  using	  a	  FacsCalibur	  flow	  cytometer	  (Becton	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Dickinson,	  Europe).	  The	  intact	  live	  cell	  population	  was	  identified	  by	  size	  and	  density	  and	  analysed	  using	  FlowJo	  software	  (Tree	  Star,	  OR,	  USA).	  	  	  	   Intracellular	  HIV	  infection	  was	  detected	  using	  p24	  staining.	  Cells	  in	  a	  48	  well	  plate	  were	  washed	  (PBS)	  before	  adding	  0.2	  μl/well	  of	  the	  reconstituted	  LIVE/DEAD	  fixable	  Dead	  Cell	  Stain	  dye	  with	  violet	  fluorescent	  reactive	  (Invitrogen,	  Carlsbad,	  CA).	  After	  incubating	  on	  ice,	  at	  darkness	  for	  30	  minutes,	  cells	  were	  then	  washed	  with	  200μl/well	  of	  FACS	  washing	  buffer	  (PBS/0.5%BSA/2mM	  EDTA)	  and	  stained	  with	  2μl/well	  of	  anti-­‐CD4-­‐APC	  antibody	  (BD	  Biosciences,	  San	  Jose,	  CA)	  on	  ice	  for	  20	  minutes.	  Samples	  were	  washed	  prior	  to	  being	  fixed	  by	  100μl/well	  perm/fix	  buffer	  (BD	  Biosciences).	  After	  20	  minutes	  fixation	  at	  4°C	  degree,	  samples	  were	  then	  washed	  twice	  with	  perm/washing	  buffer	  (BD	  Biosciences)	  before	  3μl/well	  of	  KC57-­‐RD1	  P24	  specific	  antibody	  (Beckman	  Coulter)	  being	  added	  to	  each	  sample.	  Samples	  were	  then	  incubated	  on	  ice	  for	  30	  minutes	  before	  a	  final	  wash	  step.	  Cells	  were	  fixed	  in	  200μl	  of	  cell	  fix	  (BD	  Biosciences)	  prior	  to	  being	  acquired	  on	  a	  FacsCalibur	  flow	  cytometer	  (Becton	  Dickinson,	  Europe)	  as	  above.	  	  	  	   For	  analysis	  of	  the	  cell	  cycle,	  cells	  were	  fixed	  in	  ice-­‐cold	  methanol	  for	  10	  minutes.	  Cells	  were	  washed	  x	  2	  in	  PBS	  and	  then	  permeabilised	  with	  PBS	  containing	  1%	  BSA	  and	  0.1%	  saponin.	  7AAD	  (Sigma-­‐Aldrich),	  which	  binds	  to	  double	  stranded	  DNA,	  was	  added	  to	  the	  blocking/permeabilisation	  buffer	  at	  1	  in	  100	  dilution.	  Cells	  were	  incubated	  at	  room	  temperature	  for	  20-­‐30	  minutes	  prior	  to	  being	  washed	  x2	  PBS	  and	  acquired	  on	  a	  FacsCalibur	  flow	  cytometer.	  Analysis	  of	  the	  cell	  cycle	  was	  done	  using	  the	  Dean/Jett/Fox	  algorithm	  on	  FlowJo.	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2.2.4	  Real-­‐Time	  Reverse-­‐Transcription	  Polymerase	  Chain	  Reaction	  	  	   For	  cells	  used	  in	  quantitative	  PCR	  assays,	  purified	  cellular	  or	  tissue	  RNA	  samples	  were	  extracted	  (RNEasy	  MiniKit,	  Qiagen)	  according	  to	  the	  manufacturers	  instructions.	  The	  RNA	  was	  eluted	  in	  35μl	  of	  RNA	  free	  water	  as	  the	  end	  step.	  Purified	  cellular	  RNA	  samples	  were	  amplified	  for	  HCV	  RNA	  (Primer	  Design	  Ltd)	  or	  specific	  primers	  in	  a	  single	  tube	  RT-­‐PCR	  in	  accordance	  with	  the	  manufacturer's	  guidelines	  (CellsDirect	  One	  Step	  qPCR	  Kit,	  Invitrogen).	  Fluorescence	  was	  monitored	  in	  an	  ABI	  7500	  PCR	  machine	  (Applied	  Biosystems).	  The	  housekeeping	  gene	  GAPDH	  was	  included	  as	  an	  internal	  endogenous	  control	  for	  amplification	  efficiency	  and	  RNA	  quantification	  (ABI).	  The	  assay	  cutoff	  for	  HCV	  RNA	  was	  100	  copies	  and	  the	  number	  of	  copies	  was	  calculated	  using	  a	  standard	  curve.	  The	  relative	  expression	  of	  all	  target	  genes	  were	  evaluated	  by	  normalizing	  the	  Ct-­‐values	  with	  the	  internal	  GAPDH	  expression	  (2^Δ	  ct).	  Specific	  primers	  were	  all	  commercially	  available	  Taqman	  primers	  (Applied	  Biosystems).	  	  
	  
Total	  miRNA	  for	  mir-­‐122	  and	  other	  micro-­‐RNA	  expression	  was	  prepared	  by	  using	  the	  using	  the	  miRNeasy	  minikit	  (Qiagen)	  according	  to	  manufacturers	  instructions.	  miR-­‐122	  and	  other	  miR	  expression	  was	  determined	  using	  the	  specific	  RT	  and	  PCR	  primers	  provided	  in	  the	  Taqman	  microRNA	  assays	  according	  to	  the	  manufacturers	  instructions	  (Life	  Technologies,	  ThermoFischer).	  	  The	  micro-­‐RNA	  miR-­‐130	  was	  used	  as	  the	  endogenous	  control	  as	  this	  was	  expressed	  stably	  across	  cell	  lines	  used	  (Schaefer,	  2010).	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2.2.5	  Enzyme	  Linked	  Immunosorbent	  Assay	  (ELISA)	  	  	   HIV-­‐1-­‐p24,	  as	  a	  marker	  of	  HIV	  infectivity	  was	  measured	  by	  ELISA.	  Supernatant	  was	  collected	  from	  infected	  cells	  and	  stored	  at	  -­‐20°C.	  p24	  was	  measured	  as	  per	  manufacturers	  instructions	  (Aalto	  Bio	  Reagants	  Ltd,	  Dublin,	  Ireland)	  and	  absorbance	  measured	  at	  450nm	  using	  a	  Multiskan	  Ascent	  platereader.	  	  	  	   IL-­‐29	  was	  measured	  using	  ELISA.	  Supernatant	  was	  collected	  from	  infected	  cells	  at	  various	  time	  points	  post	  infection	  for	  quantification	  of	  extracellular	  IL-­‐29	  and	  stored	  at	  -­‐20°C.	  For	  intracellular	  IL-­‐29	  duplicate	  wells	  of	  a	  12	  well	  plate	  were	  treated	  with	  trypsin	  and	  cell	  pellets	  re-­‐suspended	  in	  200μl	  of	  10%	  DMEM.	  Cells	  were	  then	  rapidly	  freeze	  thawed	  three	  times	  prior	  to	  be	  centrifuged	  at	  2000rpm	  to	  clarify.	  Samples	  were	  stored	  at	  -­‐20°C.	  IL-­‐29	  was	  measured	  as	  per	  manufacturers	  instructions	  (eBioscience,	  ThermoFisher	  Scientific)	  and	  absorbance	  measured	  at	  450nm	  using	  a	  Multiskan	  Ascent	  platereader.	  	  	  
2.3:	  Specific	  techniques	  
 
2.3.1	  Confocal	  microscopy	  	  	   Huh-­‐7.5	  were	  plated	  onto	  collagen-­‐coated	  coverslips	  (Fisher	  Scientific,	  Leicester,	  United	  Kingdom)	  and	  maintained	  in	  the	  presence	  of	  DMSO	  for	  up	  to	  21	  days.	  Non-­‐DMSO	  treated	  controls	  were	  plated	  and	  used	  24	  hours	  later.	  Cells	  were	  fixed	  with	  ice-­‐cold	  methanol	  (claudin-­‐1,	  occludin,	  ZO-­‐1)	  or	  3%	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paraformaldehyde	  (CD81).	  After	  incubation	  with	  primary	  antibodies	  cells	  were	  incubated	  with	  Alexa	  488	  secondary	  antibodies,	  counterstained	  with	  4′,6-­‐diamidino-­‐2-­‐phenylindole,	  and	  viewed	  by	  laser	  scanning	  confocal	  microscopy	  on	  a	  Zeiss	  (Dublin,	  CA)	  MetaHead	  microscope	  with	  a	  100×	  oil	  immersion	  objective.	  
2.3.2	  Measurements	  of	  polarity	  	  	   To	  determine	  the	  functionality	  of	  tight	  junctions	  and	  whether	  they	  restricted	  paracellular	  diffusion	  of	  solutes	  from	  circular	  structures,	  presumed	  to	  be	  bile	  cannaliculi	  (BC)	  to	  the	  basolateral	  medium,	  Huh-­‐7diff	  were	  incubated	  with	  5 mM	  CMFDA	  (Invitrogen)	  at	  37 °C	  for	  10 min	  to	  allow	  translocation	  to	  the	  BC	  lumen.	  After	  washing	  extensively	  with	  PBS,	  the	  capacity	  of	  BC	  to	  retain	  CMFDA	  was	  enumerated	  using	  a	  fluorescence	  microscope.	  
Huh-­‐7.5	  cells	  were	  seeded	  onto	  transwells	  and	  grown	  in	  normal	  media	  for	  up	  to	  7	  days.	  Caco-­‐2	  cells	  were	  used	  as	  a	  positive	  control.	  FITC-­‐labelled	  dextran	  FD-­‐4	  (4	  kDa)	  (Sigma	  Chemical	  Co.,	  St.	  Louis,	  MO,	  USA)	  was	  added	  to	  the	  apical	  side	  of	  the	  filters	  at	  a	  concentration	  of	  250	  µg/ml.	  The	  media	  in	  the	  basolateral	  compartment	  were	  sampled	  every	  15	  min	  for	  2	  h.	  The	  concentration	  of	  FD-­‐4	  was	  determined	  using	  a	  fluorimeter	  (Spectra	  Max	  Gemini,	  Molecular	  Devices,	  Sunnyvale,	  CA,	  USA)	  with	  an	  excitation	  wavelength	  of	  490	  nm	  and	  an	  emission	  wavelength	  of	  515	  nm.	  Apparent	  permeability	  (cm/s)	  was	  calculated	  as	  previously	  described	  (Artursson	  P,	  J	  Pharm	  Sci,	  1990).	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2.3.3	  Viral	  entry	  timeline	  	  	   Virus	  containing	  medium	  was	  added	  to	  cells	  in	  48	  well	  plates	  and	  every	  30	  minutes	  (up	  to	  150	  minutes	  post	  infection)	  triplicate	  wells	  were	  washed	  three	  times	  with	  phosphate	  buffered	  saline	  and	  normal	  media	  replaced.	  Cells	  were	  incubated	  for	  72	  hours.	  Cells	  were	  lysed,	  and	  luciferase	  activity	  was	  measured	  (Lumat	  LB9507	  luminometer,	  Bertholt,	  Bad	  Weilbad,	  Germany).	  Infectivity	  is	  expressed	  as	  relative	  light	  units,	  where	  the	  no-­‐envelope	  signal	  is	  subtracted	  from	  HCVpp	  or	  VSVpp	  signals.	  
2.3.4	  Iron	  assay	  	  	   Cell	  pellets	  from	  DMSO	  treated	  Huh-­‐7.5	  and	  Huh-­‐7	  were	  collected	  after	  7	  and	  14	  days	  post	  plating	  in	  6	  well	  plates	  and	  re-­‐suspended	  in	  100µl	  HEPES	  saline	  (10mM	  HEPES	  in	  0.9%	  (w/v)	  sodium	  chloride	  at	  pH	  7.4).	  Ferrozine	  assay	  was	  carried	  out	  as	  previously	  described	  by	  E	  Shawcross,	  University	  of	  Birmingham,	  UK	  (Riemer	  J,	  Anal	  Biochem	  2004).	  	  
2.3.5	  Glucose	  assay	  	   Huh-­‐7diff	  were	  propagated	  in	  DMEM	  with	  varying	  concentrations	  of	  glucose	  as	  indicated.	  Standard	  DMEM	  (glucose	  4.5g/L)	  was	  added	  to	  glucose	  free	  DMEM	  in	  addition	  to	  10%	  FCS,	  1%	  nonessential	  amino	  acids	  and	  1%	  penicillin/streptomycin	  (Invitrogen,	  Carlsbad,	  CA)	  and	  1.5%	  DMSO	  (vol/vol)	  in	  order	  to	  achieve	  glucose	  concentrations	  as	  indicated.	  24	  hours	  later	  cells	  were	  infected	  with	  HCVcc.	  72	  hours	  post	  infection	  cells	  were	  fixed	  and	  stained	  for	  NS5A	  as	  a	  marker	  of	  infectivity.	  Duplicate	  wells	  were	  also	  treated	  with	  RLT	  lysis	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buffer	  and	  expression	  of	  enzymes	  associated	  with	  glucose	  metabolism	  was	  quantified	  by	  qPCR	  as	  indicated.	  	  
2.3.6	  miR122	  assay	  	  	   Huh	  7	  cells	  were	  seeded	  in	  24	  well	  plates	  and	  1.5%	  DMSO	  added	  as	  described.	  Cells	  were	  transfected	  with	  a	  reporter	  firefly	  luciferase	  RNA,	  a	  capped	  renilla	  luciferase	  control	  RNA	  and	  either	  a	  2’-­‐O-­‐methylated	  antisense	  oligonucleotide	  to	  sequester	  miR122	  (122-­‐2’OMe)	  or	  a	  randomized	  control	  2’O-­‐methylated	  nucleotide	  (Rand-­‐2’OMe)	  as	  described	  (Roberts,	  Nucleic	  Acid	  Research,	  2011).	  Cells	  were	  lysed	  at	  6h	  post	  transfection	  in	  50	  µl	  Passive	  Lysis	  Buffer	  (Promega)	  per	  well.	  Firefly	  and	  Renilla	  luciferase	  activity	  was	  determined	  in	  5	  µl	  of	  each	  sample	  using	  the	  Dual	  Luciferase	  Assay	  Kit	  (Promega),	  with	  25	  µl	  of	  each	  reagent,	  using	  a	  Glomax	  96	  microplate	  luminometer	  (Promega).	  Firefly/Renilla	  luciferase	  ratios	  were	  determined	  and	  plotted	  as	  a	  percentage	  of	  the	  value	  obtained	  in	  untreated	  Huh7	  cells	  containing	  Rand-­‐2’OMe.	  miR122	  assays	  were	  kindly	  carried	  out	  by	  C	  Joplin	  (University	  of	  Nottingham,	  UK).	  	  
2.3.7	  HCV	  dissemination	  and	  spread	  	  	   Huh-­‐7	  and	  Huh-­‐7diff	  were	  plated	  in	  24	  well	  plates.	  Cells	  were	  infected	  with	  HCV	  SA13	  at	  a	  comparable	  MOI	  to	  achieve	  matched	  number	  of	  infected	  cells	  48	  hours	  post	  infection.	  12	  hours	  post	  infection	  HCV(+)IgG	  and	  HCV(-­‐)IgG	  were	  added	  to	  duplicate	  wells.	  Cells	  were	  then	  incubated	  for	  2,	  3	  and	  4	  days	  post	  infection.	  Cells	  were	  trypsinised,	  fixed	  with	  1%	  paraformaldehyde	  and	  stained	  using	  anti-­‐NS5A	  NE10	  at	  1:1000	  in	  Phosphate	  Buffered	  Saline/0.5%	  Bovine	  Serum	  Albumin/0.1%	  Saponin.	  Bound	  antibody	  was	  detected	  with	  Alexa-­‐Fluor	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488	  secondary	  and	  analysed	  by	  flow	  cytometry	  using	  a	  FACSCalibur	  (BD	  Biosciences)	  and	  FlowJo	  software	  (TreeStar,	  Ashland,	  OR).	  
2.3.8	  Cell-­‐to-­‐cell	  viral	  dissemination	  	   A	  co-­‐culture	  method	  was	  used	  to	  assess	  cell-­‐to-­‐cell	  and	  cell-­‐free	  spread	  of	  HCV	  within	  a	  culture	  of	  Huh-­‐7diff	  and	  control	  Huh-­‐7	  (Meredith	  et	  al,	  2013).	  ‘Producer’	  cells	  were	  electroporated	  with	  SA13/JFH	  (Jensen)	  or	  J6/JFH	  (Lindenbach	  et	  al,	  2005)	  and	  then	  labeled	  with	  CMFDA	  Cell-­‐tracker	  Green	  (Invitrogen).	  ‘Producer’	  cells	  were	  co-­‐	  cultured	  with	  an	  equal	  number	  of	  naïve	  Huh-­‐7diff	  cells	  (used	  at	  7-­‐10	  days	  post	  differentiation)	  or	  Huh-­‐7.	  Extracellular	  virus	  was	  neutralized	  by	  treating	  cultures	  with	  anti-­‐HCV	  Ig	  or	  control	  Ig	  (150	  μg/ml)	  and	  antibody	  efficacy	  confirmed	  by	  analysing	  the	  culture	  media	  after	  24	  h	  co-­‐culture	  for	  the	  levels	  of	  infectious	  virus.	  Cells	  were	  harvested	  at	  defined	  time	  points.	  Infected	  target	  cells	  were	  identified	  by	  staining	  for	  HCV	  NS5A	  and	  flow	  cytometry	  and	  can	  be	  differentiated	  from	  producer	  cells,	  or	  producer	  cell	  division,	  as	  these	  were	  CMFDA	  labeled.	  Cell-­‐to-­‐cell	  transmission	  is	  defined	  as	  the	  frequency	  of	  infection	  events	  in	  the	  presence	  of	  neutralizing	  anti-­‐HCV-­‐Ig,	  and	  subtraction	  of	  this	  value	  from	  the	  total	  number	  of	  infected	  cells	  (from	  duplicate	  wells	  in	  the	  presence	  of	  control	  Ig)	  provides	  an	  estimate	  of	  cell-­‐free	  infection.	  	  
2.3.9	  Innate	  signaling	  assays	  	  	   Huh-­‐7	  (+/-­‐	  DMSO)	  or	  HepG2	  NTCP	  IOV	  cells	  at	  1	  x	  105/ml	  were	  seeded	  in	  12	  well	  plates.	  In	  duplicate	  wells	  HCV	  J6	  RNA	  and	  PolyIC	  (low	  or	  high	  MW)	  (SigmaAldrich)	  were	  transfected	  using	  Fugene	  6	  (Promega,	  Canada)	  and	  Optimem.	  Cells	  were	  transfected	  for	  4	  hours	  prior	  to	  washing	  with	  PBS	  and	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normal	  media	  +/-­‐	  1.5%	  DMSO	  replaced.	  Wells	  were	  also	  infected	  with	  HCVcc	  at	  1.5	  FFU/ml.	  Huh-­‐7	  ‘producer’	  cells	  electroporated	  with	  SA13/JFH	  were	  added	  at	  equal	  cell	  numbers.	  4	  hours	  post	  infection	  cells	  were	  washed	  and	  the	  anti-­‐viral	  drug	  VX950	  (1μg/ml)	  was	  added	  to	  duplicate	  wells	  to	  prevent	  HCV	  replication.	  Sendai	  virus	  (5.3x104	  pfu/well)	  and	  EMCV	  (5.3x104	  pfu/well)	  were	  added	  to	  wells	  for	  4	  hours	  prior	  to	  being	  washed	  x	  2	  in	  PBS	  and	  normal	  media	  replaced.	  At	  indicated	  time	  points	  post	  infection	  (24,48	  or	  72	  hours)	  the	  supernatant	  was	  collected	  and	  IL29	  quantified	  by	  ELISA.	  Cells	  were	  trypsinised	  and	  the	  cell	  pellet	  freeze/thawed	  x	  3	  in	  order	  to	  release	  intracellular	  IL29.	  The	  pellet	  was	  resuspended	  in	  200μl	  DMEM	  and	  clarified	  prior	  to	  IL29	  quantification	  by	  ELISA.	  Cells	  were	  also	  collected	  for	  IL29	  and	  IFNα	  qPCR	  as	  described	  in	  section	  2.2.4.	  	  
2.3.10	  HCV	  Trans-­‐infection	  assay	  	   Target	  cells	  (Huh-­‐7	  or	  LucA2	  replicon	  cells)	  were	  plated	  at	  2.5	  x	  104/cm2	  in	  48	  well	  plates	  for	  24	  hours	  prior	  to	  use.	  Lymphocytes	  (T	  cell	  lines	  or	  primary	  CD4+	  T	  cells)	  in	  complete	  RPMI	  medium	  were	  infected	  with	  HIV-­‐1	  (at	  a	  concentration	  of	  50ng	  p24/ml).	  At	  the	  indicated	  time	  points	  post	  infection	  cells	  were	  washed	  twice	  in	  RPMI.	  	  T	  cell	  +/-­‐	  HIV	  were	  then	  incubated	  at	  37oC	  with	  HCVcc	  (150μl	  neat	  virus	  per	  1	  million	  T	  cells)	  for	  2	  hours.	  After	  virus	  association,	  the	  lymphocytes	  were	  washed	  5x	  with	  serum	  free	  RPMI	  and	  the	  last	  wash	  was	  tested	  to	  confirm	  removal	  of	  virus.	  Lymphocytes	  were	  then	  co-­‐cultured	  at	  the	  indicated	  cell	  numbers	  per	  well	  with	  Huh-­‐7or	  LucA2	  replicon	  cells	  for	  72	  hours	  and	  trans-­‐infection	  enumerated	  by	  NS5A	  staining	  of	  infected	  hepatomas	  as	  described	  (Stamataki	  et	  al.,	  2009).	  The	  effect	  of	  trans-­‐infection	  on	  established	  replication	  in	  a	  LucA2	  replicon	  was	  quantified	  by	  lysing	  cells	  and	  measuring	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luciferase	  activity	  (Lumat	  LB9507	  luminometer,	  Bertholt,	  Bad	  Weilbad,	  Germany).	  Replication	  is	  expressed	  as	  relative	  light	  units,	  where	  the	  media	  only	  control	  signal	  is	  subtracted	  from	  LucA2	  signal.	  Supernatant	  collected	  from	  wells	  and	  pooled	  at	  the	  end	  of	  the	  trans-­‐infection	  experiment	  was	  added	  in	  serial	  dilutions	  to	  LucA2	  replicons.	  48	  hours	  later	  cells	  were	  lysed	  and	  replication	  measured	  by	  luciferase	  activity.	  	  HIV	  infected	  T	  cells	  and	  control	  T	  cells	  were	  collected	  following	  incubation	  with	  HCVcc	  and	  the	  subsequent	  washing	  steps,	  pelleted	  and	  suspended	  in	  RLT	  lysis	  buffer	  for	  HCV	  RNA	  qPCR.	  	  
2.3.11	  Statistical	  analysis	  	  Statistical	  analyses	  were	  performed	  using	  Student	  t-­‐test	  for	  bar	  charts	  or	  linear	  regression	  for	  XY	  graphs	  in	  Prism	  6.0	  (GraphPad,	  USA)	  with	  P	  ≤0.05	  being	  considered	  statistically	  significant.	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  3.1:	  Introduction	  	  	   The	  study	  of	  Hepatitis	  C	  Virus	  (HCV)	  in	  vitro	  is	  largely	  restricted	  to	  hepatoma	  cells,	  derived	  from	  a	  de-­‐differentiated	  tumour	  cell	  line	  (Blight	  et	  al,	  2000;	  Blight	  et	  al,	  2002).	  These	  cells	  are	  highly	  permissive	  and	  allow	  study	  of	  the	  viral	  lifecycle,	  however	  they	  do	  not	  permit	  study	  of	  viral-­‐host	  interactions	  in	  a	  differentiated	  system.	  The	  ideal	  model	  for	  the	  study	  of	  HCV	  is	  one	  that	  physiologically	  resembles	  the	  liver;	  cells	  that	  upregulate	  liver	  specific	  genes	  and	  are	  fully	  responsive	  to	  double	  stranded	  RNA	  (Sainz	  and	  Chisari,	  2006).	  Primary	  human	  hepatocytes	  are	  the	  gold	  standard;	  they	  are	  differentiated	  and	  polarised.	  However,	  they	  support	  variable	  and	  low	  level	  HCV	  replication	  in	  vitro	  (Gondeau	  et	  al,	  2014;	  Podevin	  et	  al,	  2010;	  Wilson	  et	  al,	  2015).	  Furthermore,	  they	  de-­‐differentiate	  rapidly	  ex-­‐vivo,	  are	  highly	  variable	  between	  individuals,	  and	  are	  difficult	  and	  expensive	  to	  obtain.	  Therefore	  there	  is	  the	  need	  for	  a	  differentiated	  cell	  system	  that	  is	  reproducible,	  easy	  to	  maintain	  and	  not	  costly.	  	  	   There	  are	  various	  methods	  that	  have	  been	  used	  to	  differentiate	  hepatoma	  cells,	  including	  using	  human	  serum	  (Steenbergen	  et	  al,	  2013),	  DMSO	  (Sainz	  and	  Chisari,	  2006)	  and	  with	  media	  containing	  insulin,	  DMSO	  and	  other	  growth	  factors	  (verbal	  communication,	  J	  Graf).	  DMSO	  (dimethlysulfoxide)	  is	  widely	  available	  and	  is	  well	  known	  for	  its	  ability	  to	  induce	  differentiation	  of	  numerous	  cell	  lines.	  It	  can	  differentiate	  myeloid	  cell	  lines	  into	  mature	  granulocytes	  or	  macrophage-­‐like	  cells	  (Makowske	  et	  al,	  1987;	  Collins	  et	  al,	  1978;	  Myers	  and	  Siegel,	  1984).	  It	  has	  also	  been	  shown	  to	  differentiate	  osteoclasts	  (at	  0.5%	  vol/vol)	  (Lemieux	  et	  al,	  2001)	  and	  enhance	  differentiation	  of	  pluripotent	  stem	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cells	  into	  multiple	  lineages	  (Chetty	  et	  al,	  2013),	  including	  hepatic	  differentiation	  (Czysz	  et	  al,	  2015).	  Furthermore,	  DMSO	  has	  been	  used	  to	  differentiate	  hepatocytes,	  including	  HepaRG	  cells	  (Gripon	  et	  al,	  2002)	  and	  human	  hepatoma	  Huh-­‐7.5	  (Sainz	  and	  Chisari,	  2006).	  It	  can	  also	  maintain	  the	  differentiated	  phenotype	  of	  rat	  hepatocytes	  (Isom	  et	  al,	  1985)	  and	  primary	  human	  hepatocytes	  in	  culture	  (Zhou	  et	  al,	  2014).	  	  	  Several	  reports	  have	  shown	  that	  at	  low	  concentrations	  (1%	  vol/vol)	  DMSO	  can	  differentiate	  human	  hepatoma	  cells	  through	  upregulation	  of	  key	  hepatocyte	  genes,	  such	  as	  HNF4α,	  albumin	  and	  cytochrome	  P450	  enzymes	  (Sainz	  and	  Chisari,	  2006;	  Choi	  et	  al,	  2009).	  These	  cells	  can	  be	  maintained	  in	  culture	  due	  to	  cell	  cycle	  growth	  arrest,	  and	  support	  HCV	  replication	  in	  vitro.	  They	  are	  increasingly	  used	  as	  a	  model	  for	  chronic	  HCV	  (Xiao	  et	  al,	  2014)	  and	  are	  interferon	  responsive,	  expressing	  a	  wide	  array	  of	  interferon	  stimulated	  genes	  (ISGs)	  compared	  to	  untreated	  hepatoma	  cells	  (Bauhofer	  et	  al,	  2012).	  We	  hypothesized	  that	  DMSO	  at	  low	  concentrations	  in	  the	  media	  (1-­‐2%)	  would	  drive	  hepatoma	  cell	  differentiation,	  allow	  the	  differentiated	  cells	  to	  persist	  in	  culture	  and	  permit	  the	  study	  of	  HCV	  replication	  in	  a	  physiological	  system.	  	  	  Studies	  assessing	  whether	  stem	  cell	  induced	  hepatocytes	  support	  HCV	  replication	  suggest	  a	  role	  for	  differentiation	  in	  viral	  permissivity,	  defined	  by	  miR122	  (Wu	  et	  al,	  2012).	  Furthermore,	  other	  hepatitis	  viruses,	  such	  as	  Hepatitis	  B	  virus	  (HBV),	  prior	  to	  the	  discovery	  of	  key	  entry	  factors,	  would	  only	  replicate	  in	  highly	  differentiated	  cells	  (Gripon	  et	  al,	  2002).	  We	  therefore	  hypothesized	  that	  differentiation	  status	  of	  hepatoma	  cells	  would	  alter	  viral	  permissivity	  of	  HCV.	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  This	  chapter	  describes	  the	  development	  of	  differentiated	  cells	  for	  the	  study	  of	  the	  HCV	  lifecycle	  in	  a	  physiological	  system	  and	  the	  impact	  of	  cellular	  differentiation	  on	  viral	  permissivity.	  	  	  Chapter	  Aims:	  	  1. To	  characterize	  differentiated	  Huh-­‐7	  treated	  with	  DMSO,	  specifically	  looking	  at:	  a. Cell	  cycle	  arrest	  and	  maintenance	  of	  cells	  in	  culture.	  b. Hepatocyte	  specific	  genes	  and	  miR	  expression.	  2. To	  define	  viral	  permissivity	  in	  differentiated	  Huh-­‐7.	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3.2:	  DMSO	  induces	  cell	  cycle	  arrest	  	   Previous	  studies	  have	  shown	  that	  DMSO,	  at	  low	  concentrations,	  can	  induce	  cell	  cycle	  arrest	  in	  hepatoma	  cells	  (Sainz	  and	  Chisari,	  2006)	  and	  promote	  differentiation.	  To	  define	  the	  optimal	  DMSO	  concentration	  for	  cell-­‐cycle	  arrest,	  cells	  were	  treated	  with	  varying	  DMSO	  concentrations	  (from	  0.5%	  to	  2%)	  for	  7	  days	  with	  cell	  cycle	  progression	  assessed	  using	  7-­‐amino-­‐actinomycin	  (7-­‐AAD).	  7-­‐AAD	  is	  a	  single	  colour	  fluorochrome	  dye	  that	  interacts	  with	  double	  stranded	  DNA	  and	  is	  widely	  used	  to	  study	  the	  cell	  cycle	  (Vignon	  et	  al,	  2013).	  	  Results	  showed	  that	  DMSO	  slows	  cell	  cycle	  progression	  compared	  to	  untreated	  cells	  with	  an	  increased	  percentage	  of	  cells	  in	  G1	  phase	  compared	  to	  untreated	  cells	  (70%	  versus	  40%	  in	  untreated	  cells)	  (Figure	  3.1).	  There	  was	  no	  observed	  difference	  in	  the	  percentage	  of	  cells	  undergoing	  active	  cell	  division,	  in	  ‘S’	  phase,	  between	  the	  different	  DMSO	  concentrations,	  with	  the	  majority	  of	  cells	  in	  G1	  phase.	  Given	  that	  cell	  cycle	  analysis	  appeared	  similar	  at	  all	  DMSO	  concentrations	  used,	  and	  previous	  publications	  had	  used	  1-­‐2%	  (Sainz	  and	  Chisari,	  2006,	  Bauhofer	  et	  al,	  2012)	  1.5%	  DMSO	  was	  utilised	  for	  all	  future	  experiments.	  Morphological	  changes	  were	  observed	  in	  DMSO-­‐treated	  cells,	  with	  results	  showing	  cells	  were	  more	  regular	  and	  compact,	  phenotypically	  resembling	  primary	  human	  hepatocytes	  (Figure	  3.2).	  	  While	  DMSO-­‐treated	  cells	  could	  be	  maintained	  in	  culture	  for	  up	  to	  6	  weeks	  post	  seeding,	  our	  results	  showed	  that	  DMSO	  must	  be	  continuously	  present	  to	  prevent	  cell	  cycle	  re-­‐activation	  (Figure	  3.3).	  Cells	  were	  treated	  with	  DMSO	  for	  7	  days	  prior	  to	  removal	  of	  DMSO	  from	  the	  media	  for	  24	  hours.	  Cell	  cycle	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Figure	  3.1	  DMSO	  treatment	  slows	  cell	  cycle	  progression	  in	  Huh-­‐7	  cells	  	  
	  Huh-­‐7	  cells	  were	  seeded	  in	  48	  well	  plates	  and	  treated	  with	  DMSO	  at	  indicated	  concentrations	  (vol/vol)	  for	  7	  days.	  Control	  cells	  were	  plated	  at	  comparable	  seeding	  density	  and	  used	  when	  confluent	  at	  48-­‐72	  hours	  post	  seeding.	  Triplicate	  wells	  were	  stained	  using	  7-­‐aminoactinomycin	  (7AAD)	  and	  analysed	  by	  flow	  cytometry	  (FACSCalibur).	  Cell	  cycle	  stage	  was	  determined	  by	  FlowJo	  Dean	  Fox	  Jett	  algorithm,	  which	  calculates	  percentage	  of	  total	  cell	  count	  by	  stage	  of	  cell	  cycle,	  based	  on	  7-­‐AAD	  fluorescence.	  Results	  represent	  means	  of	  triplicate	  wells	  and	  two	  independent	  experiments.	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3.3:	  DMSO	  induces	  hepatoma	  cell	  differentiation	  towards	  a	  hepatocyte-­‐like	  phenotype	   	  	  	   	  Previous	  results	  showed	  that	  hepatoma	  cells	  treated	  with	  DMSO	  have	  slowed	  cycle	  progression	  and	  can	  be	  maintained	  in	  culture	  over	  time,	  developing	  a	  hepatocyte-­‐like	  morphology.	  Next,	  the	  expression	  of	  hepatocyte-­‐specific	  gene	  markers	  was	  investigated	  to	  determine	  how	  “hepatocyte-­‐like”	  the	  arrested	  cells	  were	  over	  time.	  	  	   Hepatocytes	  express	  many	  liver-­‐specific	  markers	  including	  HNF4α,	  the	  cytochrome	  P450	  enzymes	  and	  albumin.	  Differentiated	  hepatocytes,	  in	  particular,	  also	  downregulate	  fetal	  markers	  such	  as	  alpha-­‐fetoprotein	  (Klaunig	  et	  al,	  1981;	  Sainz	  and	  Chisari,	  2006).	  Figure	  3.4A	  and	  B	  shows	  that	  DMSO	  treated	  Huh-­‐7	  significantly	  increase	  mRNA	  levels	  of	  several	  hepatocyte	  markers.	  These	  were	  at	  a	  level	  comparable	  to	  primary	  human	  hepatocytes	  	  (PHHs)	  cultured	  for	  48	  hours.	  Levels	  of	  liver-­‐specific	  markers	  are	  increased	  up	  to	  7	  days	  post	  DMSO	  treatment	  and	  were	  then	  maintained	  throughout	  the	  course	  of	  the	  culture.	  	  Despite	  mRNA	  levels	  being	  comparable	  to	  PHH	  in	  culture	  for	  up	  to	  48	  hours,	  relative	  levels	  in	  DMSO	  treated	  cells	  did	  not	  reach	  that	  of	  liver	  biopsies	  taken	  on	  the	  day	  of	  liver	  explant	  (Figure	  3.4C).	  	  	   Hepatocytes	  are	  metabolically	  active	  and	  the	  liver	  is	  a	  major	  site	  for	  glucose	  metabolism.	  Hepatocytes	  maintain	  glucose	  homeostasis	  and	  subsequently	  modulate	  glycolysis	  (the	  breakdown	  of	  glucose	  to	  release	  energy)	  or	  gluconeogenesis	  (the	  generation	  of	  new	  glucose	  from	  substrates)	  depending	  
	   100	  






















































































































	   102	  
	  





















































































	   104	  
Figure	  3.5	  DMSO	  upregulates	  important	  enzymes	  in	  hepatic	  glucose	  
metabolism	  	  	  A)	  A	  schematic	  diagram	  of	  glucose	  metabolism	  within	  a	  hepatocyte	  showing	  de-­‐novo	  glucose	  synthesis	  (gluconeogenesis)	  and	  glycogen	  cycling	  (adapted	  from	  Greenberg	  et	  al,	  2006)	  showing	  G-­‐6-­‐Pase	  (glucose-­‐6-­‐phosphatase),	  G-­‐6-­‐P,(glucose-­‐6-­‐phosphate)	  G-­‐1-­‐P	  (glucose-­‐1-­‐phosphate)	  UDPG	  (UDP	  glucose)	  GP	  (glycogen	  phosphorylase)	  and	  PEPCK	  (phosphoenolpyruvate	  carboxykinase).	  B)	  Huh-­‐7	  cells	  were	  seeded	  as	  previously	  and	  treated	  with	  1.5%	  DMSO	  for	  28	  days.	  Cells	  were	  lysed,	  PEPCK	  mRNA	  was	  quantified	  by	  RT-­‐qPCR,	  and	  compared	  to	  undifferentiated	  (Day	  0)	  cells	  and	  primary	  human	  hepatocytes	  48	  hours	  post	  seeding.	  (C)	  PEPCK	  mRNA	  levels	  were	  compared	  in	  Day	  7	  DMSO	  treated	  cells	  with	  primary	  human	  hepatocytes	  48	  h	  post-­‐seeding.	  Results	  plotted	  are	  means	  of	  relative	  expression	  compared	  to	  Day	  0	  cells.	  Means	  are	  from	  pooled	  triplicate	  wells	  representative	  of	  two	  independent	  experiments.	  Significant	  differences	  were	  analysed	  using	  Students	  t	  test	  and	  compared	  to	  Day	  0	  cells.	  ns	  =	  non	  significant.	  *	  p	  ≤0.05,	  **	  p	  ≤0.01,	  ***	  p	  ≤0.001,	  ****	  p	  ≤0.0001	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3.4:	  Huh-­‐7diff	  upregulate	  host	  cellular	  factors	  known	  to	  alter	  HCV	  replication	  	   Previous	  results	  were	  aimed	  at	  ascertaining	  the	  consistent	  working	  conditions	  for	  subsequent	  experiments.	  Key	  liver	  and	  metabolic	  markers	  are	  upregulated	  by	  Day	  7	  in	  DMSO	  treated	  Huh-­‐7	  and	  cells	  have	  slowed	  cell	  cycle	  progression	  and	  can	  be	  maintained	  in	  culture	  over	  time.	  Therefore	  for	  all	  future	  experiments	  Huh-­‐7	  were	  treated	  for	  7-­‐10	  days	  with	  DMSO;	  following	  this	  they	  will	  be	  considered	  differentiated	  and	  termed	  Huh-­‐7diff	  (Bauhofer	  et	  al,	  2012).	  	  	  Since	  Huh-­‐7diff	  upregulate	  a	  number	  of	  genes	  involved	  in	  hepatocyte	  function,	  the	  impact	  of	  DMSO	  treatment	  on	  host	  factors	  reported	  to	  play	  a	  role	  in	  HCV	  replication	  was	  assessed.	  miR122	  is	  the	  most	  abundant	  liver-­‐specific	  micro-­‐RNA	  and	  has	  been	  shown	  to	  be	  important	  for	  HCV	  replication	  in	  vivo	  (Jopling	  et	  al,	  2005;	  Machlin	  et	  al,	  2011;	  Goergen	  and	  Niepmann,	  2012).	  Furthermore,	  hepatocytes	  induced	  from	  stem	  cells	  show	  a	  key	  role	  for	  miR122	  in	  permissivity	  to	  HCV	  (Wu	  et	  al,	  2012).	  	  Additionally,	  several	  other	  micro-­‐RNAs	  known	  to	  alter	  key	  cellular	  processes	  such	  as	  lipid	  metabolism	  have	  been	  implicated	  in	  regulating	  HCV	  replication	  (reviewed	  in	  Pfeffer	  and	  Baumert,	  2010,	  Conrad	  and	  Niepman,	  2014).	  Table	  1	  summarizes	  hepatocellular	  micro-­‐RNAs	  (other	  than	  miR122)	  that	  have	  been	  reported	  to	  play	  a	  role	  in	  HCV	  replication	  at	  the	  time	  of	  investigation.	  Therefore	  candidate	  micro-­‐RNA	  expression	  levels	  were	  measured	  by	  qPCR	  following	  differentiation.	  Results	  showed	  that	  miR122	  (Figure	  3.6)	  and	  other	  candidate	  miRs	  were	  increased	  in	  Huh-­‐7diff	  (Figure	  3.7).	  Let-­‐7b,	  which	  has	  been	  shown	  to	  independently	  alter	  HCV	  replication	  by	  acting	  on	  the	  HCV	  genome	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(Cheng	  et	  al,	  2012),	  was	  not	  present	  in	  undifferentiated	  cells,	  however	  was	  quantifiable	  (raw	  ct	  value	  mean	  37)	  in	  Huh-­‐7diff	  7	  days	  post	  differentiation.	  	  	  Additionally,	  TAP	  1	  (tocopherol-­‐associated	  protein	  1)	  or	  SEC14L2	  was	  recently	  reported	  as	  an	  essential	  host	  cell	  factor	  required	  for	  the	  hepatocellular	  replication	  of	  primary	  HCV	  strains	  (Saeed	  et	  al,	  2015).	  SEC14L2	  is	  ubiquitously	  expressed	  in	  human	  tissues	  (Allen-­‐Baume	  et	  al,	  2002),	  despite	  being	  absent	  from	  hepatoma	  cell	  lines	  (Saeed	  et	  al,	  2015)	  and	  is	  a	  cytosolic	  lipid	  binding	  protein	  family	  member.	  SEC14L2	  mRNA	  levels	  were	  quantified	  in	  Huh-­‐7diff	  and	  showed	  gene	  expression	  in	  undifferentiated	  cells	  that	  was	  significantly	  enhanced	  following	  DMSO-­‐dependent	  differentiation	  (Figure	  3.8).	  In	  addition	  we	  confirmed	  that	  SEC14L2	  was	  expressed	  at	  comparable	  levels	  in	  Huh-­‐7	  and	  Huh-­‐7.5.	  	   	  The	  expression	  in	  Huh-­‐7diff	  of	  key	  cellular	  factors	  that	  influence	  HCV	  replication	  via	  a	  number	  of	  mechanisms	  support	  the	  use	  of	  these	  cells	  as	  a	  more	  physiologically	  relevant	  model	  system	  for	  studying	  host/viral	  interaction.	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Table	  3.1	  Micro-­‐RNAs	  that	  are	  known	  to	  interact	  with	  HCV	  	  
	  
Micro-­‐RNA	   Affect	  on	  HCV	   Reference	  130a	   Inhibits	  HCV	  replication	  by	  upregulation	  of	  Type	  I	  interferon	  pathways.	  Decreases	  miR122	   Li	  et	  al,	  2014;	  Li	  et	  al,	  2017	  27a	   Preferentially	  expressed	  in	  HCV	  infected	  livers.	  Involved	  in	  lipid	  metabolism	  and	  LDLR	  expression	  Silencing	  miR-­‐27a	  increases	  cellular	  lipids,	  reduces	  viral	  buoyant	  density	  and	  promotes	  viral	  replication.	  	  Inducing	  27a	  decreases	  viral	  replication	  
Shirasaki	  et	  al,	  2013;	  Choi	  et	  al,	  2014	  	  
29a	   Decreased	  levels	  found	  in	  livers	  of	  HCV	  infected	  patients	  Regulates	  expression	  of	  ECM*	  and	  collagen,	  and	  lipid	  droplet	  formation	  	  Overexpression	  of	  miR-­‐29	  decreases	  HCV	  replication	  modestly	  
Bandyopadhyay	  et	  al,	  2011;	  Mahdy	  et	  al,	  2016	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3.5:	  Huh-­‐7	  differentiation	  limits	  HCV	  replication.	  	   While	  the	  results	  have	  shown	  that	  Huh-­‐7diff	  provide	  a	  more	  physiological	  system	  for	  studying	  HCV	  using	  metabolic	  and	  cellular	  markers,	  the	  ability	  of	  these	  cells	  to	  support	  HCV	  infection	  has	  yet	  to	  be	  assessed.	  It	  was	  hypothesised	  that	  the	  permissivity	   of	   these	   cells	   to	   HCV	  will	   be	   altered,	   as	   primary	   hepatic	   cells	   are	  generally	  resistant	  to	  HCV	  compared	  to	  hepatoma	  cell	  lines.	  	  	  In	   order	   to	   investigate	   this,	   Huh-­‐7diff	   and	   non-­‐differentiated	   cells	   were	  inoculated	   with	   HCV	   SA13/JFH	   and	   frequency	   of	   NS5A	   expressing	   cells	  enumerated	   after	   72h.	   The	   results	   showed	   4.5%	   NS5A	   expressing	   Huh-­‐7diff	  compared	   to	   90%	  of	   non-­‐differentiated	   cells	   (Figure	   3.9),	   showing	   a	   clear	   and	  significant	  difference	  in	  permissivity.	  To	  more	  accurately	  quantify	  this,	  cells	  were	  infected	  with	  virus	  at	  various	  dilutions	  and	  72h	  later	  the	  number	  of	  infected	  cells	  and	   viral	   titre	   enumerated.	   Both	   infectious	   titre	   (Figure	   3.10A)	   and	  HCV	   RNA	  expression	   (Figure	   3.10B)	   were	   reduced	   125-­‐fold	   in	   Huh-­‐7diff.	   Furthermore,	  NS5A	   expressing	   foci	   in	   Huh-­‐7diff	   were	   infrequent	   and	   small,	   consisting	   of	   1-­‐2	  cells,	   compared	   to	   undifferentiated	   Huh-­‐7	   (Figure	   3.10C),	   which	   had	   large	  multicellular	  foci,	  suggesting	  that	  differentiation	  limits	  HCV	  spread.	  	  	  To	   investigate	   whether	   the	   time	   of	   DMSO-­‐treatment	   affected	   HCV	  infection,	  cells	  were	  differentiated	  for	  7-­‐21	  days,	  infected	  with	  HCV	  SA13/JFH	  and	  infection	   (HCV	   RNA)	   quantified	   by	   qPCR	   72h	   later	   (Figure	   3.11).	   Longer	  differentiation	  times	  resulted	   in	   less	   infection,	  confirming	  that	  differentiation	  of	  hepatoma	  cells	  significantly	  reduces	  permissivity	  to	  infection.	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Figure	  3.10	  Differentiation	  reduces	  Huh-­‐7	  permissivity	  to	  support	  HCV	  
replication.	  	  	  Relative	  infectivity	  was	  determined	  by	  titrating	  HCV	  SA13/JFH	  onto	  Huh-­‐7diff	  or	  Huh-­‐7	  cells.	  (A	  and	  B)	  Infection	  was	  determined	  at	  72h	  post-­‐infection	  by	  immunofluorescence	  for	  NS5A	  expression	  or	  by	  qPCR	  for	  viral	  RNA.	  Results	  are	  expressed	  as	  the	  number	  of	  NS5A	  positive	  cells	  per	  ml	  of	  virus	  (A)	  or	  HCV	  copies	  per	  microliter	  of	  RNA	  per	  ml	  virus	  (B).	  Results	  are	  representative	  mean	  and	  standard	  deviation	  of	  3	  separate	  experiments.	  ****p≤0.0001	  (students	  t-­‐test).	  (C)	  NS5A	  foci	  at	  72	  hours	  post	  infection.	  Images	  are	  representative	  of	  the	  whole	  plate	  and	  three	  independent	  experiments.	  	  
	   	  











Figure	  3.11	  Extended	  time	  periods	  of	  Huh-­‐7	  differentiation	  reduces	  HCV	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Figure	  3.12	  Nucleoside	  addition	  does	  not	  alter	  permissivity	  	  Huh-­‐7	  and	  Huh-­‐7diff	  were	  seeded	  at	  comparable	  density	  and	  transfected	  with	  JC1gLuc	  HCV	  RNA	  for	  8h,	  before	  transfection	  reagent	  was	  removed.	  Cells	  were	  then	  treated	  with	  uridine	  and	  cytidine	  (200	  microMolar)	  (Nelson	  and	  Tang,	  2006)	  or	  untreated.	  Supernatant	  was	  collected	  at	  72	  hours	  post	  transfection.	  Replication	  was	  assessed	  by	  measuring	  the	  luciferase	  signal	  in	  the	  supernatant	  and	  plotted	  as	  fold	  change	  over	  baseline	  (4	  hours).	  Results	  are	  the	  mean	  and	  standard	  deviation	  of	  3	  experiments.	  ns	  =	  non-­‐significant	  (Students	  t	  test).	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3.7:	  Discussion	  	   In	  this	  chapter,	  we	  have	  described	  a	  model	  system	  for	  the	  study	  of	  HCV	  that	  is	  more	  physiological	  than	  standard	  hepatoma	  cells.	  The	  addition	  of	  1.5%	  DMSO	  to	  Huh-­‐7	  cells	  for	  7-­‐10	  days,	  results	  in	  cells	  that	  are	  arrested	  and	  are	  altered	  morphologically,	  physiologically	  and	  metabolically,	  becoming	  more	  ‘liver	  like’.	  These	  cells	  are	  able	  to	  be	  maintained	  in	  culture	  for	  several	  weeks	  and	  are	  permissive	  to	  infection	  with	  HCVcc,	  although	  support	  125	  fold	  reduced	  levels	  of	  infection.	  	  	  The	  use	  of	  DMSO	  has	  many	  advantages	  over	  other	  methods	  of	  cell	  differentiation;	  it	  is	  widely	  available,	  and	  the	  methodology	  of	  differentiation	  is	  very	  straightforward.	  Previously,	  DMSO	  has	  been	  used	  to	  differentiate	  cells	  including	  hepatoma	  cell	  lines	  (Sainz	  and	  Chisari,	  2006;	  Choi	  et	  al,	  2009;	  Nikolaou	  et	  al,	  2016).	  When	  differentiation	  status	  of	  cells	  is	  important	  for	  viral	  permissivity,	  which	  is	  the	  case	  for	  hepatitis	  B	  in	  vitro,	  pre-­‐treatment	  with	  DMSO	  is	  essential	  for	  viral	  entry	  and	  replication	  (Iwamoto	  et	  al,	  2014;	  Gripon	  et	  al,	  2002;	  Ni	  and	  Urban,	  2017).	  The	  exact	  mechanism	  of	  action	  of	  DMSO	  in	  cell	  differentiation	  is	  unknown,	  although	  treatment	  with	  DMSO	  is	  known	  to	  alter	  a	  large	  number	  of	  host	  cell	  genes	  (N	  Frampton,	  verbal	  communication;	  Bauhofer	  et	  al,	  2012)	  and	  has	  also	  been	  shown	  to;	  alter	  cellular	  membrane	  integrity	  (Melkonyan	  et	  al,	  1996;	  Menorval	  et	  al,	  2012)	  induce	  cell	  cycle	  arrest	  (Chetty	  et	  al,	  2013;	  Sainz	  and	  Chisari,	  2006),	  increase	  RNA	  and	  protein	  synthesis	  (Strätling,	  1975,	  Liu,	  2001)	  and	  alter	  intracellular	  signalling	  pathways,	  such	  as	  protein	  Kinase	  C	  (Makowske	  et	  al,	  1988)	  or	  integrin	  expression(Fiore	  and	  Degrassi,	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1999).	  Although	  we	  did	  not	  investigate	  further	  the	  mechanism,	  the	  results	  showed	  that	  DMSO	  upregulated	  liver	  specific	  genes	  (Figure	  3.4),	  including	  those	  involved	  in	  glucose	  homeostasis	  and	  metabolism	  (Figure	  3.5).	  It	  is	  well	  known	  that	  primary	  human	  hepatocytes,	  differentiate	  rapidly	  ex	  vivo,	  are	  highly	  heterogeneous,	  expensive	  and	  difficult	  to	  obtain.	  Other	  methods	  of	  differentiation,	  such	  as	  using	  human	  serum	  or	  DMSO	  in	  conjunction	  with	  insulin	  and	  other	  growth	  factors,	  are	  more	  complex	  and	  do	  not	  allow	  cells	  to	  be	  maintained	  over	  a	  long	  period	  of	  time.	  Given	  the	  restrictions	  of	  other	  cells	  and	  methods,	  Huh-­‐7diff	  offers	  a	  reproducible,	  physiological	  cell	  system	  for	  studying	  HCV	  replication.	  	  	   Despite	  the	  significant	  advantages	  to	  Huh-­‐7diff	  over	  other	  cell	  systems	  for	  studying	  HCV,	  there	  are	  a	  number	  of	  limitations	  of	  the	  system.	  DMSO	  must	  be	  present	  throughout	  the	  culture	  for	  the	  cells	  to	  maintain	  viability	  (Figure	  3.3)	  which	  limits	  the	  ability	  to	  carry	  out	  any	  experiments	  free	  from	  DMSO	  and,	  as	  outlined	  above,	  this	  may	  have	  significant	  effects	  on	  other	  cells.	  Cells	  cannot	  be	  split	  and	  re-­‐seeded	  as	  they	  lose	  their	  viability	  (data	  not	  shown).	  We	  observed	  that	  cells	  were	  highly	  confluent	  after	  5-­‐7	  days	  in	  culture	  and	  remained	  like	  this	  over	  several	  weeks.	  Chetty	  et	  al	  (2013)	  showed	  that	  stem	  cells,	  differentiated	  by	  DMSO	  treatment	  lost	  differentiation	  when	  cell	  contacts	  were	  impaired.	  Taken	  with	  our	  results	  this	  suggests	  that	  cell	  contacts	  are	  important	  in	  allowing	  the	  cells	  to	  maintain	  differentiation	  status.	  	  	  	   Much	  of	  the	  data	  shown	  to	  support	  increased	  differentiation	  in	  these	  cells	  is	  transcript	  rather	  than	  functional	  data.	  Although	  this	  is	  a	  well-­‐recognised	  way	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of	  showing	  cellular	  differentiation	  (Sainz	  and	  Chisari,	  2006;	  Nikolaou	  et	  al,	  2016)	  it	  does	  mean	  more	  guarded	  conclusions	  should	  be	  drawn.	  Upregulation	  of	  the	  key	  enzymes	  involved	  in	  gluconeogenesis	  to	  levels	  similar	  to	  those	  in	  primary	  human	  hepatocytes	  in	  culture	  suggests	  that	  although	  Huh-­‐7diff	  are	  largely	  non-­‐dividing	  they	  are	  not	  metabolically	  quiescent	  (Figure	  3.5).	  	  	   The	  results	  also	  showed	  that	  Huh-­‐7diff	  upregulates	  cytochrome	  P450	  CYP3A4	  RNA.	  CYP3A4	  is	  a	  common	  and	  important	  oxidative	  enzyme	  and	  plays	  a	  crucial	  role	  in	  the	  metabolism	  of	  many	  drugs,	  including	  Telaprevir/VX950	  (drug	  information	  sheet).	  Interestingly,	  the	  action	  of	  the	  polymerase	  inhibitor	  in	  this	  study,	  which	  has	  a	  similar	  mechanism	  of	  action	  to	  Sofosbuvir	  (drug	  information	  sheet),	  is	  significantly	  altered	  by	  hepatocyte	  differentiation.	  There	  are	  likely	  to	  be	  altered	  drug	  pathways,	  including	  enzymatic	  changes	  in	  differentiated	  cells	  which	  in	  part	  may	  explain	  the	  differences	  in	  the	  IC50	  values	  seen	  between	  differentiated	  and	  standard	  hepatoma	  cells.	  It	  is	  important	  to	  consider	  these	  changes	  when	  evaluating	  drug	  activity	  in	  hepatoma	  cells,	  and	  we	  suggest	  that	  a	  differentiated	  model	  provides	  more	  translatable	  results.	  	  	  	   We	  hypothesized	  differentiated	  cells	  would	  have	  altered	  permissivity	  to	  HCVcc.	  We	  then	  went	  on	  to	  show	  that	  Huh-­‐7diff	  are	  less	  permissive	  to	  HCVcc	  and	  this	  was	  defined	  as	  125	  fold	  difference	  (Figure	  3.9-­‐3.10).	  Given	  the	  low	  and	  variable	  infectivity	  in	  vitro	  of	  other	  differentiated	  cells,	  such	  as	  primary	  human	  hepatocytes	  (Wilson	  et	  al,	  2015)	  the	  altered	  permissivity	  of	  Huh-­‐7diff	  provides	  further	  evidence	  that	  these	  cells	  provide	  an	  alternative	  model	  for	  the	  study	  of	  HCV	  replication.	  We	  were	  only	  able	  to	  infect	  these	  cells	  using	  a	  highly	  adapted	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strain	  of	  SA13	  that	  had	  been	  passaged	  and	  was	  a	  high	  MOI.	  The	  use	  of	  this	  virus,	  although	  not	  physiological,	  allowed	  sufficient	  viral	  replication	  to	  allow	  us	  to	  study	  this	  further.	  	  	  	   	   The	  results	  showed	  that	  Huh-­‐7diff	  upregulate	  a	  number	  of	  key	  genes	  involved	  in	  regulating	  HCV	  replication	  within	  a	  cell.	  miR122	  and	  a	  number	  of	  other	  candidate	  micro-­‐RNAs	  alter	  expression	  over	  time	  (Figure	  3.6).	  We	  demonstrated	  a	  3-­‐4	  fold	  induction	  of	  HNF4α,	  a	  hepatocyte	  specific	  gene,	  in	  day-­‐7	  Huh-­‐7diff	  cells	  and	  this	  is	  a	  known	  regulator	  of	  miR122	  in	  vivo	  (Li	  et	  al,	  2011).	  In	  hepatocytes	  differentiated	  from	  hepatic	  progenitor	  cells,	  permissivity	  to	  HCV	  was	  notably	  correlated	  with	  detectable	  expression	  of	  miR122	  (Wu	  et	  al,	  2012).	  miR122	  is	  an	  important	  cellular	  determinant	  of	  HCV	  replication	  whose	  induction	  or	  repression	  is	  caused	  by	  the	  hepatocyte	  specification	  process	  and	  requires	  further	  study.	  Additionally	  SEC14L2	  (TAP)	  has	  recently	  been	  shown	  to	  be	  an	  essential	  host	  cell	  factor	  required	  for	  the	  hepatocellular	  replication	  of	  primary	  HCV	  strains	  (Saeed	  et	  al.	  2015).	  Results	  showed	  that	  expression	  of	  SEC14L2	  is	  also	  increased	  in	  differentiated	  hepatoma	  cells	  and	  offers	  an	  exciting	  possibility	  of	  utilising	  this	  model	  with	  patient	  derived	  virus	  in	  the	  future.	  	  	   	  	   Summary	  	   This	  chapter	  demonstrates	  that	  Huh-­‐7diff	  cells	  are	  a	  more	  physiological	  model	  for	  the	  study	  of	  HCV.	  The	  permissivity	  of	  these	  cells	  is	  altered	  by	  differentiation	  status.	  The	  next	  steps	  therefore	  concentrate	  on	  understanding	  the	  interaction	  between	  host	  cell	  and	  virus	  and	  will	  be	  explored	  in	  the	  next	  chapter.	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Chapter	  4:	  The	  HCV	  
lifecycle	  in	  Huh-­‐7diff	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4.1:	  Introduction	  	   The	  previous	  chapter	  has	  outlined	  hepatoma	  cell	  differentiation	  and	  showed	  how	  these	  cells	  have	  significantly	  reduced	  permissivity	  to	  HCV	  infection.	  This	  is	  an	  important	  observation	  as	  it	  can	  offer	  insights	  into	  viral	  host	  interactions	  in	  vivo.	  This	  chapter	  will	  focus	  on	  exploring	  the	  reasons	  behind	  the	  alteration	  in	  viral	  permissivity.	  	  	  	   The	  Hepatitis	  C	  virus	  lifecycle	  is	  well	  described	  and	  there	  are	  known	  factors	  that	  influence	  each	  step.	  Differentiated	  hepatoma	  cells	  have	  changes	  in	  many	  cellular	  factors	  that	  are	  known	  to	  impact	  viral	  permissivity.	  We	  therefore	  looked	  at	  each	  step	  of	  the	  viral	  lifecycle	  to	  identify	  how	  the	  virus	  is	  affected	  by	  host	  cellular	  differentiation	  and	  possible	  underlying	  mechanisms.	  	  	   HCV	  entry	  into	  hepatocytes	  is	  a	  multi-­‐step	  process	  that	  is	  dependent	  on	  host	  cell	  molecules;	  scavenger	  receptor	  B1	  	  (SRB1)	  (Westhaus	  et	  al,	  2017;	  Grove	  et	  al,	  2007),	  CD81	  (Pileri	  et	  al,	  1998;	  Meulemann	  et	  al,	  2008;	  Harris	  et	  al,	  2010)	  the	  tight	  junction	  proteins	  claudin-­‐1	  (Evans	  et	  al,	  2007;	  Harris	  et	  al,	  2010;	  reviewed	  in	  Tawar	  et	  al,	  2015)	  and	  occludin	  (Ploss	  et	  al,	  2009;	  Liu	  et	  al,	  2009),	  and	  Niemann-­‐Pick	  C1-­‐like	  1	  cholesterol	  absorption	  receptor	  (NPC1L1)	  (Sainz	  et	  al,	  2012)	  prior	  to	  being	  internalized	  by	  clathrin-­‐mediated	  endocytosis.	  Figure	  
1.4	  gives	  an	  overview	  of	  the	  key	  steps	  in	  HCV	  entry	  (reviewed	  in	  Lindenbach	  and	  Rice,	  2013).	  Tight	  junctions	  play	  an	  important	  role	  in	  viral	  entry	  and	  exist	  between	  adjacent	  hepatocytes	  in	  vivo.	  Cells	  establish	  complex	  hepatic	  polarity	  by	  separating	  the	  apical	  and	  basolateral	  membranes	  of	  cells	  (Figure	  1.9).	  The	  HCV	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receptors	  localise	  distinctly	  in	  a	  polarised	  cell.	  	  Claudin	  is	  located	  at	  the	  apical	  tight-­‐junction	  region	  and	  is	  also	  found	  in	  the	  basal-­‐sinusoidal	  region	  co-­‐located	  with	  CD81	  (Reynolds	  et	  al,	  2008).	  SR-­‐B1	  is	  found	  at	  the	  basolateral	  surface	  (Reynolds,	  Harris	  2008).	  Claudin	  also	  associates	  with	  other	  proteins	  such	  as	  Zonula	  Occludens	  (ZO)	  to	  maintain	  structural	  integrity	  of	  the	  tight	  junctions	  between	  neighbouring	  hepatocytes	  (Shin	  et	  al,	  2006).	  Hepatic	  polarisation,	  as	  well	  as	  being	  essential	  to	  physiological	  functioning	  of	  the	  liver,	  also	  restricts	  HCV	  entry	  (Mee	  et	  al,	  2008;	  Mee	  et	  al;	  2009;	  Harris	  et	  al,	  2013)	  and	  consequently	  HCV	  permissivity.	  Huh-­‐7	  cells	  are	  not	  known	  to	  polarise	  and	  do	  not	  form	  tight	  junctions	  between	  cells.	  However,	  previous	  results	  have	  shown	  that	  differentiated	  cells	  alter	  morphologically.	  Therefore	  we	  investigated	  the	  localisation	  of	  HCV	  receptors,	  tight	  junction	  proteins	  and	  subsequent	  HCV	  entry	  into	  differentiated	  cells.	  	  	  Following	  entry	  the	  viral	  capsid	  uncoats	  and	  the	  RNA	  is	  translated	  to	  generate	  the	  polyprotein	  (see	  Figure	  1.3).	  The	  viral	  encoded	  non-­‐structural	  proteins	  mediate	  replication	  of	  the	  viral	  RNA	  in	  membrane	  bound	  replication	  complexes	  (Lindenbach	  et	  al,	  2005).	  Essential	  to	  this	  process	  is	  miR122,	  which	  binds	  to	  the	  5’UTR	  enhancing	  viral	  translation	  and	  stabilizing	  the	  genome	  (Jopling	  et	  al,	  2005;	  Henke	  et	  al,	  2008;	  Georgen	  et	  al,	  2012).	  Additionally,	  it	  protects	  viral	  RNA	  from	  degradation	  (Conrad	  et	  al,	  2013;	  Li	  et	  al,	  2013),	  can	  modulate	  the	  IFN	  response	  to	  virus	  (Li	  et	  al,	  2013)	  and	  has	  also	  been	  implicated	  in	  viral	  entry	  (Sendi	  et	  al,	  2015).	  Expression	  of	  miR122	  in	  stem	  cell	  derived	  hepatocytes	  correlates	  with	  permissivity	  to	  HCV	  infection	  (Wu	  et	  al,	  2012).	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Previous	  results	  have	  shown	  that	  differentiation	  of	  Huh-­‐7	  cells	  increases	  miR122	  levels	  and	  this	  may	  play	  an	  important	  role	  in	  viral	  replication	  in	  these	  cells.	  	  Furthermore,	  mir-­‐122	  is	  known	  to	  regulate	  iron	  homeostasis	  (Castoldi	  and	  Muckenthaler,	  2012).	  Iron	  inhibits	  the	  HCV	  polymerase	  and	  suppresses	  subgenomic	  replication	  of	  HCV	  (Fillebeen	  et	  al,	  2005).	  DMSO	  treatment	  of	  hepatoma	  cells	  has	  been	  reported	  to	  alter	  heam	  synthesis,	  a	  downstream	  pathway	  for	  the	  production	  of	  cellular	  iron	  (Galbraith	  et	  al,	  1988).	  Changes	  in	  cellular	  iron	  represent	  a	  possible	  mechanism	  for	  reduction	  in	  HCV	  infectivity	  in	  differentiated	  hepatoma	  cells.	  	  	   In	  addition	  to	  cellular	  iron,	  both	  lipid	  and	  glucose	  metabolism	  are	  essential	  to	  the	  normal	  function	  of	  a	  hepatocyte	  and	  are	  known	  to	  interact	  closely	  with	  HCV.	  Infected	  hepatocytes	  shift	  their	  glucose	  pathways	  to	  resemble	  glycolysis	  (Ripoli	  et	  al,	  2010)	  via	  hypoxia-­‐inducible	  factor	  (Hif)-­‐1	  stabilisation	  to	  promote	  energy	  conservation	  and	  survival	  of	  infected	  cells	  (Diamond	  et	  al,	  2010).	  There	  is	  little	  known	  about	  whether	  altering	  glucose	  pathways	  within	  infected	  cells	  can	  influence	  viral	  replication,	  however	  this	  may	  be	  important	  to	  consider.	  We	  investigated	  whether	  these	  factors	  may	  play	  a	  role	  in	  the	  alteration	  in	  viral	  permissivity	  in	  differentiated	  cells.	  	  	   One	  of	  the	  major	  restriction	  factors	  limiting	  HCV	  replication	  is	  cellular	  innate	  signalling.	  Figure	  1.12	  gives	  an	  overview	  of	  innate	  signalling	  in	  hepatocytes	  in	  response	  to	  HCV.	  The	  host	  cell	  responds	  to	  HCV	  through	  the	  pattern	  recognition	  receptors,	  TLR3	  on	  endosomal	  surfaces	  and	  cell	  membranes	  and	  cytosolic	  RIG-­‐I	  (Satoh	  and	  Akira,	  2016;	  Sumpter	  et	  al,	  2005)	  and	  MDA-­‐5	  (Du	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et	  al,	  2016).	  These	  lead	  to	  a	  downstream	  cascade	  that	  results	  in	  interferon	  production.	  The	  predominant	  interferon	  produced	  by	  immune	  competent	  hepatocytes	  in	  response	  to	  HCV	  infection	  is	  IL29	  (IFNλ1)	  a	  type	  III	  interferon	  (Park	  et	  al,	  2012).	  This	  can	  act	  independently	  of	  type	  1	  interferons	  to	  inhibit	  HCV	  replication.	  Gene	  association	  studies	  have	  also	  shown	  the	  important	  roles	  for	  IFN	  λ	  alleles	  in	  predicting	  outcome	  of	  HCV	  infection	  and	  response	  to	  infection	  (Balagopal	  et	  al,	  2010;	  Rauch	  et	  al,	  2010).	  Once	  infection	  is	  established,	  the	  virus	  can	  evade	  immune	  signalling	  as	  the	  NS3/4A	  is	  capable	  of	  cleaving	  cellular	  adaptive	  proteins	  MAVS	  (also	  called	  IPS-­‐1,	  VISA,	  Cardif)	  and	  TRIF	  (Li	  XD	  et	  al,	  2005;	  Li	  K	  et	  al,	  2005;	  reviewed	  in	  Heim	  and	  Thimme,	  2014).	  	  	  Interestingly,	  Huh-­‐7	  and	  Huh-­‐7.5	  have	  defective	  immune	  recognition;	  Huh-­‐7	  lack	  TLR3	  expression	  but	  express	  RIG-­‐I,	  and	  Huh-­‐7.5	  do	  not	  have	  TLR3	  and	  have	  a	  defective	  RIG-­‐I	  (Li	  K	  et	  al,	  2005).	  This	  is	  thought	  to	  explain	  why	  hepatoma	  cells	  are	  highly	  permissive	  to	  infection	  in	  vitro.	  There	  is	  loss	  of	  TLR3	  expression	  in	  Hepatocellular	  carcinoma	  (Wang	  et	  al,	  2009;	  Kataki	  et	  al,	  2017)	  suggesting	  that	  as	  cells	  become	  de-­‐differentiated	  they	  lose	  the	  ability	  to	  recognise	  extracellular	  or	  endosomal	  HCV.	  Transiently	  expressed	  TLR3	  in	  hepatoma	  cells	  allowed	  cells	  to	  re-­‐establish	  an	  antiviral	  response	  and	  limited	  HCV	  replication	  (Wang	  et	  al,	  2009).	  Bauhofer	  et	  al	  (2012)	  showed	  that	  Huh-­‐7	  cells	  differentiated	  with	  DMSO	  expressed	  a	  broader	  range	  of	  ISG	  mRNA	  than	  undifferentiated	  cells	  when	  stimulated	  with	  interferons.	  Changes	  in	  the	  immune	  response	  to	  HCV	  in	  differentiated	  cells,	  particularly	  production	  of	  IL29	  and	  upregulation	  of	  key	  ISGs,	  would	  likely	  lead	  to	  significantly	  reduced	  permissivity.	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We	  went	  on	  to	  investigate	  the	  role	  of	  innate	  signalling	  in	  response	  to	  viral	  infection	  within	  the	  DMSO	  differentiated	  system.	  	   Recently	  the	  discovery	  of	  the	  host	  factor	  SEC14L2	  has	  revolutionized	  the	  possibilities	  in	  HCV	  research.	  SEC14L2	  is	  a	  cytosolic	  protein	  that	  stimulates	  an	  enzyme	  in	  the	  cholesterol	  synthesis	  pathway.	  Overexpression	  of	  SEC14L2	  in	  Huh-­‐7.5	  allows	  the	  replication	  of	  a	  diverse	  range	  of	  HCV	  genotypes	  and	  plasma	  derived	  	  virus,	  which	  was	  previously	  difficult	  to	  achieve	  (Saeed	  et	  al,	  2015).	  Previous	  results	  have	  shown	  that	  differentiation	  of	  Huh-­‐7	  causes	  upregulation	  of	  SEC14L2	  mRNA.	  We	  went	  on	  to	  investigate	  whether	  this	  had	  any	  effect	  on	  viral	  permissivity.	  	  	  Once	  the	  virus	  has	  entered	  the	  host	  cell	  and	  the	  genome	  has	  replicated,	  new	  particles	  assemble	  and	  are	  secreted	  from	  the	  infected	  cell,	  in	  a	  process	  that	  involves	  viral	  proteins	  associating	  with	  lipid	  droplets	  (Miyanari	  et	  al,	  2007;	  Lindenbach,	  2013)	  and	  apoplipoproteins	  (Benga	  et	  al,	  2010).	  The	  final	  stages	  of	  viral	  maturation	  are	  closely	  linked	  with	  the	  VLDL	  secretion	  pathway	  (Gastaminza	  et	  al,	  2008;	  Lindenbach,	  2013).	  The	  mature	  particle	  can	  then	  infect	  naïve	  target	  cells	  via	  cell-­‐free	  or	  cell-­‐to-­‐cell	  transmission	  routes	  (Timpe	  et	  al,	  2008;	  Brimacombe	  et	  al,	  2011).	  Some	  HCV	  strains	  (J6/JFH)	  are	  more	  efficient	  at	  spreading	  cell-­‐to-­‐cell	  than	  cell-­‐free,	  whereas	  other	  strains	  (SA13/JFH	  and	  (HK6/JFH)	  show	  comparable	  rates	  in	  undifferentiated	  hepatoma	  cells	  (Meredith	  et	  al,	  2013).	  The	  mechanism	  of	  HCV	  direct	  cell-­‐cell	  spread	  is	  not	  fully	  understood,	  but	  may	  be	  less	  dependent	  on	  CD81	  and	  SRB1	  expression	  (Lindenbach	  and	  Rice,	  2013).	  Studies	  of	  clusters	  of	  HCV	  infected	  cells	  within	  
	   131	  
livers	  of	  patients	  (Liang	  et	  al,	  2009;	  Kandathil	  et	  al,	  2013)	  suggest	  that	  cell-­‐cell	  transmission	  is	  a	  potentially	  important	  route	  in	  vivo	  and	  may	  be	  influenced	  by	  cellular	  differentiation	  status.	  	  	   Previous	  results	  showed	  that	  DMSO	  differentiates	  human	  hepatoma	  cells	  to	  become	  more	  ‘hepatocyte	  like’,	  whilst	  being	  easily	  accessible,	  cost	  effective	  and	  stable	  in	  culture	  over	  many	  days.	  They	  can	  provide	  an	  excellent	  model	  system	  for	  studying	  viral-­‐host	  cell	  interactions.	  Driving	  cellular	  differentiation	  is	  associated	  with	  a	  significantly	  reduced	  permissivity	  to	  support	  HCV	  infection.	  This	  chapter	  will	  investigate	  the	  viral	  lifecycle	  and	  associated	  pathways	  aiming	  to	  understand	  how	  HCV	  enters,	  replicates	  and	  disseminates	  in	  differentiated	  cells.	  	  	  Aims	  -­‐ To	  understand	  how	  HCV	  enters,	  replicates	  and	  disseminates	  in	  differentiated	  Huh-­‐7	  cells.	  -­‐ To	  identify	  steps	  in	  the	  viral	  lifecycle	  regulated	  by	  cellular	  differentiation	  status.	  	  	  -­‐ To	  investigate	  the	  role	  of	  associated	  host	  pathways,	  such	  as	  interferon	  signalling	  and	  miR122	  expression	  on	  viral	  replication	  in	  differentiated	  Huh-­‐7	  cells.	  	  	   	  
	   132	  
4.2:	  HCV	  receptor	  expression	  and	  localisation	  in	  Huh-­‐7diff	  	  	   Hepatocytes	  in	  the	  liver	  are	  highly	  polarised.	  Currently	  available	  in	  vitro	  models	  to	  study	  hepatocyte	  polarity	  include	  HepG2	  cells	  and	  HepaRG	  cells	  that	  differentiate	  over	  time	  into	  hepatocyte-­‐like	  and	  biliary-­‐like	  cells.	  Polarised	  cells	  support	  low	  level	  HCV	  replication	  with	  limited	  viral	  dissemination	  (Mee	  et	  al,	  2009)	  much	  like	  the	  phenotype	  of	  HCV	  infected	  differentiated	  cells.	  Since	  receptor	  expression	  and	  localisation	  can	  define	  cellular	  susceptibility	  to	  HCV	  entry	  and	  viral	  permissivity	  we	  assessed	  whether	  DMSO	  treatment	  affects	  receptor	  localisation	  and	  cell	  polarisation.	  	  	  Hepatoma	  cells	  were	  treated	  with	  DMSO	  for	  up	  to	  21	  days	  and	  stained	  for	  HCV	  receptors	  CD81,	  tight	  junction	  proteins	  Claudin-­‐1,	  Occludin	  and	  ZO-­‐1	  along	  with	  bile	  cannaliculi	  marker	  MRP2	  (multidrug-­‐resistant-­‐protein	  2).	  Receptor	  localisation	  was	  analysed	  by	  confocal	  microscopy.	  Unlike	  hepatocytes	  that	  have	  multipolar	  organization,	  Claudin-­‐1	  in	  differentiated	  cells	  is	  expressed	  almost	  exclusively	  at	  the	  apical	  surface	  (Figure	  4.1).	  This	  does	  not	  suggest	  that	  cells	  are	  developing	  complex	  hepatocyte	  polarity,	  rather	  that	  receptor	  localisation	  is	  more	  consistent	  with	  columnar	  epithelial-­‐type	  polarisation	  (Singh	  and	  Harris,	  2003;	  Treyer	  and	  Müsch,	  2013)	  where	  the	  cell	  is	  polarised	  in	  one	  direction	  (i.e.	  from	  apical	  to	  basolateral	  surface)	  (see	  Figure	  1.9).	  CD81	  was	  ubiquitously	  expressed	  and	  there	  was	  no	  alteration	  with	  differentiation.	  There	  were	  several	  small	  circular	  structures	  staining	  for	  MRP2,	  a	  bile	  cannalicular	  marker,	  and	  ZO-­‐1,	  a	  tight	  junction	  protein,	  in	  Day	  21	  differentiated	  cells.	  These	  were	  seen	  specifically	  in	  areas	  where	  the	  cells	  were	  highly	  compact	  (Figure	  4.2).	  We	  utilised	  CMFDA	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4.3:	  Differentiated	  cells	  do	  not	  restrict	  HCV	  entry	  	   Results	   have	   shown	   that	   differentiated	   cells	   alter	   the	   localisation	   of	  receptors	   important	   for	   HCV	   entry	   into	   a	   permissive	   cell.	   We	   therefore	  hypothesised	   that	   differentiated	   cells	   may	   restrict	   viral	   entry	   resulting	   in	  reduced	  permissivity.	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HCVpp	   Huh-­‐7	  
Rate	  entry	  (RLU	  x	  
104/min)	  
Huh-­‐7diff	  	  
Rate	  entry	  (RLU	  x	  
104/min)	  
P	  value	  
H77pp	   0.15	  ±	  0.05	   0.23	  ±	  0.02	   0.1	  1A51002pp	   0.09	  ±	  0.01	   0.125	  ±	  0.02	   0.24	  1A80pp	   0.07	  ±	  0.01	   0.04	  ±	  0.01	   0.23	  1A46pp	  	   0.17	  ±	  0.02	   0.11	  ±	  0.01	   0.6	  1B51pp	   0.23	  ±	  0.03	   0.22	  ±	  0.02	   0.9	  1B46pp	   0.04	  ±	  0.01	   0.03	  ±	  0.01	   0.8	  1B49pp	   0.13	  ±	  0.03	   0.07	  ±	  0.02	   0.4	  
	  
Table	  4.1	  HCV	  entry	  rate	  was	  not	  affected	  by	  differentiation	  	  Rate	  of	  viral	  entry	  for	  H77	  and	  patient	  derived	  strains	  expressed	  as	  RLU/min.	  	  These	  were	  calculated	  from	  the	  slope	  of	  the	  line	  by	  linear	  regression	  and	  any	  differences	  analysed	  for	  significance	  by	  a	  two-­‐way	  ANOVA.	  Results	  are	  expressed	  relative	  to	  uninfected	  controls	  minus	  ‘No	  Envelope’	  values	  and	  corrected	  for	  cell	  number.	  Results	  represent	  the	  mean	  of	  triplicate	  wells	  and	  4	  independent	  experiments.	  p	  values	  =	  not	  significant.	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4.4:	  Differentiation	  of	  Huh-­‐7	  cells	  restricts	  HCV	  replication	  	   Previous	  results	  have	  shown	  that	  restriction	  in	  permissivity	  in	  Huh-­‐7diff	  is	  not	  due	  to	  altered	  viral	  entry	  in	  differentiated	  cells.	  The	  next	  step	  was	  to	  assess	  subsequent	  steps	  in	  the	  HCV	  lifecycle	  in	  differentiated	  cells	  to	  try	  and	  identify	  the	  point	  at	  which	  viral	  replication	  and/or	  dissemination	  is	  altered.	  	  	  	  Viral	   translation	   and	   early	   replication	   was	   assessed	   by	   utilising	   the	  JC1gLuc	  reporter	  virus	  (Gottwein	  et	  al,	  2011).	   JC1gLuc	  or	  the	  replicase-­‐negative	  JC1gLuc-­‐GNN	  RNA	  were	  transfected	  into	  Huh-­‐7diff	  or	  control	  cells	  and	  replication	  assessed	  by	  measuring	  secreted	  luciferase	  at	  indicated	  time	  points	  over	  the	  next	  72h.	  Results	  show	  comparable	  transfection	  efficiency	  at	  4h	  post-­‐delivery	  (Figure	  
4.7A),	  however	  by	  72h	  there	  was	  a	  10-­‐fold	  reduction	  in	  luciferase	  values	  in	  Huh-­‐7diff	   cells	   (Figure	   4.7	   C	   and	  D).	   The	   protease	   inhibitor	   VX950	  was	   included	   to	  confirm	  authentic	  HCV	  RNA	  replication.	  	  	  Replication	  is	  reduced	  in	  Huh-­‐7diff	  and	  a	  key	  cellular	  factor,	  miR122,	  is	  able	  to	   alter	   HCV	   replication.	   Initiation	   of	   replication	   of	   HCV	   is	   affected	   by	  miR122	  expression,	   and	   we	   have	   previously	   shown	   that	   levels	   are	   increased	   with	  differentiation	  (Figure	  3.6).	  Therefore,	  we	  assessed	  the	  effect	  of	  miR122	  on	  HCV	  IRES	  driven	   translation.	  A	   firefly	   luciferase	  reporter	  RNA	   flanked	  by	   the	  HCV	  5’	  and	  3’UTRs	  (Figure	  4.8A)	  was	  introduced	  into	  differentiated	  cells,	  with	  a	  miR122	  inhibitor	   or	   oligonucleotide	   control	   (Figure	   4.8B).	   Results	   indicate	   that	  differentiation	  decreases	  HCV	  replication	  in	  a	  miR122	  independent	  manner.	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In	  order	  to	  test	  the	  impact	  of	  differentiation	  on	  established	  replication	  we	  used	   a	   replicon-­‐based	   system.	   Huh-­‐7	   expressing	   full-­‐length	   H77	   replicon	  were	  treated	  with	  1.5%	  DMSO	  for	  up	  to	  14	  days.	  HCV	  RNA	  copies	  were	  quantified	  by	  qPCR.	   Results	   indicate	   that	   differentiation	   has	   no	   impact	   on	   HCV	   RNA	   levels	  (Figure	   4.9)	   in	   an	  established	   replicon	   line,	   suggesting,	   together	  with	   the	  gLuc	  results,	  that	  the	  defect	  is	  at	  the	  level	  of	  early	  replication.	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Figure	  4.7	  Huh-­‐7diff	  show	  a	  10-­‐fold	  reduction	  in	  initial	  HCV	  replication	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Figure	  4.8	  Differentiation	  of	  Huh-­‐7	  cells	  reduces	  HCV	  RNA	  replication	  in	  a	  
miR122	  independent	  manner.	  
	  (A)	  A	  firefly	  luciferase	  reporter	  RNA	  flanked	  by	  the	  HCV	  5’	  and	  3’UTRs	  was	  introduced	  into	  Huh-­‐7diff	  or	  control,	  with	  either	  a	  control	  oligonucleotide	  or	  miR122	  inhibitor.	  Cells	  were	  harvested	  at	  6h	  post	  transfection.	  (B)	  Results	  show	  firefly	  luciferase	  activity	  relative	  to	  a	  Renilla	  luciferase	  transfection	  control	  as	  a	  percentage	  of	  the	  Huh-­‐7	  control	  level,	  showing	  a	  reduction	  in	  HCV	  IRES-­‐driven	  translation	  with	  miR122	  inhibition.	  (C)	  The	  proportion	  of	  total	  translation	  that	  is	  mir122	  dependent	  is	  plotted	  and	  represents	  the	  difference	  between	  HCV	  translation	  in	  each	  cell	  type	  with	  or	  without	  the	  inhibitor.	  Data	  represent	  a	  mean	  and	  standard	  deviation	  of	  three	  independent	  experiments.	  ns	  =	  non	  significant.	  *	  p	  ≤0.05,	  **	  p	  ≤0.01,	  ***	  p	  ≤0.001,	  ****	  p	  ≤0.0001	  (Students	  t-­‐test).	  	   	  










Figure	  4.9	  Differentiation	  does	  not	  impact	  established	  HCV	  replication	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4.5:	  Key	  cellular	  factors	  that	  alter	  HCV	  replication	  in	  vivo	  do	  not	  play	  a	  role	  in	  viral	  permissivity	  in	  Huh-­‐7diff	  	  Differentiated	  Huh-­‐7	  cells	  are	  a	  more	  physiological	  system	  that	  becomes	  more	  ‘hepatoctye-­‐like’	  over	  time.	  Therefore,	  key	  cellular	  factors,	  that	  are	  altered	  by	  cellular	  differentiation	  and	  are	  known	  to	  impact	  HCV	  replication,	  were	  investigated.	  	  	  	  The	  liver	  is	  a	  major	  regulator	  of	  iron	  metabolism	  and	  there	  is	  clinical	  and	  molecular	  evidence	  that	  iron	  can	  impact	  HCV	  replication	  (reviewed	  in	  Drakesmith	  and	  Prentice,	  2008;	  Fillebeen	  et	  al,	  2015).	  In	  addition	  to	  this	  known	  interaction	  between	  HCV	  and	  cellular	  iron,	  DMSO	  can	  alter	  hepatoma	  haem	  synthesis	  (Galbraith	  et	  al,	  1986).	  Therefore,	  it	  was	  important	  to	  study	  the	  effect	  of	  DMSO	  on	  Huh-­‐7	  iron	  levels.	  A	  cell	  based	  ferrozine	  colorimetric	  assay	  was	  used	  to	  quantitate	  the	  amount	  of	  cellular	  iron	  within	  Huh-­‐7diff	  (Riemer	  et	  al,	  2004).	  Results	  show	  that	  there	  was	  no	  appreciable	  induction	  of	  iron	  seen	  in	  DMSO	  treated	  cells	  (Figure	  4.10).	  Given	  there	  were	  no	  changes	  in	  the	  amount	  of	  iron	  seen	  we	  did	  not	  go	  on	  to	  investigate	  the	  interaction	  between	  iron	  and	  HCV	  replication.	  Changes	  in	  cellular	  iron	  levels	  are	  unlikely	  to	  be	  playing	  a	  role	  in	  the	  reduced	  permissivity	  noted	  in	  Huh-­‐7diff.	  	   Huh-­‐7diff	  upregulate	  key	  markers	  of	  gluconeogenesis	  (PEPCK	  and	  G-­‐6-­‐Pase)	  when	  grown	  in	  physiological	  amounts	  of	  glucose	  (Figure	  3.5).	  Hepatocytes	  maintain	  glucose	  homeostasis.	  In	  relatively	  de-­‐differentiated	  cells,	  such	  as	  those	  from	  hepatocellular	  carcinoma	  and	  in	  HCV-­‐infected	  hepatocytes,	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gluconeogenesis	  is	  downregulated	  and	  glycolytic	  pathways	  are	  increased	  (Koike,	  2007;	  Ripoli	  et	  al,	  2010).	  We	  therefore	  attempted	  to	  switch	  cells	  into	  a	  glycolytic	  state	  by	  reducing	  the	  amount	  of	  available	  glucose	  and	  assessing	  the	  effect	  on	  HCV	  replication.	  Cells	  were	  grown	  in	  reducing	  amounts	  of	  glucose	  (by	  diluting	  DMEM	  4.5g/dl	  glucose	  with	  glucose	  free	  DMEM)	  and	  G-­‐6-­‐Pase	  levels	  measure	  by	  qPCR.	  G-­‐6-­‐Pase	  is	  the	  irreversible	  rate-­‐limiting	  step	  for	  cells	  to	  generate	  new	  glucose.	  Results	  show	  G-­‐6-­‐Pase	  is	  downregulated	  in	  Huh-­‐7diff	  cultured	  in	  media	  with	  reduced	  amounts	  of	  glucose	  (Figure	  4.11A)	  as	  a	  marker	  of	  cells	  metabolizing	  predominantly	  via	  glycolysis.	  Utilising	  LucA2	  replicon	  cells	  to	  assess	  the	  effect	  of	  glycolysis	  on	  viral	  replication,	  cells	  were	  treated	  with	  DMSO	  for	  7	  days	  and	  then	  grown	  in	  reducing	  amounts	  of	  glucose.	  HCV	  replication	  was	  assessed	  by	  luciferase	  activity	  (Figure	  4.11B).	  Similarly,	  Huh-­‐7diff	  infected	  with	  HCVcc	  after	  exposure	  to	  reducing	  concentrations	  of	  glucose	  (Figure	  4.11C)	  showed	  a	  trend	  to	  reducing	  viral	  copies	  by	  qPCR	  although	  this	  was	  not	  significant.	  Importantly,	  altering	  metabolism	  in	  these	  cells	  failed	  to	  rescue	  the	  reduced	  permissivity	  in	  differentiated	  cells.	  Although	  glucose	  metabolism	  may	  play	  an	  important	  role	  in	  vivo,	  there	  was	  no	  direct	  effect	  of	  altering	  the	  metabolic	  profile	  of	  differentiated	  cells	  on	  HCV	  replication	  in	  vitro.	  	  	  In	  addition	  to	  iron	  and	  glucose	  metabolism,	  Saeed	  et	  al	  (2015)	  have	  shown	  that	  SEC14L2	  is	  an	  important	  cellular	  factor	  that	  allows	  hepatoma	  cells	  to	  support	  a	  wide	  range	  of	  non-­‐JFH	  based	  genotypes.	  Cellular	  differentiation	  increases	  SEC14L2	  mRNA	  expression	  (Figure	  3.8A).	  We	  assessed	  whether	  overexpression	  of	  SEC14L2	  altered	  HCV	  permissivity.	  Cells	  were	  infected	  with	  an	  early	  SA13	  virus	  (containing	  no	  laboratory	  adaptation	  mutations)	  using	  Huh-­‐7.5	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Figure	  4.10	  Differentiation	  of	  Huh-­‐7	  cells	  has	  a	  modest	  effect	  on	  iron	  
expression.	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Figure	  4.11	  Changing	  glucose	  concentration	  does	  not	  alter	  HCV	  
permissivity	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Figure	  4.12	  Overexpression	  of	  SEC14L2	  does	  not	  restore	  permissivity	  of	  
Huh-­‐7.5diff	  	  (A)	  Huh-­‐7.5	  cells	  were	  transduced	  to	  over-­‐express	  SEC14L2	  by	  Jeroen	  Witteveld	  (University	  of	  Edinburgh)	  and	  selected	  clones	  for	  experiments	  are	  depicted.	  (B)	  Huh-­‐7.5	  and	  SEC14L2	  overexpressing	  JW	  clones	  were	  infected	  with	  early	  passage	  HCV	  SA13/JFH.	  48	  hours	  post	  infection	  cells	  were	  fixed	  and	  stained	  for	  NS5A.	  Results	  are	  FFU/ml	  and	  are	  means	  of	  3	  wells	  in	  duplicate	  experiments.	  (C)	  Huh-­‐7.5	  and	  JW	  clone	  23	  cells	  were	  differentiated	  for	  10	  days	  as	  previously	  described	  and	  infected	  with	  HCVcc	  (early	  SA13/JFH	  MOI	  10).	  72	  hours	  post	  infection	  cells	  were	  fixed,	  stained	  and	  NS5A	  positive	  foci	  counted.	  Viral	  infectivity	  represents	  FFU/ml	  and	  fold	  change	  was	  calculated	  by	  infectivity	  of	  undifferentiated	  cells/infectivity	  of	  differentiated	  cells.	  Results	  are	  means	  of	  4	  wells	  and	  represent	  two	  independent	  experiments	  ****p≤0.0001	  **p≤0.01	  *p≤0.05	  ns=	  not	  significant	  (Students	  t-­‐test).	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4.6:	  Differentiated	  cells	  upregulate	  innate	  HCV	  sensors	  	  	  	   One	  of	  the	  major	  factors	  defining	  human	  hepatocyte	  permissivity	  to	  HCV	  is	  innate	  cellular	  signalling.	  Huh-­‐7	  and	  derivatives	  support	  high	  level	  HCV	  replication	  and	  are	  known	  to	  have	  defects	  in	  innate	  signalling	  pathways	  (Sumpter	  et	  al,	  2005)	  and	  do	  not	  produce	  interferons	  when	  infected	  with	  HCVcc.	  This	  allows	  permissivity	  to	  HCVcc	  in	  vitro,	  however,	  does	  not	  support	  the	  study	  of	  virus	  host	  immune	  interaction.	  	  	  	  Primary	  human	  hepatocytes	  robustly	  upregulate	  an	  innate	  immune	  response	  when	  infected	  with	  HCV	  (Dill	  et	  al,	  2012)	  and	  Huh-­‐7diff	  have	  been	  shown	  to	  express	  a	  broad	  range	  of	  ISGs	  in	  response	  to	  interferons	  in	  vitro	  (Bauhofer	  et	  al,	  2012)	  suggesting	  that	  differentiation	  alters	  the	  anti-­‐viral	  state	  of	  the	  cell.	  Furthermore,	  de-­‐differentiated	  cells	  downregulate	  TLR3	  (Wang	  e	  al,	  2009;	  Li	  et	  al,	  2005),	  losing	  the	  ability	  to	  recognise	  and	  respond	  to	  extracellular	  or	  endosomal	  HCV.	  To	  investigate	  the	  impact	  of	  differentiation	  on	  TLR3	  expression	  Huh-­‐7	  and	  Huh-­‐7.5	  cells	  were	  differentiated	  for	  up	  to	  10	  days	  and	  TLR3	  mRNA	  assessed	  by	  qPCR.	  Both	  Huh-­‐7	  and	  Huh-­‐7.5	  were	  included	  as	  they	  are	  known	  to	  have	  altered	  innate	  signalling	  pathways	  with	  Huh-­‐7.5	  having	  a	  single	  point	  mutation	  in	  RIG-­‐I.	  Results	  show	  there	  was	  a	  robust	  upregulation	  of	  TLR3	  mRNA	  over	  time,	  that	  was	  enhanced	  by	  ongoing	  differentiation	  (Figure	  
4.13)	  and	  this	  level	  was	  similar	  between	  Huh-­‐7	  and	  Huh-­‐7.5.	  	  
 Viral	  RNA	  is	  also	  recognised	  by	  RIG-­‐I,	  which	  is	  known	  to	  be	  functionally	  present	  in	  Huh-­‐7.	  RIG-­‐I	  exists	  in	  various	  locations	  within	  the	  cell;	  mitochondrial	  membranes,	  peroxisomal	  membranes	  or	  the	  mitochondrial	  associated	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membranes	  of	  the	  endoplasmic	  reticulum	  (Seth	  et	  al,	  2005;	  Dixit	  et	  al,	  2010;	  Horner	  et	  al,	  2011).	  The	  location	  of	  the	  RIG-­‐I	  engaged	  by	  dsRNA	  then	  signals	  a	  downstream	  cascade	  that	  results	  in	  numerous	  antiviral	  activities.	  RIG-­‐I	  on	  peroxisomes,	  is	  known	  to	  induce	  widespread	  ISGs	  but	  not	  Type	  I	  interferon,	  consistent	  with	  the	  response	  seen	  in	  hepatoma	  cells	  to	  HCV	  (Odendall,	  et	  al,	  2014).	  Interestingly,	  peroxisomal	  abundance	  increases	  during	  cellular	  differentiation	  and	  polarisation	  in	  intestinal	  cells	  (Odendall	  et	  al,	  2014).	  We	  therefore	  assessed	  peroxisome	  abundance	  in	  Huh-­‐7	  during	  the	  process	  of	  differentiation	  using	  a	  surrogate	  marker	  Pex11β	  which	  is	  a	  master	  regulator	  of	  peroxisome	  proliferation	  (Odendall	  et	  al,	  2014).	  Both	  Huh-­‐7diff	  and	  Huh-­‐7.5diff	  showed	  Pex11β	  mRNA	  increases	  over	  time	  (Figure	  4.14),	  suggesting	  that	  differentiated	  hepatomas	  have	  increased	  peroxisome	  abundance.	  Although	  further	  investigation	  into	  localisation	  of	  RIG-­‐I	  in	  these	  cells	  is	  required.	  	  	  Despite	  possible	  changes	  in	  RIG-­‐I	  localisation,	  we	  did	  not	  go	  on	  to	  fully	  investigate	  the	  role	  of	  differentiation	  status	  on	  function	  or	  downstream	  signalling	  of	  RIG-­‐I	  in	  hepatoma	  cells.	  Permissivity	  of	  Huh-­‐7diff	  and	  Huh-­‐7.5diff	  is	  comparable,	  with	  both	  showing	  a	  significantly	  altered	  RNA	  replication	  compared	  to	  undifferentiated	  cells	  (Figure	  4.15).	  Given	  the	  mutated	  RIG-­‐I	  present	  in	  Huh-­‐7.5,	  it	  is	  unlikely	  that	  RIG-­‐I	  is	  key	  for	  restricting	  HCV	  replication	  and	  this	  was	  not	  investigated	  further.	  	  	  Differentiated	  cells	  upregulate	  the	  innate	  sensor	  TLR-­‐3	  and	  potentially	  alter	  RIG-­‐I	  localisation.	  Altered	  TLR-­‐3	  may	  be	  an	  important	  observation	  in	  the	  antiviral	  state	  of	  differentiated	  cells	  and	  requires	  further	  investigation.	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Figure	  4.13	  Differentiated	  hepatomas	  upregulate	  TLR3	  	  Huh-­‐7	  and	  Huh-­‐7.5	  were	  treated	  with	  DMSO	  for	  up	  to	  14	  days,	  cellular	  RNA	  extracted	  and	  TLR3	  quantified	  by	  qPCR.	  Fold	  induction	  in	  Huh-­‐7.5diff	  is	  plotted	  (over	  untreated	  controls).	  Results	  are	  means	  of	  triplicate	  wells	  and	  two	  independent	  experiments.	  Significant	  changes	  were	  analysed	  using	  the	  Students	  ‘t’	  test	  and	  compared	  to	  Day	  0	  cells.	  ****p≤000.1	  ***	  p≤0.001**p≤0.01.	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Figure	  4.14	  Differentiated	  hepatomas	  upregulate	  the	  peroxisome	  marker	  
Pex-­‐11β	  	  (A)	  Huh-­‐7	  and	  Huh-­‐7.5	  were	  treated	  with	  DMSO	  for	  up	  to	  14	  days,	  cellular	  RNA	  extracted	  and	  Pex-­‐11β	  quantified	  by	  qPCR.	  Raw	  delta	  ct	  values	  are	  plotted	  to	  allow	  direct	  comparison	  between	  quantification	  in	  Huh-­‐7	  and	  Huh-­‐7.5.	  (B)	  Fold	  induction	  is	  plotted	  relative	  to	  untreated	  controls.	  Results	  are	  means	  of	  triplicate	  wells	  and	  two	  independent	  experiments.	  Significant	  differences	  in	  fold	  change	  were	  analysed	  using	  a	  students	  t-­‐test	  and	  compared	  to	  Day	  0	  cells	  **p≤0.01	  *p≤0.05.	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Figure	  4.15.	  There	  is	  comparable	  viral	  permissivity	  between	  Huh-­‐7diff	  and	  
Huh-­‐7.5diff	  
	  Relative	  infectivity	  was	  determined	  by	  titrating	  HCV	  SA13/JFH	  onto	  Huh-­‐7diff	  or	  Huh-­‐7	  cells.	  Infection	  was	  determined	  at	  72h	  post-­‐infection	  by	  immunofluorescence	  for	  NS5A	  expression	  or	  by	  qPCR	  for	  viral	  RNA.	  Results	  are	  expressed	  as	  the	  number	  of	  NS5A	  positive	  cells	  per	  ml	  of	  virus.	  Results	  are	  mean	  and	  standard	  deviation	  of	  triplicate	  wells	  and	  representative	  of	  3	  separate.	  Results	  were	  analysed	  using	  students	  t-­‐test.	  ns=	  non	  significant	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4.7:	  Differentiated	  cells	  exhibit	  an	  innate	  immune	  response	  to	  HCV	  infection	  
 	   Results	  have	  shown	  that	  differentiated	  hepatoma	  cells	  have	  an	  increased	  abundance	  of	  TLR3	  mRNA	  and	  are	  known	  to	  express	  a	  broad	  range	  of	  ISGs	  (Bauhofer	  et	  al,	  2012).	  We	  investigated	  whether	  differentiated	  hepatoma	  cells	  respond	  to	  innate	  signalling	  by	  HCV	  and	  produce	  interferons.	  	  	   The	  predominant	  interferon	  produced	  by	  primary	  human	  hepatocytes	  infected	  with	  HCV	  is	  IL-­‐29	  (IFN	  λ1)	  and	  this	  exerts	  an	  anti-­‐viral	  effect	  in	  vitro	  (Park	  et	  al,	  2012;	  Marukian	  et	  al,	  2011).	  This	  response	  is	  not	  restricted	  to	  primary	  human	  hepatocytes,	  as	  HepG2	  cells	  also	  produce	  Interferon	  λ	  in	  response	  to	  HCV	  which	  attenuates	  replication	  (Israelow	  et	  al,	  2014).	  Mouse	  derived	  liver	  cells	  were	  able	  to	  produce	  both	  type	  1	  (IFN	  α)	  and	  type	  3	  (IFN	  λ)	  interferon	  when	  transfected	  with	  a	  HCV	  subgenomic	  replicon,	  which	  led	  to	  abrogation	  of	  infection	  (Anggakusuma	  et	  al,	  2015).	  We	  investigated	  whether	  Huh-­‐7diff	  were	  able	  to	  produce	  IL29	  (IFN	  λ1)	  and	  IFNα	  in	  response	  to	  HCV	  or	  synthetic	  analogues.	  	  The	  early	  innate	  response	  of	  Huh-­‐7diff	  	  (6	  hours)	  to	  stimulators	  of	  TLR3,	  RIG-­‐I	  and	  MDA-­‐5	  was	  investigated.	  PolyIC	  was	  used	  to	  mimic	  dsRNA	  both	  transfected	  into	  the	  cell	  (RIG-­‐I,	  MDA-­‐5)	  and	  delivered	  extracellularly	  (TLR3).	  Specific	  viral	  activators	  of	  RIG-­‐I	  and	  MDA5	  were	  also	  used;	  Sendai	  virus	  is	  a	  RIG-­‐I	  activator	  (Kell	  and	  Gale,	  2015)	  and	  Encephalomyocarditis	  virus	  (EMCV)	  a	  specific	  MDA-­‐5	  activator	  (Rodriguez	  et	  al,	  2014).	  Results	  show	  that	  there	  was	  no	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IFNα	  mRNA	  detectable	  in	  either	  cell	  type.	  However,	  Huh-­‐7diff	  increased	  IFNλ	  mRNA	  in	  response	  to	  both	  extracellular	  PolyIC	  (TLR3)	  and	  transfected	  PolyIC	  (RIG-­‐I)	  and	  EMCV	  (MDA-­‐5)	  (Figure	  4.16).	  Results	  confirm	  that	  innate	  signalling	  pathways	  via	  TLR3,	  RIG-­‐I	  and	  MDA5	  are	  active	  in	  differentiated	  cells	  and	  upregulate	  IL29	  mRNA	  in	  response	  to	  ligand	  activation.	  	  
	  
Previous	  authors	  have	  shown	  that	  the	  innate	  response	  in	  human	  fetal	  liver	  cells	  to	  HCV	  is	  maximal	  at	  24	  hours	  post	  stimulation	  (Park	  et	  al,	  2012).	  	  We	  confirmed	  this,	  showing	  that	  the	  IFNλ	  mRNA	  level	  was	  greatest	  at	  24	  hours	  post	  stimulation	  both	  to	  PolyIC	  and	  to	  transfected	  HCV	  RNA	  (J6/JFH)	  (Figure	  4.17A).	  	  We	  also	  looked	  at	  Mx1,	  a	  key	  ISG,	  which	  is	  induced	  within	  6	  hours	  of	  HCV	  infection	  in	  the	  livers	  of	  chimpanzees	  (Park	  et	  al,	  2012).	  Results	  show	  comparable	  data,	  with	  Huh-­‐7diff	  showing	  an	  early	  Mx1	  response	  (Figure	  4.17B).	  There	  was	  minimal	  IFNα	  mRNA	  at	  24	  hours,	  confirming	  the	  predominance	  of	  Type	  3	  signalling	  in	  Huh-­‐7diff	  (Figure	  4.17C)	  and	  an	  antiviral	  state	  within	  the	  cells.	  	   	  Given	  the	  significant	  upregulation	  of	  IL29	  mRNA	  we	  went	  on	  to	  investigate	  whether	  this	  was	  translated	  into	  IL29	  protein.	  HepG2	  cells	  were	  used	  as	  a	  positive	  control,	  as	  they	  are	  known	  to	  be	  responsive	  to	  PolyIC,	  producing	  and	  secreting	  detectable	  extracellular	  IL29	  protein	  24	  hours	  post	  stimulation	  (Israelow	  et	  al,	  2014).	  Figure	  4.18A	  shows	  that	  despite	  significant	  mRNA	  levels,	  there	  is	  no	  detectable	  IL29	  protein	  produced	  after	  PolyIC	  or	  HCV	  RNA	  transfection	  in	  Huh-­‐7diff.	  IL29	  is	  known	  to	  have	  paracrine	  effects	  when	  secreted,	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however	  it	  also	  has	  autocrine	  effects	  (Bruening	  et	  al,	  2017)	  and	  may	  act	  locally	  without	  significant	  amounts	  being	  secreted	  into	  the	  media.	  Similarly,	  another	  closely	  related	  interferon,	  IFNλ4	  is	  produced	  in	  response	  to	  HCV	  infection,	  in	  HepG2	  and	  primary	  human	  hepatocytes,	  however	  is	  partially	  retained	  within	  the	  cytoplasm	  (Onabajo	  et	  al,	  2015).  Therefore	  we	  tested	  for	  the	  presence	  of	  IL29	  intracellularly	  by	  stimulating	  the	  cells	  as	  previously,	  and	  lysing	  cells	  at	  24	  hours,	  looking	  for	  evidence	  of	  IL29	  protein.	  Detectable	  IL29	  was	  present	  in	  the	  lysed	  cells,	  suggesting	  that	  Huh-­‐7diff	  can	  produce	  protein	  in	  response	  to	  RIGI/MDA5	  stimulation,	  although	  this	  was	  at	  a	  very	  low	  level	  (Figure	  4.18B).	  In	  contrast	  to	  HepG2	  cells,	  Huh-­‐7diff	  do	  not	  secrete	  significant	  amounts	  of	  protein.	  Furthermore,	  supernatant	  from	  Huh-­‐7diff	  stimulated	  with	  PolyIC	  and	  HCV	  RNA	  did	  not	  impact	  upon	  established	  HCV	  replication	  (Figure	  4.18C),	  suggesting	  that	  there	  were	  not	  antiviral	  mediators	  secreted	  in	  the	  media.	  	  
	   Despite	  the	  robust	  upregulation	  of	  IL29	  mRNA	  with	  synthetic	  stimulators	  a	  key	  questions	  was	  whether	  Huh-­‐7diff	  would	  respond	  to	  HCVcc	  in	  the	  same	  way,	  confirming	  their	  physiological	  response	  to	  infection	  compared	  to	  Huh-­‐7.	  Huh-­‐7diff	  were	  infected	  with	  HCVcc	  (SA13/JFH)	  at	  high	  MOI	  and	  IL29	  mRNA	  measured	  at	  24,	  48	  and	  72	  hours	  post	  infection.	  Interestingly,	  Huh-­‐7diff	  showed	  detectable	  levels	  of	  IL29	  mRNA,	  which	  was	  completely	  abrogated	  with	  the	  addition	  of	  VX950	  (Figure	  4.19).	  	  In	  summary,	  we	  have	  shown	  that	  Huh-­‐7diff	  exhibit	  a	  robust	  innate	  immune	  response	  to	  HCV	  infection	  that	  was	  associated	  with	  an	  increase	  in	  IL29	  and	  Mx1	  levels	  in	  a	  pattern	  consistent	  with	  that	  found	  in	  primary	  human	  hepatocytes	  and	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HepG2	  cells.	  	  However,	  cells	  failed	  to	  secrete	  measurable	  IL29	  protein,	  even	  though	  small	  amounts	  were	  found	  intracellularly,	  and	  supernatant	  was	  not	  able	  to	  inhibit	  established	  HCV	  replication.	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Figure	  4.17	  An	  Type	  3	  interferon	  response	  is	  seen	  in	  differentiated	  cells	  in	  
response	  to	  RLR	  stimulation	  
	  	  Huh-­‐7	  and	  Huh-­‐7diff	  were	  transfected	  with	  HCV	  RNA	  (J6/JFH)	  and	  PolyIC	  (LMW).	  Cells	  were	  lysed	  at	  6	  or	  24	  hours	  post	  transfection.	  IL29	  (A),	  Mx1	  (B)	  and	  INFα1(C)	  mRNA	  quantified	  by	  qPCR.	  Results	  are	  means	  of	  duplicate	  wells	  (IFN)	  or	  triplicate	  wells	  (Mx1)	  and	  representative	  of	  three	  independent	  experiments.	  Results	  were	  analysed	  by	  students	  t-­‐test	  and	  compared	  to	  undifferentiated	  cells	  unless	  indicated	  ***	  p≤0.001	  **	  p≤0.01	  *	  p≤0.05	  ns=	  not	  significant.	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Figure	  4.18	  RIG-­‐I	  stimulation	  results	  in	  very	  low	  levels	  of	  IL29	  protein	  in	  
differentiated	  cells.	  	  	  Huh-­‐7diff	  and	  HepG2	  control	  were	  transfected	  with	  J6/JFH	  and	  PolyIC	  (LMW).	  (A)	  24	  hours	  post	  transfection	  cells	  supernatant	  was	  removed	  and	  IL29	  was	  quantified	  by	  ELISA.	  (B)	  Cells	  were	  trypsinised	  and	  freeze	  thawed	  (3	  times)	  in	  200	  μl	  media	  to	  release	  intracellular	  IL29.	  Protein	  was	  quantified	  by	  ELISA	  according	  to	  manufacturers	  instructions	  using	  a	  standard	  curve	  (lower	  limit	  of	  sensitivity	  8pcg/ml	  indicated	  by	  dotted	  line).	  Results	  are	  means	  of	  triplicate	  wells	  and	  representative	  of	  4	  independent	  experiments.	  (C)	  Supernatant	  was	  added	  (1:1)	  to	  LucA2	  replicons.	  48	  hours	  later	  cells	  were	  lysed	  and	  replication	  quantified	  by	  luciferase.	  Results	  were	  analysed	  by	  students	  t-­‐test	  and	  compared	  to	  untreated	  cells	  ****p≤0.0001	  ns=non	  significant.	  	   	  











Figure	  4.19	  HCV	  infection	  can	  trigger	  an	  innate	  response	  in	  Huh-­‐7diff	  	  Huh-­‐7diff	  were	  infected	  with	  HCVcc	  at	  MOI	  10,	  with	  duplicate	  wells	  being	  treated	  with	  VX950	  (1mcg/ml).	  At	  indicated	  time	  points	  post	  infection	  cells	  were	  lysed	  and	  IL29	  mRNA	  levels	  quantified	  by	  qPCR.	  Results	  are	  IL29	  fold	  induction	  over	  baseline	  (24	  hours	  Huh-­‐7diff)	  and	  are	  means	  of	  two	  independent	  experiments	  and	  triplicate	  wells.	  Results	  were	  compared	  to	  24	  hours	  Huh-­‐7diff	  and	  analysed	  by	  students	  t-­‐test	  **p≤0.01	  ns=	  not	  significant.	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4.8:	  Differentiation	  of	  Huh-­‐7	  cells	  limits	  the	  infectivity	  of	  secreted	  extracellular	  HCV	  particles	  
	   Differentiation	  of	  Huh-­‐7	  cells	  results	  in	  reduced	  HCV	  RNA	  replication	  and	  translation.	   There	   is	   upregulation	   of	   innate	   signalling	   within	   cells,	   however	  results	  have	  not	  shown	  that	  this	  has	  a	  significant	  impact	  on	  viral	  replication.	  The	  next	  steps	  in	  the	  viral	  lifecycle	  were	  investigated	  in	  order	  to	  understand	  how	  HCV	  replicates	  and	  disseminates	  in	  a	  differentiated	  host.	  	  	  Huh-­‐7diff	  or	  non-­‐differentiated	  cells	  were	  infected	  with	  HCV	  SA13/JFH	  at	  an	   equivalent	  MOI	   and	   after	   72h	  HCV	  RNA	   and	   infectious	   virus	  measured.	   The	  results	   showed	   comparable	   levels	   of	   intracellular	   and	   extracellular	   HCV	   RNA	  expressed	   in	   Huh-­‐7diff	   and	   non-­‐differentiated	   cells	   (Figure	   4.20A),	   suggesting	  that	  virus	  release	  is	  not	  impaired.	  However	  there	  was	  a	  10-­‐fold	  reduction	  in	  the	  infectivity	   of	   extracellular	   virus	   collected	   from	   Huh-­‐7diff	   cells	   (Figure	   4.20B),	  suggesting	   a	   loss	   of	   particle	   infectivity.	  We	   have	   previously	   shown	   that	   DMSO	  does	  not	  have	  an	  effect	  on	  the	  viral	  particle	  and	  therefore	  loss	  of	  infectivity	  is	  due	  to	   the	   differentiation	   process	   and	   not	   DMSO	   itself	   (Figure	   3.13).	   Similarly,	  differentiation	   of	   cells	   using	   other	   methods	   (personal	   communication,	   N	  Frampton)	   results	   in	   a	   loss	   of	   permissivity,	   suggesting	   this	   is	   due	   to	   the	  differentiation	   process	   itself	   (Figure	   4.21)	   rather	   than	   an	   off	   target	   effect	   of	  DMSO.	  	   	  The	  reduction	  in	  specific	  infectivity	  of	  released	  virus	  suggests	  that	  there	  is	  likely	  to	  be	  a	  difference	  in	  viral	  spread.	  As	  HCV	  can	  spread	  via	  cell-­‐to-­‐cell	  and	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cell-­‐free	   routes	   (Brimacombe	   et	   al,	   2011),	   we	   utilised	   HCV	   neutralizing	  antibodies	   that	   prevent	   cell-­‐free	   infection	   to	   investigate	  whether	   differentiated	  cells	   support	   different	   viral	   transmission	   routes.	   Huh-­‐7diff	   or	   Huh-­‐7	   cells	   were	  infected	  with	  HCV	  SA13/JFH	  at	  an	  equivalent	  MOI	  in	  the	  presence	  of	  anti-­‐HCV	  IgG	  or	  control	  IgG,	  to	  measure	  viral	  dissemination	  via	  cell-­‐cell	  or	  cell-­‐free	  routes	  over	  a	  72h	  period.	  HCV	  infected	  90%	  of	  the	  non-­‐differentiated	  Huh-­‐7	  cells	  by	  72h	  that	  was	   largely	   explained	   via	   cell-­‐free	   infection	   (Figure	   4.22A).	   In	   contrast,	   there	  were	  minimal	   new	   infection	   events	   in	  Huh-­‐7diff	   cells	   and	   the	  majority	   occurred	  via	   cell-­‐cell	   transmission	   (Figure	   4.22B).	   Given	   that	   new	   viral	   transmission	  events	  can	  be	  masked	  by	  cell	  division	  (representing	  infected	  cell	  division	  rather	  than	   true	   de-­‐novo	   infection)	   we	   corrected	   for	   cell	   division	   in	   Huh-­‐7	   cells.	  Meredith	  et	  al	  (2013)	  showed	  that	  Huh-­‐7	  cells	  double	  in	  number	  every	  24	  hours,	  whereas	  Huh-­‐7diff	  are	  cell	  cycle	  arrested	  and	  do	  not	  alter	  cell	  number	  over	  time.	  Therefore	  we	  were	  able	  to	  estimate	  the	  number	  of	  cells	  infected	  by	  cell	  division	  over	  2,	  3	  and	  4	  days	  post	  infection.	  We	  normalised	  this,	  so	  infection	  events	  were	  representative	   of	   de-­‐novo	   infection	   and	   not	   cell	   division.	   When	   Huh-­‐7	   cell	  division	  is	  taken	  into	  account	  (Figure	  4.22C),	  we	  observed	  comparable	  rates	  of	  estimated	  cell-­‐cell	  HCV	  transmission	  suggesting	  that	  the	  reduced	  viral	  spread	  in	  Huh-­‐7diff	  cells	  is	  explained	  by	  the	  limited	  infectivity	  of	  extracellular	  virus.	  	  	  	  In	  summary	  results	  show	  that	  virus	  released	  from	  differentiated	  cells	  has	  a	  10	   fold	   reduction	   in	   specific	   infectivity.	   Cell	   spread	   is	   reduced	  which	   is	   likely	  due	   to	   limited	   infectivity	   of	   extracellular	   virus	   and	   suggests	   that	   cell-­‐to-­‐cell	  spread	  may	  be	  equally	  as	  efficient	  in	  Huh-­‐7diff	  as	  standard	  hepatoma	  cells.	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Figure	  4.21	  Differentiated	  cells	  show	  reduced	  permissivity	  to	  HCVcc	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Figure	  4.22	  Huh-­‐7diff	  support	  minimal	  amounts	  of	  cell	  free	  viral	  spread	  	  Huh-­‐7(A)	  and	  Huh-­‐7diff	  (B)	  were	  infected	  with	  SA13/JFH	  at	  an	  equivalent	  MOI.	  24h	  post	  infection,	  anti-­‐HCV	  or	  control	  IgG	  was	  added	  to	  inhibit	  cell-­‐free	  infection.	  Cells	  were	  fixed	  and	  stained	  for	  NS5A	  expression	  at	  indicated	  timepoints,	  and	  quantified	  by	  flow	  cytometry.	  Results	  are	  represented	  as	  relative	  infectivity	  with	  number	  of	  infected	  cells	  as	  a	  proportion	  of	  total	  cells	  in	  culture.	  (C)	  Spread	  was	  then	  corrected	  for	  cell	  division,	  allowing	  for	  doubling	  of	  cell	  number	  in	  the	  Huh-­‐7	  cells	  every	  24	  hours	  resulting	  in	  direct	  comparison	  of	  estimated	  cell-­‐cell	  viral	  spread	  with	  Huh-­‐7diff.	  Results	  are	  analysed	  using	  students	  t-­‐test	  **	  p≤0.01	  *	  p≤0.05	  ns=	  not	  significant	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4.9:	  The	  defect	  in	  permissivity	  can	  be	  overcome	  by	  cell	  delivered	  virus	  	   Previous	  results	  showed	  that	  HCV	  has	  limited	  cell	  free	  viral	  spread	  in	  the	  differentiated	  system.	  However,	  cell-­‐to-­‐cell	  spread	  appeared	  comparable.	  Therefore	  we	  investigated	  the	  role	  of	  cell-­‐cell	  viral	  delivery	  in	  Huh-­‐7diff.	  	  	   We	  utilised	  a	  previously	  published	  co-­‐culture	  assay	  where	  infected	  Huh-­‐7	  cells	  (HCV	  SA13/JFH	  and	  J6)	  were	  labelled	  with	  CMFDA	  and	  co-­‐cultured	  with	  naïve	  Huh-­‐7diff	  or	  non-­‐differentiated	  targets	  cells	  (Figure	  4.23)	  (Meredith	  et	  al,	  2013;	  Xiao	  et	  al,	  2014).	  Co-­‐cultures	  were	  incubated	  for	  1	  hour	  to	  allow	  cell	  contacts	  to	  form	  before	  adding	  anti-­‐HCV	  IgG	  or	  control	  IgG	  to	  neutralize	  extracellular	  infectious	  particles.	  Co-­‐cultures	  were	  incubated	  for	  a	  further	  72	  hours	  and	  the	  frequency	  of	  newly	  infected	  target	  cells	  normalized	  to	  the	  number	  of	  infected	  producer	  cells	  (Figure	  4.24).	  Comparable	  frequencies	  of	  HCV	  infected	  Huh-­‐7diff	  and	  non-­‐differentiated	  cells	  were	  observed	  for	  both	  viral	  strains.	  Given	  the	  upregulation	  of	  innate	  IL29	  responses	  in	  differentiated	  cells,	  we	  investigated	  whether	  cell-­‐to-­‐cell	  delivery	  of	  virus	  altered	  IL29	  mRNA.	  Figure	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Figure	  4.24	  Cell-­‐to-­‐cell	  transmission	  can	  overcome	  the	  defect	  in	  
permissivity	  of	  differentiated	  cells	  	  Huh-­‐7diff	  cells	  were	  co-­‐cultured	  with	  CMFDA-­‐labelled	  SA13/JFH	  infected	  producer	  cells	  (Huh-­‐7).	  Co-­‐cultures	  were	  then	  incubated	  for	  48	  h	  in	  the	  presence	  of	  control	  or	  anti-­‐HCV	  IgG,	  before	  being	  fixed,	  and	  infection	  quantified	  by	  flow	  cytometry,	  detecting	  NS5A.	  Results	  are	  the	  mean	  and	  standard	  deviation	  of	  three	  independent	  experiments.	  Results	  are	  analysed	  by	  students	  t-­‐test	  **	  p≤0.01	  *	  p≤0.05	  ns=	  not	  significant	  
























Figure	  4.25	  IL29	  levels	  are	  increased	  by	  cell–to-­‐cell	  delivery	  of	  HCV	  	  Huh-­‐7diff	  or	  Huh-­‐7	  control	  cells	  were	  co-­‐cultured	  with	  CMFDA-­‐labelled,	  SA13/JFH	  infected	  producer	  cells	  (Huh-­‐7).	  Co-­‐cultures	  were	  then	  incubated	  for	  the	  indicated	  timepoints	  +/-­‐	  VX950	  in	  duplicate	  wells.	  Cellular	  IL29	  mRNA	  was	  quantified	  by	  qPCR.	  Means	  from	  triplicate	  wells	  are	  plotted	  and	  representative	  of	  two	  independent	  experiments.	  Results	  were	  analysed	  using	  students	  t-­‐test	  and	  are	  compared	  to	  Huh-­‐7.	  ****p≤0.0001	  *	  p≤0.05.	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4.10:	  Discussion	  	   	   Results	  showed	  that	  DMSO	  induced	  differentiation	  of	  Huh-­‐7	  cells	   limits	  HCV	  RNA	   translation,	   early	   replication	   and	   the	   infectivity	   of	   extracellular	   HCV	  particles,	   resulting	   overall	   in	   a	   100-­‐fold	   reduction	   in	   viral	   infectivity.	  Importantly,	   the	   reduction	   in	   cellular	   permissivity	   to	   support	   viral	   replication	  was	  only	  apparent	  following	  extracellular	  virus	  inoculation.	  When	  the	  virus	  was	  delivered	   via	   cell	  mediated	   contact	   the	   restrictions	  were	   overcome,	   suggesting	  cell-­‐cell	  dependent	  signalling	  events	  between	  differentiated	  hepatoma	  cells	  that	  promote	  viral	  replication.	  	  	  Assessing	  steps	  in	  the	  viral	  lifecycle	  to	  investigate	  reduced	  permissivity	  in	  differentiated	  cells,	  we	  have	  shown	  that	  there	  was	  no	  difference	  in	  viral	  entry.	  Using	   a	   pseudoparticle	   system,	   of	   varying	   genotypes,	   rates	   of	   viral	   entry	  were	  not	   altered	   (Figure	   4.5	   and	   Table	   4.1).	   This	   was	   particularly	   interesting,	   as	  receptor	   localisation	   changes	   over	   time.	   Cells	   appear	   to	   become	   polarised,	  although	   these	   changes	   are	   not	   consistent	   or	   convincing	   enough	   to	   be	  comparable	  to	  other	  polarised	  cells,	  such	  as	  HepG2	  (Mee	  et	  al,	  2009).	  	  
Hepatocytes	   in	   the	   liver	   are	   highly	   polarised	   with	   bile	   canaliculi,	  surrounded	   by	   tight	   junctions,	   running	   between	   adjacent	   cells	   at	   the	   apical	  membrane	  (Thorley	  et	  al,	  2010).	  HCV	  enters	  through	  the	  sinusoidal	  blood	  and	  is	  likely	  to	  encounter	  the	  basolateral	  surface	  of	  hepatocytes,	  where	  CD81	  and	  SRB1	  localise	   (Reynolds	   et	   al,	   2008).	   In	   our	   model	   system	   CD81	   was	   expressed	  throughout	   the	   culture	   and	   there	   was	   no	   alteration	   with	   increasing	  differentiation	  (Figure	  4.2).	  Similarly,	   there	  were	  small	  circular	  structures	  that	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retained	  CMFDA	  (Figure	  4.3),	  but	  these	  were	  not	  consistently	  expressed	  and	  we	  did	  not	  go	  on	  to	  confirm	  whether	  these	  were	   functionally	   important.	  There	  did	  appear	   to	   be	   a	   restriction	   in	   para-­‐cellular	   permeability	   as	   a	   surrogate	   for	  polarisation	  (Figure	  4.4),	  but	  is	  unlikely	  to	  impact	  on	  viral	  entry	  as	  disruption	  of	  tight	  junctions	  did	  not	  alter	  this	  (Figure	  4.6).	  	  	  
Results	  showed	  that	  receptor	  localisation	  continued	  to	  change	  for	  up	  to	  21	  days	  post	   differentiation	   (Figure	   4.1).	  However,	   all	   the	  data	   presented	  has	  been	  on	  cells	  differentiated	  for	  7-­‐10	  days,	  based	  on	  maximal	  expression	  of	  liver	  markers,	  such	  as	  CYP3A4	  and	  Albumin.	  Although	  we	  did	  not	  look	  at	  viral	  entry	  at	  21	   days	   post	   differentiation,	   it	   is	   unlikely	   this	   will	   make	   a	   difference	   to	   the	  results.	  Claudin-­‐1	  had	  already	  moved	  baso-­‐laterally	  by	  7	  days	  (Figure	  4.1)	  and	  there	   was	   a	   significant	   difference	   in	   para-­‐cellular	   permeability.	   Therefore	   we	  were	   likely	   to	   see	   a	  decrease	   in	   viral	   entry	  by	  7	  days	   if	   this	  was	   an	   important	  mechanism	  in	  restricting	  permissivity.	  	  
Using	  a	  g-­‐Luc	  virus	  we	  showed	  that	  viral	  translation	  and	  early	  replication	  were	   delayed	   in	   differentiated	   cells	   (Figure	   4.7).	   The	   addition	   of	   VX950	   to	  abrogate	   viral	   replication,	   allowed	   us	   to	   be	   more	   certain	   about	   the	   luciferase	  signal	   in	   the	   differentiated	   cells,	   as	   g-­‐Luc	   delivery	   and	   subsequent	   levels	   of	  replication	  were	  low.	  HCV	  translation	  occurs	  at	  the	  rough	  ER	  and	  is	  facilitated	  by	  a	  number	  of	   viral	   and	   cellular	  proteins	   (Reviewed	   in	  Paul	   et	   al,	   2014).	   Cellular	  factors	   include	   nuclear	   factor	   proteins	   (Isken	   et	   al,	   2007),	   insulin-­‐like	   growth	  factor	   II	   mRNA	   binding	   protein	   (Weinlich	   et	   al,	   2009),	   eukaryotic	   initiation	  factors	  (eIF)	  (Jaafar	  et	  al,	  2016),	  ErbB3	  binding	  protein	  1	  (Ebp-­‐1)	  (Mishra	  et	  al,	  2017)	   and	  micro-­‐RNAs	   particularly	  miR122	   (Jopling	   et	   al,	   2005;	   Roberts	   et	   al,	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2011).	   miR122	   is	   an	   important	   factor,	   and	   expression	   correlates	   with	   cellular	  permissivity	   to	   HCV	   (Wu	   et	   al,	   2012;	   Coto-­‐Llerena	   et	   al,	   2017).	   Utilising	   a	  luciferase	  reporter	  construct	  with	  a	  miR122	  inhibitor	  we	  were	  able	  to	  show	  that	  although	  overall	  translation	  was	  reduced	  in	  Huh-­‐7diff	  as	  compared	  to	  Huh-­‐7,	  the	  proportion	  of	  miR122	  driven	   translation	  was	   comparable	   (Figure	   4.8).	  We	  did	  not	  go	  on	  to	  look	  at	  any	  specific	  cellular	  factors	  associated	  with	  HCV	  translation	  in	  differentiated	  cells,	  even	  though	  several	  candidate	  micro-­‐RNAs	  were	  identified	  as	  being	  altered	  by	  differentiation.	  It	  is	  known	  that	  DMSO	  can	  alter	  a	  broad	  range	  of	  genes	  involved	  in	  cellular	  processing	  (N	  Frampton,	  personal	  communication).	  Therefore	  this	  would	  be	  an	  important	  area	  for	  future	  work	  and	  may	  be	  important	  in	  understanding	  how	  the	  virus	  initiates	  translation	  and	  replication	  in	  the	  liver.	  	  
Cells	   infected	  with	  HCV	  are	  known	  to	  have	  altered	  glucose	  metabolism.	  (Ripoli	   et	   al,	   2010)	   and	   can	   affect	   glucose	   homeostasis	   within	   the	   liver.	   We	  attempted	   to	   switch	   cells	   into	   a	   glycolytic	   state,	   by	   limiting	   cellular	   glucose	  availability.	  This	  resulted	   in	  a	  step-­‐wise	  decline	   in	  HCV	  replication	   in	  a	  replicon	  cell	   line	   (Figure	   4.11).	   There	   is	   also	   significant	   interplay	   between	   glucose	  homeostasis	  and	  cellular	  oxygen	  levels.	  Hepatocytes	  within	  the	  liver	  are	  exposed	  to	  a	  significant	  oxygen	  gradient	  across	  the	  lobe,	  and	  peri-­‐venous	  cells	  are	  exposed	  to	   low	   oxygen	   levels	   (pO2	   3-­‐5%).	   These	   cells	   respond	   to	   hypoxia	   by	   a	  transcriptional	   response	   mediated	   by	   hypoxia	   inducible	   factors	   (reviewed	   by	  Wilson	  et	  al,	  2014),	  leading	  to	  upregulation	  of	  enzymes	  in	  the	  glycolytic	  pathway.	  Cellular	  hypoxia	  can	  promote	  HCV	  replication	  (Wilson	  et	  al,	  2012)	  and	  HCV	  itself	  can	  also	  stabilize	  Hif	  and	  lead	  to	  a	  ‘pseudohypoxic’	  state	  in	  the	  cell	  and	  is	  likely	  to	  perturb	   glucose	  metabolism.	  We	  have	  not	   shown	   convincingly	   that	   altering	   the	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glucose	   environment	   can	   affect	   established	   HCV	   replication	   in	   these	   cells.	  Furthermore,	  we	  did	  not	  confirm	  with	  functional	  data,	  such	  as	  lactate	  production,	  that	  we	  were	   able	   to	   induce	   glycolysis	   in	   these	   cells,	   relying	   on	  mRNA	   of	   G-­‐6-­‐Pase,	   a	  key	  enzyme	   in	   the	  glycolytic	  pathway.	   	   It	  would	  be	   interesting	   to	  go	  on	  and	   look	   at	   metabolic	   functioning	   in	   these	   cells,	   including	   lipid	   metabolism,	  cellular	   response	   to	   hypoxia	   and	   Hif	   expression.	   Additionally,	   HCV	   infection	   in	  Huh-­‐7	   has	   been	   shown	   to	   activate	   the	   glucocorticoid	   receptor	   via	   Hif	   1	   alpha,	  which	  blunts	  the	  response	  to	   interferons	  (IFNα	  and	  IFNλ),	  allowing	  the	  virus	  to	  evade	   the	   innate	   immune	   response	   (Wilson	  et	   al,	   2014).	  Given	   the	   significantly	  more	  robust	  innate	  response	  in	  Huh-­‐7diff	  there	  is	  much	  scope	  for	  looking	  at	  this	  in	  a	  differentiated	  system.	  	  
An	  important	  recent	  discovery	  in	  the	  field	  of	  HCV	  is	  SEC14L2	  (SEC14	  like	  lipid	  binding	  2),	  a	  cytosolic	  protein	  that	  stimulates	  an	  enzyme	  in	  the	  cholesterol	  biosynthesis	  pathway.	  This	  protein	  enables	  hepatoma	  cell	   lines	   to	   support	  HCV	  replication	  with	  patient	  sera,	  which	  has	  previously	  proved	  impossible	  (Saeed,	  et	  al,	  2015).	   	  SEC14L2	  is	  increased	  in	  differentiated	  cells,	  however	  using	  a	  Huh-­‐7.5	  cell	   overexpressing	   SEC14L2,	   results	   showed	   that	   this	   phenotype	   was	   not	  sufficient	  to	  restore	  HCV	  permissivity	  to	  Huh-­‐7.5diff	  (Figure	  4.12).	  We	  used	  Huh-­‐7.5	   in	   these	   experiments,	   in	   order	   to	   be	   able	   to	   compare	   results	  with	   parental	  cells	  (JW	  cells).	  Results	  confirmed	  that	  both	  Huh-­‐7	  and	  Huh-­‐7.5	  had	  comparable	  loss	  of	  permissivity	  when	  infected	  and	  therefore	  this	  change	  in	  hepatoma	  cell	  line	  is	  not	  likely	  to	  be	  a	  significant.	  
We	   have	   shown	   that	   differentiated	   cells	   upregulate	   the	   innate	   sensor	  TLR3	   and	   can	   signal	   via	   TLR3	   and	   RIGI/MDA5	   to	   increase	   interferon	   lambda	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levels	   (Figure	   4.13-­‐4.17).	   Although	   Bauhofer	   et	   al	   (2012)	   has	   shown	   that	  differentiated	  cells	  express	  a	  broad	  range	  of	  ISGs	  in	  response	  to	  exogenous	  type	  1	  interferon,	   the	   finding	   that	   hepatoma	   cells	   can	   initiate	   an	   innate	   response	   to	  replicating	  virus	  when	  differentiated,	   is	  novel	  and	  exciting	  (Figure	  4.19).	   It	  was	  previously	   established	   that	   hepatoma	   cells	   do	   not	   express	   TLR3,	   however	   we	  have	  shown	  significant	  and	  robust	  upregulation	  of	  mRNA,	  although	  a	  limitation	  of	  this	  is	  that	  we	  did	  not	  confirm	  protein	  or	  localisation.	  We	  attempted	  to	  show	  that	  cell	   surface/endosomal	   TLR3	   and	   the	   associated	   pathway	   was	   active	   by	  stimulation	  with	  PolyIC,	  a	  well-­‐known	  synthetic	  viral	  mimic.	  Given	  that	  we	  did	  not	  simultaneously	  inhibit	  RIGI	  signalling	  we	  cannot	  say	  for	  certain	  that	  TLR3	  protein	  is	  present	  and	  active.	  This	  requires	  further	  investigation.	  	  
Stimulation	   via	   RIGI/MDA5	   resulted	   in	   a	   massive	   increase	   in	   IL29	  expression	   in	   Huh-­‐7diff,	   although	   we	   failed	   to	   show	   any	   significant	   protein	  expression	   extracellularly	   (Figure	   4.18).	   Supernatant	   failed	   to	   inhibit	   HCV	  replication,	  using	  a	  replicon	  cell	  line.	  Interestingly,	  we	  were	  able	  to	  show	  increase	  in	   IL29	  mRNA	  levels	  using	  a	   full	   length	  HCVcc	   infection.	   It	   is	  known	  that	  during	  infection	  with	  HCV	  that	  hepatocytes	  are	  able	  to	  limit,	  but	  not	  completely	  eliminate	  infection.	   The	   virus	   is	   able	   to	   evade	   innate	   signalling	   due	   to	   NS3/4A	   protease	  cleaving	  the	  accessory	  proteins	  for	  both	  TLR3	  (TRIF)	  (Li	  K	  et	  al,	  2005)	  and	  RIG-­‐I	  (MAVS)	   (Li	  XD	  et	  al,	  2005).	  Therefore	  eliciting	  an	   innate	  response	   in	   these	  cells	  when	   infected	   with	   HCV	   has	   potential	   for	   helping	   our	   understanding	   of	   viral	  persistence	  despite	  a	  host	  innate	  response.	  	  
There	   are	   a	  number	  of	   limitations	   associate	  with	   these	  particular	   sets	   of	  experiments.	  We	  did	  not	  measure	  or	  localise	  TLR3	  protein	  or	  RIG-­‐I	  within	  these	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cells	   and	   therefore	   conclusions	   drawn	   are	   based	   largely	   on	   mRNA	   levels.	  Furthermore	  we	  did	  not	  investigate	  the	  relative	  contributions	  of	  the	  RLRs,	  MDA5	  and	  RIG-­‐I	   to	   the	  downstream	  upregulation	  of	   IL29,	   although	   all	   are	   likely	   to	   be	  active.	  The	   liver	   itself	   is	   complex,	  and	  any	   innate	   immune	  response	  needs	   to	  be	  considered	   in	   the	   light	   of	   associated	   contributions	   from	   Kupffer	   cells,	   stellate	  cells,	   liver	  sinusoidal	  endothelial	  cells	  and	  infiltrating	  immune	  cells	  (reviewed	  in	  Protzer	   et	   al,	   2012).	   For	   example,	   a	   recently	   discovered	  mouse	  model	   of	   HCV-­‐related	  hepacivirus	   infection	  (Billerbeck	  et	  al,	  2017)	  highlighted	   the	   importance	  of	   a	   predominantly	   T-­‐cell	   response	   in	   controlling	   infection.	   Even	   the	   most	  physiological	   cell	   line	   cannot	   recapitulate	   the	   environment	  within	   the	   liver	   and	  this	   is	   a	   limitation	   of	   many	   experiments	   done	   with	   cell	   lines	   or	   primary	  hepatocytes	  alone.	  	  
Interestingly,	   the	   reduced	   permissivity	   of	   differentiated	   cells	   to	   support	  HCV	  replication	  is	  overcome	  when	  the	  virus	  is	  delivered	  cell-­‐to-­‐cell	  suggesting	  the	  defect	  is	  mediated	  by	  extracellular	  virus	  infection	  (Figure	  4.22	  and	  4.24).	  Cell-­‐to-­‐cell	  transmission	  is	  utilised	  by	  a	  number	  of	  viruses,	   including	  HCV	  (Brimacombe	  et	  al,	  2011;	  Timpe	  et	  al,	  2008]	  and	  has	  a	  number	  of	  advantages	  including	  efficient	  viral	  spread	  (Meredith	  et	  al,	  2013),	  direct	  infection	  of	  target	  cells	  by	  neighbouring	  cells	  and	  kinetic	  and	  stearic	  shielding	  of	  the	  virus	  from	  the	  host	  immune	  response.	  Mechanisms	   for	   cell-­‐to-­‐cell	   transmission	   have	   been	   described	   for	   a	   number	   of	  other	  viruses	  (reviewed	  in	  Sattentau,	  2008)	  however	  this	  is	  not	  well	  understood	  for	  HCV.	   It	   is	   likely	   that	   the	   virus	   is	   transmitted	   across	   a	   synapse	  between	   two	  adjacent	  cells	  and	  although	  many	  of	   the	  HCV	  receptors	  are	  known	  to	   localise	   to	  tight	   junctions	   the	   abrogation	   of	   cell-­‐cell	   transmission	   with	   anti-­‐E2	   antibodies	  
	   188	  
(Brimacombe	   et	   al,	   2011]	   or	   nanoparticles	   [Tarr	   et	   al,	   2013]	   suggests	   that	   the	  synapse	   is	  not	  completely	  shielded	   from	  neutralization.	  Other	   receptors	  such	  as	  CD81	  do	  not	  appear	  essential	  for	  HCV	  cell-­‐to-­‐cell	  transmission	  (Timpe	  et	  al,	  2008;	  Witteveld	  et	  al,	  2009),	  although	  Claudin-­‐1	  and	  Niemann	  Pick	  cholesterol	  uptake	  receptor	   are	   important	   (Timpe	   et	   al,	   2008;	   Barretto	   et	   al,	   2014).	   HCV	   may	   be	  exploiting	  the	  virological	  synapse	  similar	  to	  that	  used	  by	  HIV.	  Furthermore,	  given	  the	  observation	   that	  cell-­‐cell	  delivery	  can	  overcome	   the	  reduction	   in	  replication	  initiation	  in	  non-­‐differentiated	  cells	  it	  is	  likely	  that	  there	  are	  additional	  effects	  on	  the	   target	   cell	   of	   the	   virus	   being	   delivered	   cell-­‐to-­‐cell.	   Nanbo	   et	   al	   (2012),	   for	  example,	   described	   altered	   cell	   signalling	   in	   B	   cells	   (producers)	   and	   epithelial	  cells	   (targets)	   in	   cell-­‐cell	   delivery	   of	   EBV.	   This	   allowed	   the	   enhancement	   of	   the	  viral	   lytic	   cycle	   and	   increased	   viral	   transmission.	   The	   effects	   of	   cell	   contact	  mediated	   viral	   delivery	   on	   the	   target	   cell	   are	   not	   well	   studied,	   however	   the	  differentiated	  cell	  model	  system	  suggests	  this	  is	  an	  area	  that	  may	  be	  important	  in	  fully	  understanding	  cell-­‐cell	  transmission.	  	  
Xiao	   et	   al	   (2014)	   also	   showed	   that	   cell-­‐to-­‐cell	   transmission	   was	   the	  predominant	   route	   of	   spread	   for	   direct	   acting	   antiviral-­‐resistant	   HCV	   (in	  differentiated	   hepatoma	   cells).	   Given	   the	   recent	   advances	   in	   treatment	   of	   HCV,	  and	  concern	  about	  resistance,	  Huh-­‐7diff	  may	  provide	  an	  excellent	  model	  system	  for	  studying	   the	   HCV	   dissemination	   route,	   which	   is	   likely	   to	   be	   increasingly	  important.	  	  
A	   significant	   limitation	  with	   this	   study,	   and	   an	   important	  next	   step,	   is	   to	  investigate	  lipid	  metabolism	  with	  Huh-­‐7diff,	  particularly	  when	  considering	  the	  loss	  of	   specific	   infectivity	   of	   the	   viral	   particle.	   Lipid	   droplets	   are	   known	   to	   be	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important	   for	   HCV	   production	   [Miyanari	   et	   al,	   2007].	   Furthermore,	   DMSO	   is	  known	   to	   affect	   cellular	   lipid	   and	   results	   in	   a	   reduction	   in	   lipid	   accumulation	  within	   hepatoma	   cell	   lines	   [Song	   at	   al,	   2014].	   Huh-­‐7	   are	   known	   to	   have	   VLDL	  defects	  and	  virus	  released	  from	  these	  cells	  is	  associated	  with	  apoE	  but	  not	  apoB	  (Jammart	   et	   al,	   2013].	   This	   in	   part	   could	   account	   for	   altered	   viral	   packaging	  within	  Huh-­‐7diff,	  since	  alteration	  of	  density	  of	   the	  viral	  particle	  by	  serial	  passage	  has	   direct	   implications	   for	   RNA	   replication	   and	   specific	   infectivity	   of	   released	  virus	  [Lindenbach	  et	  al,	  2006],	  which	  is	  likely	  to	  impact	  on	  cell-­‐free	  virus	  spread.	  The	   VLDL	   pathway,	   despite	   being	   involved	   in	   the	   secretion	   of	   infectious	   viral	  particles,	   is	   interestingly	   redundant	   in	   cell-­‐cell	   viral	   spread	   in	   DMSO	  differentiated	  cells	  [Barretto	  et	  al,	  2014].	  It	  is	  therefore	  possible	  that	  alterations	  in	  the	  VLDL	  pathway	  in	  differentiated	  cells	  allow	  the	  virus	  to	  spread	  efficiently	  cell-­‐cell	  but	  inhibit	  cell-­‐free	  spread	  and	  this	  requires	  investigating.	  	  
	   We	   have	   used	   this	   physiological	   system	   to	   understand	   how	   viral	  replication	  is	  altered	  in	  a	  differentiated	  cell,	  which	  allows	  insight	   into	  viral/host	  interaction	   in	   vivo.	   The	   system	   has	   significant	   advantages	   over	   other	  differentiated	  model	  systems,	  as	  cells	  are	  readily	  available,	  easy	  and	  relatively	  fast	  to	   differentiate	   and	   can	  be	  maintained	   in	   culture	   for	   a	   long	  period	  of	   time.	  The	  parental	   cells,	   Huh-­‐7,	   are	   readily	   available.	   Therefore	   they	   are	   an	   ideal	   model	  system	  for	  studying	  the	  HCV	  lifecycle,	  particularly	  cell-­‐to-­‐cell	  viral	  transmission.	  	  
In	   addition	   to	   the	   limitations	   discussed	   above,	   a	   further	   limitation	   was	  using	  a	  laboratory-­‐adapted	  strain	  for	  most	  of	  the	  experiments.	  This	  was	  the	  only	  virus	  available	  that	  allowed	  us	  to	  get	  high	  levels	  of	  infection	  in	  Huh-­‐7diff.	  This	  virus	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has	  been	  serially	  passaged	  and	  is	  a	  highly	  infectious	  SA13	  (genotype	  5a)	  that	  has	  developed	  mutations	   that	   increase	   specific	   infectivity	   of	   virus	   (Mathieson	   et	   al,	  2015).	   The	   virus	   has	   comparable	   rates	   of	   cell-­‐to-­‐cell	   and	   cell-­‐free	   spread	  (Meredith	  et	  al,	  2013),	  although	  cell	  culture	  adaptations	  may	  make	  the	  virus	  more	  efficient	  at	  cell-­‐to-­‐cell	  spread	  than	  wild	  type	  virus	  (Mathieson	  et	  al,	  2015).	  Ideally	  many	  of	  the	  experiments	  should	  be	  confirmed	  with	  an	  early	  passage	  virus,	  other	  viral	  genotypes	  and	  virus	  derived	  from	  patient	  sera.	  However	  this	  was	  practically	  difficult.	  
Summary	  	  	   In	   summary,	   we	   have	   shown	   that	   Huh-­‐7diff	   limit	   HCV	   translation/early	  replication	   and	   have	   reduced	   specific	   infectivity	   of	   the	   released	   viral	   particle.	  Furthermore	  we	  have	  shown	  that	  Huh-­‐7diff	  produce	  a	   robust	   innate	  response	   to	  HCV	   infection.	   Virus	   delivered	   directly	   between	   cells	   does	   not	   show	   altered	  permissivity.	  	  
The	  observation	   that	  direct	   cell-­‐to-­‐cell	  delivery	  of	  HCV	   is	   efficient	   in	   this	  physiological	   system	   raises	   further	   questions	   and	   hypotheses	   regarding	   HCV	  dissemination	   in	  vivo.	   HCV	   can	   infect	   other	   cell	   lines,	   such	   as	   neuroepithelioma	  cells	  (Fletcher	  et	  al,	  2010),	  and	  can	  cause	  clinical	  multi-­‐system	  involvement.	  We	  were	   particularly	   interested	   in	   cell-­‐to-­‐cell	   delivery	   of	   HCV	   by	   cells	   other	   than	  hepatocytes,	  which	  may	  allow	  distant	  viral	  spread.	  The	  following	  chapter	  outlines	  the	  cell-­‐to-­‐cell	  delivery	  of	  HCV	  by	  T	  cells.	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5.1	  :	  Introduction	  	   HCV	  can	  transmit	  rapidly	  between	  hepatocytes	  by	  direct	  cell-­‐to-­‐cell	  contact	  (Brimacombe	  et	  al,	  2011;	  Timpe	  et	  al,	  2008;	  Witteveldt	  et	  al,	  2009)	  which	  can	  offer	  many	  advantages	  including	  evasion	  of	  the	  adaptive	  immune	  response	  (reviewed	  in	  Sattentau,	  2008).	  In	  the	  previous	  chapter	  we	  have	  shown	  that	  direct	  cell-­‐to-­‐cell	  delivery	  of	  HCV	  (SA13:JFH)	  can	  efficiently	  infect	  differentiated	  hepatoma	  cells,	  whereas	  infection	  using	  cell-­‐free	  virus	  was	  significantly	  reduced.	  Previous	  work	  has	  shown	  that	  cells	  other	  than	  hepatocytes,	  such	  as	  B	  cells,	  can	  internalize	  and	  are	  able	  to	  deliver	  infectious	  HCV	  to	  hepatocytes	  (Stamataki	  et	  al,	  2009).	  The	  infectious	  JFH-­‐1	  HCV	  strain	  can	  bind	  primary	  B	  cells	  and	  B	  cell	  lines	  but	  is	  not	  able	  to	  establish	  a	  productive	  infection	  within	  these	  cells.	  Other	  blood	  cells	  (PBMCs)	  have	  been	  reported	  to	  have	  HCV	  cellular	  RNA	  detected,	  however	  HCVcc	  clones	  do	  not	  infect	  lymphocytes	  themselves	  (Marukian,	  2008).	  B	  cells	  are	  able	  to	  bind	  HCV	  on	  their	  surface	  using	  viral	  receptors	  CD81,	  SRB1,	  DC-­‐SIGN	  and	  L-­‐SIGN	  (Stamataki	  et	  al,	  2009)	  and	  transfer	  infection	  to	  Huh7.5	  showing	  enhanced	  levels	  of	  infection	  compared	  to	  cell-­‐free	  virus	  delivery,	  which	  is	  resistant	  to	  neutralizing	  antibody	  infection.	  HCV	  cellular	  associations	  with	  other	  cell	  types,	  such	  as	  B	  cells,	  therefore,	  provides	  further	  mechanisms	  for	  immune	  evasion	  and	  transfer	  of	  HCV	  to	  the	  liver.	  	  Other	  cell	  types	  are	  known	  to	  trans-­‐infect	  viruses;	  dendritic	  cells	  expressing	  the	  C-­‐type	  lectin	  DC-­‐SIGN,	  can	  capture	  and	  internalize	  HIV-­‐1	  at	  mucosal	  surfaces	  and	  efficiently	  transfer	  to	  CD4+	  T	  cells	  in	  lymph	  nodes,	  where	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viral	  replication	  then	  occurs	  (Arrighi	  et	  al,	  2004;	  van	  Montfort,	  2007).	  Interestingly,	  C-­‐type	  lectin	  domain	  family	  4	  (CLEC4M)	  is	  a	  trans-­‐membrane	  protein	  expressed	  on	  liver	  sinusoidal	  endothelial	  cells,	  and	  has	  been	  shown	  to	  capture	  HCV	  and	  transinfect	  a	  permissive	  hepatoma	  cell	  line	  (Ishibashi	  et	  al,	  2014).	  This	  may	  allow	  virus	  to	  be	  captured	  from	  the	  circulation	  and	  transferred	  to	  hepatocytes.	  These	  models	  provide	  biological	  plausibility	  to	  T	  cell	  trans-­‐infection	  of	  HCV.	  	  	  	  Further	  recent	  work	  by	  Stamataki	  et	  al	  (unpublished	  data)	  has	  shown	  that	  activated	  CD4+	  T	  cells	  are	  capable	  of	  transferring	  HCV	  on	  their	  surface	  and	  infecting	  differentiated	  polarized	  hepatoma	  cells	  (HepG2)	  and	  neuroepithelioma	  cells	  (hCEMC/D3)	  which	  are	  difficult	  to	  infect	  with	  cell	  free	  virus.	  Stimulated	  CD4+	  T	  cells	  were	  not	  amenable	  to	  support	  HCV	  replication	  however	  provide	  a	  mechanism	  for	  cell	  delivery	  to	  differentiated	  cells	  and	  distant	  sites	  such	  as	  the	  blood-­‐brain	  barrier	  or	  the	  placenta.	  We	  therefore	  hypothesized	  that	  stimulated	  CD4+	  T	  cells	  (both	  primary	  and	  immortalized	  lines)	  could	  be	  used	  to	  transfer	  HCV	  (SA13)	  to	  Huh-­‐7	  and	  Huh-­‐7diff	  and	  could	  provide	  an	  alternative	  mechanism	  for	  differentiated	  cell	  infection.	  	  	   Given	  that	  CD4+	  T	  cells	  are	  the	  primary	  host	  cell	  for	  replicating	  HIV	  we	  were	  interested	  to	  see	  whether	  HIV	  infection	  of	  CD4+	  T	  cells	  altered	  HCV	  trans-­‐infection.	  Co-­‐infection	  with	  HIV-­‐1	  and	  HCV	  is	  common,	  and	  is	  reaching	  epidemic	  proportions	  in	  certain	  parts	  of	  the	  world,	  particularly	  Eastern	  Europe	  and	  Central	  Asia	  where	  around	  40%	  of	  people	  with	  HIV	  are	  HCV	  co-­‐infected,	  accounting	  for	  over	  one	  quarter	  of	  HIV/HCV	  co-­‐infections	  worldwide	  (Platt	  et	  al,	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2016).	  Clinically,	  co-­‐infected	  individuals	  are	  at	  increased	  risk	  of	  rapid	  and	  progressive	  liver	  cirrhosis	  than	  HCV	  mono-­‐infected	  individuals	  (de	  Lédinghen	  et	  al,	  2008),	  with	  over	  49%	  of	  co-­‐infected	  patients	  having	  cirrhosis	  within	  30	  years	  (Thein	  et	  al,	  2008)	  with	  an	  increased	  risk	  of	  hepatitis/liver	  related	  deaths	  despite	  anti-­‐retroviral	  therapy	  in	  co-­‐infected	  patients	  (Smit	  et	  al,	  2008).	  The	  landscape	  of	  liver	  disease	  in	  co-­‐infected	  patients	  is	  changing	  due	  to	  DAA’s,	  however,	  these	  patients	  are	  still	  complex	  to	  manage	  due	  to	  drug	  interactions	  and	  the	  management	  of	  rampant	  liver	  disease	  (Schlabe	  and	  Rockstroh,	  2018).	  	  	  Co-­‐infection	  is	  also	  relevant	  in	  the	  context	  of	  pregnancy	  where	  co-­‐infection	  with	  HIV/HCV	  doubles	  the	  transmission	  of	  HCV	  from	  mother	  to	  child	  (5.8%	  to	  10.8%)	  and	  maternal	  HIV	  co-­‐infection	  is	  the	  single	  most	  important	  determinant	  of	  HCV	  vertical	  transmission	  risk	  (Benova	  et	  al,	  2012).	  This	  is	  often	  thought	  to	  result	  from	  higher	  HCV	  viral	  load	  in	  women	  who	  are	  also	  co-­‐infected	  with	  HIV	  (Thomas	  et	  al,	  1998),	  however	  the	  mechanism	  behind	  vertical	  transmission	  is	  not	  well	  defined.	  Azzari	  et	  al	  (2000)	  reported	  that	  virus	  associated	  with	  PBMCs	  is	  related	  to	  vertical	  transmission	  of	  HCV	  independent	  of	  viral	  genotype	  or	  maternal	  viral	  load.	  We	  therefore	  hypothesized	  that	  HIV	  infection	  of	  CD4+ve	  T	  cells	  altered	  HCV	  carriage	  and	  delivery,	  thereby	  providing	  a	  novel	  mechanism	  for	  HIV-­‐1	  promotion	  of	  HCV	  infectivity	  and	  transmission.	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Chapter	  Aims:	  	   -­‐ To	   determine	   whether	   T	   cells	   bind	   HCV	   and	   trans-­‐infect	   permissive	  hepatoma	  cells.	  -­‐ To	   investigate	   the	   effect	   of	   activated	   T	   cells	   on	   HCV	   hepatocellular	  replication.	  -­‐ To	   investigate	   the	   effect	   of	   HIV	   co-­‐infection	   of	   T	   cell	   HCV	   trans-­‐infection.	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5.2	  :	  Hepatitis	  C	  virus	  can	  be	  transferred	  on	  the	  surface	  of	  a	  CD4+	  T	  cell	  	   Stamataki	  et	  al	  (unpublished)	  showed	  that	  HCV	  could	  be	  trans-­‐infected	  by	  a	  T	  cell.	  In	  order	  to	  confirm	  these	  results,	  SupT1	  cells	  were	  incubated	  with	  HCVcc	  (SA13:JFH)	  prior	  to	  washing	  to	  remove	  unbound	  virus.	  Cells	  were	  then	  incubated	  with	  Huh-­‐7	  cells	  for	  48	  hours.	  HCV	  infection	  was	  quantified	  by	  staining	  for	  NS5A.	  
Figure	  5.1	  outlines	  the	  method	  of	  T	  cell	  trans-­‐infection.	  SupT1	  cells	  were	  used	  as	  they	  are	  easy	  to	  replicate	  between	  experiments	  and	  are	  a	  robust	  model	  for	  HIV	  infection.	  Results	  confirm	  that	  T	  cells	  are	  able	  to	  trans-­‐infect	  permissive	  Huh-­‐7	  with	  HCV	  (Figure	  5.2).	  	  	  Results	  show	  that	  inoculating	  T	  cell	  number	  is	  important	  and	  can	  mediate	  cytotoxicity	  of	  the	  hepatoma	  cell	  monolayer.	  SupT1	  added	  as	  high	  number	  per	  well	  (2x107/ml)	  resulted	  in	  T	  cells	  being	  tightly	  adhered	  to	  Huh-­‐7	  and	  loss	  of	  viability	  of	  the	  monolayer	  (Figure	  5.2).	  SupT1	  added	  at	  a	  lower	  number	  of	  cells	  per	  well	  (1	  x107/ml)	  resulted	  in	  a	  healthy	  monolayer	  with	  spaces	  between	  the	  T	  cells	  where	  the	  Huh-­‐7	  can	  be	  visualised.	  NS5A	  staining	  in	  Huh-­‐7	  reveals	  clusters	  of	  infected	  cells,	  confirming	  that	  T	  cells	  can	  trans-­‐infect	  HCV,	  although	  they	  have	  a	  cytopathic	  effect	  on	  healthy	  hepatoma	  cells	  at	  high	  numbers.	  	  	   Previous	  results	  have	  shown	  that	  Huh-­‐7diff	  are	  permissive	  to	  HCVcc	  delivered	  cell-­‐to-­‐cell.	  Therefore	  we	  investigated	  whether	  cell	  delivered	  HCV	  by	  a	  T	  cell	  could	  overcome	  the	  inherent	  replication	  restriction	  of	  HCV	  seen	  when	  virus	  is	  delivered	  cell	  free	  in	  Huh-­‐7diff.	  Figure	  5.3	  shows	  that	  Huh-­‐7diff	  can	  be	  infected	  with	  HCV	  delivered	  by	  a	  T	  cell,	  however	  have	  a	  100-­‐fold	  reduced	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Figure	  5.3	  Huh-­‐7diff	  support	  reduced	  HCV	  infection	  when	  virus	  is	  delivered	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5.3:	  Primary	  CD4+	  T	  cells	  and	  immortalized	  T	  cell	  lines	  can	  support	  HCV	  trans-­‐infection	  	   Results	  have	  showed	  that	  the	  immortalized	  T	  cell	  line,	  SuptT1,	  is	  able	  to	  mediate	  trans-­‐infection	  of	  a	  permissive	  cell	  line	  with	  HCV	  (SA13).	  It	  is	  important	  to	  confirm	  that	  these	  results	  are	  reproducible	  with	  other	  T	  cell	  lines	  and	  primary	  CD4+	  T	  cells.	  	  	   The	  T	  cell	  lines	  SupT1,	  Jurkats	  and	  MOLT-­‐4	  cells	  were	  identified	  as	  candidate	  cell	  lines,	  due	  to	  their	  availability	  and	  ability	  to	  support	  HIV-­‐1	  infection	  (Dejucq,	  2000;	  Hesselgesser	  et	  al,	  2000).	  Figure	  5.4A	  shows	  that	  all	  cell	  lines	  tested	  are	  equally	  able	  to	  trans-­‐infect	  HCV.	  The	  number	  of	  T	  cells	  used	  in	  each	  trans-­‐infection	  were	  titrated,	  as	  high	  T	  cell	  numbers	  appeared	  to	  disrupt	  the	  monolayer.	  These	  results	  suggest	  that	  T	  cell	  number	  has	  a	  direct	  effect	  on	  HCV	  delivery.	  	  	   Stamataki	  et	  al	  showed	  that	  resting	  PBMC	  derived	  T	  cells	  were	  unable	  to	  support	  HCV	  trans-­‐infection,	  and	  that	  T	  cells	  needed	  to	  be	  activated.	  Therefore	  the	  addition	  of	  T	  cell	  stimulatory	  molecules	  was	  investigated	  to	  assess	  impact	  on	  trans-­‐infection	  by	  a	  T	  cell	  line.	  T	  cell	  lines	  were	  grown	  in	  the	  presence	  of	  anti-­‐CD3/anti-­‐CD28	  antibody	  (Raulf-­‐Heimsoth,	  2008)	  for	  7	  days	  prior	  to	  use.	  This	  provides	  antigen-­‐independent	  signaling	  of	  the	  TCR.	  IL-­‐2	  was	  added	  to	  the	  media	  as	  a	  T	  cell	  proliferating	  agent	  (Hedfors	  and	  Brinchman,	  2003;	  Stamataki	  unpublished).	  Figure	  5.4B	  shows	  that	  the	  addition	  of	  anti-­‐CD3/anti-­‐CD28	  in	  the	  media	  to	  T	  cell	  lines	  does	  not	  alter	  HCVcc	  trans-­‐infection.	  These	  are	  already	  a	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Figure	  5.5	  Primary	  CD4+	  T	  cells	  are	  able	  to	  support	  trans-­‐infection	  of	  
HCVcc	  Primary	  CD4+	  T	  cells	  were	  isolated	  from	  healthy	  anonymous	  donors	  as	  described.	  Cells	  were	  activated	  with	  anti-­‐CD3/anti-­‐CD8	  (1mcg/ml).	  5-­‐7	  days	  post	  isolation	  cells	  were	  used	  to	  trans-­‐infect	  HCV	  as	  previously	  described	  alongside	  SupT1	  cells.	  48	  hours	  post	  infection	  Huh-­‐7	  were	  fixed	  and	  stained	  for	  NS5A.	  Results	  are	  means	  of	  triplicate	  wells	  and	  representative	  of	  three	  independent	  experiments.	  Analysis	  was	  done	  using	  a	  students	  t-­‐test	  and	  results	  compared	  to	  number	  foci	  at	  2x107	  cells/ml.	  Non-­‐significant	  results	  are	  not	  marked.	  **p≤0.01	  *p≤0.05	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5.4	  :	  T	  cell	  number	  affects	  HCV	  foci	  and	  size	  via	  a	  cell	  contact	  mediated	  effect	  	   Results	  have	  consistently	  shown	  that	  T	  cell	  number	  affects	  HCV	  infectivity	  in	  a	  trans-­‐infection.	  In	  order	  to	  optimise	  the	  assay	  we	  therefore	  investigated	  the	  role	  of	  T	  cell	  number	  on	  HCV	  trans-­‐infection.	  T	  cells	  were	  titrated	  from	  2x107	  to	  1.5x106	  cells/ml	  and	  used	  in	  a	  trans-­‐infection.	  Figure	  5.6A	  shows	  NS5A	  positive	  cells	  by	  T	  cell	  number.	  Both	  high	  and	  low	  T	  cell	  numbers	  are	  associated	  with	  a	  reduction	  in	  the	  amount	  of	  HCV	  transferred.	  The	  optimum	  number	  of	  T	  cells	  per	  well	  is	  6x106	  T	  cells/ml	  cultured	  in	  a	  48	  well	  plate	  and	  therefore	  will	  be	  used	  at	  this	  number	  in	  future	  experiments	  for	  SupT1	  cells.	  This	  represents	  a	  2:1	  T	  cell:Huh-­‐7	  ratio	  (at	  24	  hours	  post	  plating).	  Figure	  5.6B	  shows	  NS5A	  staining;	  at	  high	  T	  cell	  numbers	  there	  are	  fewer	  foci	  and	  these	  are	  small	  or	  single	  cell.	  At	  lower	  T	  cell	  numbers	  much	  larger	  foci	  are	  seen.	  These	  results	  indicate	  that	  T	  cells	  are	  mediating	  an	  anti-­‐viral	  effect	  at	  high	  numbers	  inhibiting	  initial	  HCV	  infection	  and	  spread	  within	  Huh-­‐7.	  	  	   We	  hypothesize	  that	  there	  is	  a	  direct	  anti-­‐viral	  effect	  associated	  with	  high	  T	  cell	  numbers.	  In	  order	  to	  test	  this	  an	  HCV	  trans-­‐infection	  was	  repeated	  using	  SupT1	  cells	  and	  primary	  cell	  lines	  with	  the	  target	  cell	  harboring	  a	  subgenomic	  replicon	  (LucA2)	  to	  study	  the	  effect	  of	  T	  cells	  on	  HCV	  replication	  directly.	  48	  hours	  post	  infection	  cells	  were	  lysed	  and	  HCV	  replication	  measured	  by	  luciferase.	  Figure	  5.7A	  shows	  that	  T	  cells	  inhibit	  established	  HCV	  replication	  in	  a	  dose	  dependent	  manner,	  whether	  they	  are	  loaded	  with	  HCV	  or	  not.	  Primary	  cells	  also	  appear	  to	  have	  a	  larger	  effect	  per	  cell	  than	  the	  cell	  lines.	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5.5	  :	  Infecting	  T	  cells	  with	  HIV	  	  	   Results	  have	  shown	  that	  T	  cells	  are	  able	  to	  trans-­‐infect	  HCV	  to	  a	  permissive	  cell	  line.	  Given	  that	  T	  cells	  are	  the	  target	  cell	  for	  HIV	  infection	  in	  vivo	  we	  were	  interested	  to	  see	  whether	  HIV	  infection	  altered	  HCV	  trans-­‐infection.	  The	  first	  step	  was	  to	  confirm	  strains	  of	  HIV	  that	  efficiently	  infect	  T	  cell	  lines	  and	  primary	  cells.	  	  	  HIV	  strains	  HXB2,	  NL4.3	  and	  NL4.3	  GFP	  (CXCR-­‐4)	  and	  R5	  (CCL-­‐5)	  were	  made	  as	  previously	  described.	  Infectivity	  of	  virus	  was	  tested	  using	  an	  ELISA	  for	  HIV-­‐1-­‐p24	  antigen.	  NL4.3	  consistently	  had	  higher	  measured	  extracellular	  p24	  (Figure	  5.8A)	  and	  was	  able	  to	  infect	  GHOST	  cells	  (Figure	  5.8B).	  NL4.3	  was	  therefore	  used	  for	  all	  subsequent	  experiments	  with	  HIV,	  unless	  stated	  otherwise.	  	  	   HIV	  strain	  NL4.3	  was	  then	  used	  to	  infect	  T	  cell	  lines	  and	  primary	  CD4+	  T	  cells.	  T	  cell	  lines	  shown	  to	  support	  HCV	  transfer	  (SupT1,	  MOLT4	  and	  Jurkats)	  and	  primary	  activated	  CD4+	  T	  cells	  from	  4	  healthy	  anonymous	  donors	  were	  infected	  with	  HIV	  (pnL4.3	  20ng/ml).	  Supernatant	  was	  harvested	  48	  hours	  post	  infection	  and	  extracellular	  p24	  as	  a	  marker	  of	  HIV	  infection	  was	  measured.	  Figure	  5.9A	  shows	  that	  SupT1	  cells	  supported	  the	  most	  productive	  HIV	  infection	  as	  indicated.	  Primary	  CD4+	  T	  cells	  did	  support	  infection	  however	  at	  a	  much	  lower	  level.	  Extracellular	  p24	  is	  a	  recognized	  sensitive	  test	  of	  HIV	  infectivity	  (Klein	  et	  al,	  2003),	  however	  for	  this	  cell-­‐based	  assay	  it	  was	  important	  to	  identify	  the	  number	  of	  cells	  infected	  with	  HIV.	  Therefore,	  SupT1	  cells	  infected	  with	  HIV-­‐1	  (NL4.3)	  were	  additionally	  stained	  for	  intracellular	  p24.	  Figure	  5.9B	  shows	  that	  only	  
	   210	  





































































































































































	   213	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  5.10	  T	  cells	  show	  maximally	  HIV	  infectivity	  3	  days	  post	  infection.	  	  SupT1	  and	  primary	  CD4+	  T	  cells	  isolated	  from	  three	  anonymous	  donors	  (A,	  B	  and	  C)	  were	  infected	  with	  NL4.3	  for	  8	  hours.	  Cells	  were	  then	  washed	  and	  incubated	  for	  up	  to	  6	  days	  in	  RPMI	  (+/-­‐	  IL2).	  Supernatant	  was	  taken	  daily	  post	  infection	  (and	  replenished	  in	  the	  wells	  to	  keep	  a	  constant	  volume)	  and	  extracellular	  p24	  quantified	  by	  ELISA	  as	  described.	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5.6	  :	  HIV	  Infection	  boosts	  HCV	  transfer	  by	  T	  cells	  	  	   Results	  have	  previously	  shown	  that	  T	  cells	  are	  able	  to	  support	  HIV	  infection	  and	  replication,	  and	  can	  transfer	  HCV	  to	  permissive	  cells.	  There	  is	  a	  known	  correlation	  between	  HIV	  infection	  and	  HCV	  viral	  load	  (Thomas	  et	  al,	  2000;	  Matthews-­‐Greer	  et	  al,	  2001)	  and	  we	  hypothesize	  that	  HIV	  infected	  T	  cells	  may	  be	  able	  to	  deliver	  more	  HCV	  to	  target	  cells	  via	  trans-­‐infection.	  Therefore	  we	  investigated	  whether	  the	  presence	  of	  HIV	  infection	  altered	  HCV	  trans-­‐infection.	  	  	  	   SupT1	  cells	  were	  infected	  with	  HIV	  (NL4.3	  X4	  tropic	  strain)	  for	  72	  hours.	  HIV	  infection	  was	  confirmed	  by	  intracellular	  p24	  staining	  and	  p24	  ELISA,	  as	  described.	  1.5%	  of	  cells	  were	  intracellular	  p24	  positive,	  and	  mean	  extracellular	  p24	  levels	  were	  25ng/ml	  at	  72	  hours	  post	  infection.	  Cells	  were	  washed	  to	  remove	  inoculating	  virus	  and	  incubated	  with	  HCV	  (SA13)	  or	  media	  for	  2	  hours.	  Cells	  were	  washed	  again	  to	  remove	  cell	  free	  virus,	  and	  T	  cells	  co-­‐cultured	  with	  human	  hepatoma	  cells	  for	  48	  hours	  to	  allow	  trans-­‐infection.	  Infected	  target	  cells	  were	  detected	  by	  NS5A	  staining	  as	  described.	  Figure	  5.11A	  shows	  representative	  images	  of	  wells	  with	  NS5A	  positive	  cells.	  Figure	  5.11B	  shows	  mean	  foci	  per	  well.	  T	  cells	  that	  had	  been	  incubated	  with	  HIV	  were	  associated	  with	  higher	  levels	  of	  HCV	  trans-­‐infection	  than	  control	  cells.	  To	  ensure	  that	  HIV	  itself	  was	  not	  altering	  the	  antiviral	  activity	  of	  T	  cells	  as	  shown	  in	  Figure	  5.7,	  T	  cells	  were	  infected	  with	  HIV	  and	  used	  to	  trans-­‐infect	  HCV	  onto	  LucA2	  replicon	  cells.	  Uninfected	  T	  cells	  and	  HIV	  infected	  T	  cells	  that	  were	  not	  incubated	  with	  HCV	  were	  used	  as	  controls.	  Figure	  5.11C	  shows	  that	  HIV	  infected	  and	  uninfected	  
	   215	  
T	  cells	  have	  an	  equal	  antiviral	  effect	  on	  HCV	  replication.	  These	  results	  confirm	  that	  HIV	  infection	  can	  boost	  HCV	  trans-­‐infection	  mediated	  by	  T	  cells.	  	  	   Results	  were	  confirmed	  with	  primary	  CD4+	  T	  cells.	  CD4+	  T	  cells	  were	  isolated	  from	  4	  anonymous	  donors.	  72	  hours	  post	  infection	  with	  HIV,	  T	  cells	  were	  used	  to	  trans-­‐infect	  HCV	  to	  permissive	  Huh-­‐7.	  HIV	  infection	  was	  confirmed	  by	  p24	  ELISA.	  All	  donors	  showed	  detectable	  p24	  in	  the	  supernatant	  (Figure	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5.7	  :	  HIV	  co-­‐receptor	  engagement	  is	  not	  required	  for	  HCV	  transfer	  	  	  	   Results	  have	  shown	  that	  HCV	  trans-­‐infection	  is	  boosted	  by	  the	  presence	  of	  an	  X4	  tropic	  HIV-­‐1	  strain.	  We	  wanted	  to	  investigate	  the	  mechanism	  behind	  HIV	  boosted	  HCV	  transfer	  by	  T	  cells.	  	  	   Results	  so	  far	  have	  all	  been	  with	  an	  X4-­‐tropic	  virus.	  HIV-­‐1	  uses	  both	  X4	  and	  R5	  as	  major	  co-­‐receptors	  for	  viral	  entry	  and	  viral	  tropism	  is	  associated	  with	  clinical	  deterioration	  in	  patients	  (Clapham	  et	  al,	  2001).	  We	  therefore	  investigated	  whether	  HCV	  delivery	  by	  a	  T	  cell	  was	  altered	  by	  co-­‐receptor	  use.	  T	  cells	  (SupT1)	  were	  infected	  with	  pNL4.3	  (X4)	  and	  BAL	  (R5)	  for	  48	  hours	  and	  then	  used	  for	  trans-­‐infection	  as	  described.	  Figure	  5.13A	  shows	  NS5A	  positive	  foci	  per	  well.	  HIV	  infectivity	  was	  confirmed	  with	  supernatant	  p24	  ELISA	  48	  hours	  after	  infection	  (Figure	  5.13B).	  Results	  indicate	  that	  both	  X4	  and	  R5	  tropic	  virus	  are	  associated	  with	  boosted	  HCV	  delivery	  and	  the	  effect	  is	  not	  co-­‐receptor	  dependent.	  	  	   To	  confirm	  this	  the	  HIV	  pseudoparticle	  system	  was	  used.	  Pseudoparticles	  harbouring	  the	  pnL4.3	  genome	  with	  a	  luciferase	  reporter	  and	  with	  HIV	  envelopes	  ADA	  (R5)	  or	  LAI	  (X4),	  VSV	  envelope	  or	  no	  envelope	  (NE)	  control	  were	  used	  to	  infect	  SupT1	  cells	  for	  48	  hours.	  Cells	  were	  then	  used	  in	  a	  trans-­‐infection.	  Infection	  of	  T	  cells	  was	  confirmed	  by	  quantifying	  luciferase.	  Interestingly	  VSV,	  LAI	  and	  BAL	  all	  mediated	  a	  boost	  in	  HCV	  transfer	  (over	  NE	  control)	  (Figure	  
5.14).	  The	  amount	  of	  HCVcc	  transferred	  was	  comparable,	  even	  by	  VSVpp,	  and	  significantly	  more	  than	  uninfected	  SupT1	  cells.	  Overall	  these	  results	  indicate	  that	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Figure	  5.14:	  HIV	  pseudoparticle	  infected	  T	  cells	  can	  boost	  HCV	  transfer	  to	  
hepatoma	  cells	  	  SupT1	  cells	  were	  infected	  with	  LAIpp,	  ADApp	  (1:2	  dilution),	  VSVpp	  and	  No	  Envelope	  (NE)	  control	  (1:100	  viral	  dilution)	  for	  48	  hours.	  Cells	  infected	  with	  pseudoparticles	  or	  control	  (NE)	  were	  used	  in	  a	  T	  cell	  trans-­‐infection	  as	  described.	  HCV	  infection	  was	  quantified	  using	  NS5A	  staining	  and	  number	  of	  positive	  foci	  per	  well	  was	  plotted.	  Results	  are	  means	  of	  duplicate	  wells	  and	  representative	  of	  two	  independent	  experiments.	  Pseudoparticle	  infection	  was	  confirmed	  by	  luciferase	  and	  was	  comparable	  for	  HIV-­‐1	  and	  VSV	  envelopes.	  Analysis	  is	  by	  students	  t-­‐test	  and	  compared	  to	  control	  (NE)	  *p≤0.05	  ns=not	  significant.	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5.8	  :	  Replicating	  HIV	  is	  required	  for	  boosted	  HCV	  transfer	  	  	   Results	  so	  far	  have	  shown	  that	  HIV	  infection,	  in	  a	  small	  number	  of	  T	  cells,	  can	  mediate	  increased	  HCV	  delivery	  via	  T	  cell	  trans-­‐infection.	  This	  is	  independent	  of	  HIV-­‐1	  co-­‐receptor	  engagement.	  We	  therefore	  wanted	  to	  investigate	  whether	  HIV	  replication	  is	  required.	  	  	   The	  ACH2	  cell	  line,	  a	  model	  of	  HIV	  latency	  (Clouse	  et	  al,	  1989;	  Folks	  et	  al,	  1989),	  was	  used	  to	  investigate	  whether	  latently	  infected	  T	  cells	  can	  transfer	  HCVcc.	  ACH2	  cells	  can	  become	  active	  with	  the	  addition	  of	  TNFα	  or	  PMA	  (10nM)	  and	  rapidly	  start	  replicating	  HIV-­‐1.	  This	  model	  was	  used	  to	  assess	  whether	  the	  amount	  of	  replicating	  intracellular	  HIV	  has	  an	  effect	  on	  HCV	  transfer.	  Figure	  
5.15A	  and	  B	  show	  the	  percentage	  of	  cells	  positive	  for	  intracellular	  p24	  within	  a	  culture	  of	  activated	  ACH2	  cells	  at	  24	  hours	  post	  activation.	  There	  was	  baseline	  p24	  positivity	  in	  ACH2	  cells	  of	  around	  15%	  and	  this	  increased	  markedly	  with	  both	  PMA	  and	  TNFα	  treatment.	  	  	   ACH2	  cells	  were	  then	  used	  to	  trans-­‐infect	  HCVcc	  following	  activation.	  ACH2	  cells	  were	  activated	  with	  TNFα	  and	  used	  to	  trans-­‐infect	  Huh-­‐7	  with	  HCV	  at	  24	  hours	  post	  activation.	  48	  hours	  post	  co-­‐culture	  Huh-­‐7	  were	  fixed	  and	  stained	  for	  NS5A	  positive	  foci	  (Figure	  5.16A).	  There	  was	  significantly	  more	  HCV	  trans-­‐infected	  in	  activated	  compared	  to	  latently	  infected	  ACH2.	  Control	  cells	  (SupT1)	  were	  used	  alongside,	  showing	  that	  the	  addition	  of	  TNFα	  to	  T	  cells	  alone	  did	  not	  alter	  HCV	  transfer	  or	  infectivity	  (Figure	  5.16B).	  Results	  indicate	  that	  HCV	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transfer	  may	  be	  related	  to	  the	  amount	  of	  replicating	  HIV	  present	  within	  the	  transferring	  T	  cell.	  	  	  In	  order	  to	  confirm	  this	  observation	  SupT1	  cells	  were	  infected	  with	  HIV	  and	  then	  cured	  using	  the	  anti-­‐viral	  Zidovudine	  (AZT).	  SupT1	  were	  infected	  with	  HIV	  (NL4.3)	  then	  treated	  with	  AZT	  (4	  nM)	  to	  inhibit	  HIV	  replication	  (Mitsuya	  et	  al,	  1985.	  Broder,	  2009).	  Cells	  were	  washed	  and	  incubated	  with	  HCV	  as	  previously	  described	  prior	  to	  co-­‐culture	  with	  hepatoma	  cells	  for	  48	  hours.	  Cells	  were	  fixed	  and	  HCV	  infectivity	  quantified	  by	  enumerating	  NS5A	  positive	  cells	  (Figure	  5.17A).	  SupT1	  infected	  with	  HIV	  have	  boosted	  HCVcc	  transfer,	  which	  is	  reduced	  to	  control	  levels	  when	  treated	  with	  AZT.	  Controls	  confirm	  that	  AZT	  itself	  is	  not	  having	  an	  effect	  on	  the	  HCVcc	  transfer.	  Supernatant	  from	  T	  cells	  were	  taken	  at	  the	  end	  of	  the	  experiment	  to	  confirm	  that	  p24	  was	  significantly	  reduced	  in	  cells	  treated	  with	  AZT	  (Figure	  5.17B).	  	  	  In	  order	  to	  show	  that	  HIV	  itself	  is	  not	  having	  an	  effect	  on	  HCVcc	  replication	  in	  permissive	  cells,	  HIV	  (pnL4.3)	  was	  added	  (20ng/ml)	  to	  an	  end-­‐point	  dilution	  of	  SA13	  titrated	  onto	  permissive	  Huh-­‐7.	  Figure	  5.17C	  shows	  that	  the	  presence	  of	  HIV	  alone	  does	  not	  have	  an	  effect	  on	  HCVcc	  infectivity.	  To	  confirm	  that	  HIV	  infection	  of	  T	  cells	  is	  not	  altered	  by	  the	  presence	  of	  HCV	  in	  the	  media,	  HIV	  infected	  T	  cells	  were	  incubated	  with	  HCVcc	  for	  48	  hours.	  Supernatant	  taken	  at	  the	  end	  of	  48	  hours	  shows	  no	  difference	  in	  p24	  production	  and	  therefore	  the	  presence	  of	  HCVcc	  does	  not	  alter	  HIV	  infectivity	  of	  SupT1	  cells	  (Figure	  5.17D).	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Figure	  5.17:	  Ablation	  of	  HIV	  replication	  results	  in	  HCV	  transfer	  at	  the	  level	  
of	  control	  	  A)	  SupT1	  cells	  were	  infected	  with	  HIV	  for	  48	  hours	  as	  described.	  Cells	  were	  then	  washed	  and	  incubated	  with	  AZT	  (at	  4nM)	  for	  48	  hours.	  Cells	  were	  then	  used	  in	  a	  HCV	  trans-­‐infection	  as	  previously	  described	  onto	  Huh-­‐7.	  48	  hours	  post	  trans-­‐infection	  cells	  were	  fixed	  and	  stained	  for	  NS5A	  as	  described.	  Results	  are	  foci	  per	  well	  (mean	  of	  3	  wells	  48	  well	  plate)	  and	  representative	  of	  two	  independent	  experiments.	  (B)	  Supernatant	  from	  AZT	  treated	  SupT1	  was	  pooled	  and	  p24	  quantified	  using	  ELISA	  as	  previously	  described.	  Results	  are	  means	  of	  duplicate	  wells	  and	  representative	  of	  two	  independent	  experiments.	  (C)	  HCVcc	  was	  added	  to	  Huh-­‐7	  (MOI	  0.1))	  and	  HIV	  (20	  ng/ml)	  was	  added	  to	  duplicate	  wells.	  48	  hours	  post	  infection	  cells	  were	  fixed	  and	  stained	  for	  NS5A.	  Results	  are	  means	  of	  foci	  per	  well.	  (D)	  SupT1	  infected	  with	  HIV	  for	  48	  hours	  were	  then	  washed	  and	  incubated	  for	  48	  hours	  with	  SA13	  HVCcc	  (MOI	  0.1).	  Supernatant	  was	  taken	  and	  p24	  was	  quantified	  by	  ELISA.	  Results	  are	  analysed	  by	  Students	  t-­‐test.	  *p≤0.05,	  ns=not	  significant	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5.9:	  HIV	  increases	  HCV	  capture	  by	  T	  cells	  	  	   In	  order	  to	  understand	  the	  mechanism	  behind	  HCV	  trans	  infection	  by	  T	  cells	  containing	  replicating	  HIV,	  HCV	  capture	  was	  investigated.	  	  	  Stamataki	  et	  al	  (2009)	  showed	  that	  the	  amount	  of	  HCV	  captured	  by	  a	  B	  cell	  directly	  translates	  to	  the	  amount	  of	  HCV	  delivered	  to	  a	  permissive	  cell.	  Furthermore,	  robust	  work	  has	  shown	  that	  PBMC	  cannot	  be	  infected	  with	  HCV	  (Laskus	  et	  al,	  2007;	  Blackard	  et	  al,	  2007;	  Marukian	  et	  al,	  2008).	  However	  many	  authors	  have	  shown	  HCV	  associated	  with	  PBMC	  (Qian	  et	  al,	  1992;	  Zignego	  et	  al,	  1992;	  Wang,	  et	  al,	  1992;	  Muller	  et	  al,	  1993;	  Azzari	  et	  al,	  2000),	  which	  may	  represent	  HCV	  capture	  but	  not	  infection.	  Therefore	  SupT1	  cells	  were	  infected	  with	  HIV	  (pNL4.3)	  as	  previously	  and	  then	  incubated	  with	  HCVcc	  (SA13:JFH)	  for	  2	  hours.	  Cells	  were	  then	  fixed	  and	  HCV	  RNA	  load	  quantified	  by	  qPCR.	  Interestingly,	  results	  show	  that	  cells	  infected	  with	  HIV	  were	  associated	  with	  significantly	  more	  HCV	  RNA	  than	  cells	  that	  were	  not	  infected	  with	  HIV	  (Figure	  5.18).	  Duplicate	  plates	  in	  this	  experiment	  were	  used	  for	  T	  cell	  trans-­‐infection	  (see	  Figure	  5.17A)	  to	  confirm	  that	  increased	  RNA	  correlated	  with	  increased	  HCV	  transfer.	  	  	  HIV	  infection	  of	  T	  cells	  associate	  with	  significantly	  increased	  levels	  of	  HCV	  RNA	  than	  uninfected	  cells.	  This	  is	  likely	  to	  represent	  HCV	  carriage	  and	  is	  likely	  to	  be	  a	  significant	  mechanism	  when	  considering	  the	  way	  in	  which	  HCV	  is	  delivered	  to	  naïve	  hepatoma	  cells	  in	  the	  presence	  of	  HIV.	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5.10	  :	  Discussion	  	  	   Work	  throughout	  this	  chapter	  aimed	  to	  show	  that	  HCVcc	  could	  be	  transferred	  by	  a	  CD4+	  T	  cell	  and	  used	  to	  infect	  a	  permissive	  cell	  (trans-­‐infection).	  Results	  confirm	  that	  all	  T	  cell	  lines	  tested,	  in	  addition	  to	  activated	  primary	  CD4+	  T	  cells,	  were	  able	  to	  transfer	  HCVcc	  (late	  adapted	  SA13	  virus)	  to	  Huh-­‐7	  cells	  (Figures	  5.4	  and	  5.5).	  T	  cells	  were	  repeatedly	  washed	  after	  incubation	  with	  HCVcc	  to	  remove	  the	  presence	  of	  any	  cell	  free	  virus	  and	  negative	  controls	  were	  included	  in	  all	  experiments	  (outlined	  in	  Figure	  5.1)	  in	  order	  to	  confirm	  that	  the	  virus	  transferred	  was	  cell-­‐associated	  and	  not	  cell-­‐free.	  HCVcc	  infection	  of	  Huh-­‐7diff	  	  using	  T	  cell	  transinfection	  was	  significantly	  reduced	  compared	  to	  Huh-­‐7.	  T	  cell	  delivered	  virus	  is	  not	  able	  to	  overcome	  the	  inherent	  restrictions	  when	  Huh-­‐7	  are	  differentiated,	  thereby	  suggesting	  that	  efficient	  cell-­‐to-­‐cell	  delivery	  shown	  in	  previous	  chapters	  is	  dependent	  on	  the	  type	  of	  cell	  used.	  Furthermore,	  T	  cell	  transfer	  is	  less	  likely	  to	  be	  an	  important	  mechanism	  within	  the	  liver	  of	  viral	  dissemination	  and	  spread.	  However,	  we	  have	  shown	  that	  T	  cells	  are	  able	  to	  associate	  virus	  and	  deliver	  to	  permissive	  cells,	  which	  may	  be	  important	  in	  setting	  up	  distant	  sites	  of	  infection.	  	  	   Results	  also	  show	  that	  HCV	  transfer	  and	  infectivity	  occurred	  even	  in	  the	  presence	  of	  an	  anti-­‐viral	  (Figure	  5.7)	  and	  cytotoxic	  (Figure	  5.2)	  effect	  of	  high	  T	  cell	  numbers.	  We	  observed	  a	  direct	  effect	  of	  the	  activated	  CD4+	  T	  cells	  and	  T	  cell	  lines	  on	  the	  monolayer,	  with	  adherent	  cells	  leading	  to	  monolayer	  breakdown.	  CD4+	  T	  cells	  can	  have	  a	  direct	  cytotoxic	  effect,	  through	  cell	  contact	  mediated	  apoptosis	  (Fas/Fas	  Ligand)	  (reviewed	  in	  Green	  and	  Ferguson,	  2001)	  or	  through	  
	   233	  
release	  of	  toxic	  effector	  molecules	  such	  as	  perforin	  or	  granzyme	  resulting	  in	  target	  cell	  death	  (Trapani	  and	  Smyth,	  2002).	  We	  did	  not	  investigate	  the	  mechanism	  behind	  this,	  however	  noted	  that	  T	  cell	  lines	  had	  much	  greater	  effect	  than	  primary	  cells	  on	  direct	  cytotoxicity.	  T	  cell	  from	  immortalised	  cell	  lines	  were	  much	  larger	  than	  primary	  cells	  and	  may	  have	  had	  more	  cell	  contact	  mediating	  direct	  cell	  toxicity.	  	  	  In	  addition	  we	  noted	  that	  CD4+	  primary	  T	  cells	  and	  T	  cell	  lines	  had	  a	  significant	  anti-­‐viral	  effect,	  inhibiting	  HCV	  replication	  in	  a	  dose	  dependent	  manner	  (Figure	  5.7A).	  Direct	  cell	  contact	  was	  necessary	  as	  supernatant	  did	  not	  have	  the	  same	  effect	  (Figure	  5.7B).	  However,	  primary	  cells	  do	  appear	  to	  secrete	  anti-­‐viral	  mediators	  into	  the	  supernatant	  that	  have	  a	  modest	  effect	  on	  replication	  and	  may	  explain	  why	  primary	  cells	  have	  a	  much	  larger	  effect	  on	  replication	  than	  T	  cell	  lines.	  This	  difference	  may	  also	  be	  explained	  by	  innate	  immune	  gene	  expression	  between	  cell	  lines	  and	  primary	  cells.	  SupT1	  cells,	  for	  example	  downregulate	  TLR7/8	  and	  are	  unable	  to	  produce	  IL-­‐6	  in	  response	  to	  TLR	  stimulation,	  a	  pathway	  that	  is	  intact	  in	  primary	  cells	  (Rausell	  et	  al,	  2016).	  Remarkably,	  HCVcc	  is	  able	  to	  trans-­‐infect	  permissive	  cells	  and	  establish	  a	  spreading	  infection,	  despite	  the	  direct	  anti-­‐replicative	  effect.	  Understanding	  this	  further	  may	  be	  important	  in	  identifying	  therapeutic	  targets	  for	  modulating	  T	  cell	  mediated	  trans-­‐infection.	  	  	  	   We	  then	  went	  on	  to	  show	  that	  HIV-­‐1	  infection,	  using	  primarily	  an	  X4	  tropic	  virus	  boosts	  T	  cell	  trans-­‐infection	  using	  a	  T	  cell	  line	  and	  primary	  CD4+	  T	  cells	  (Figure	  5.11).	  There	  was	  inter-­‐experimental	  variability	  and	  donor	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variation,	  particularly	  in	  the	  amount	  of	  HCV	  transferred;	  however	  the	  presence	  of	  HIV	  boosted	  this	  in	  all	  experiments.	  This	  occurred	  even	  with	  very	  low	  numbers	  of	  T	  cells	  within	  the	  culture	  being	  infected	  with	  HIV	  (Figure	  5.9),	  although	  numbers	  of	  infected	  cells	  are	  comparable	  to	  that	  seen	  in	  vivo,	  even	  in	  the	  presence	  of	  high	  viraemia	  (Walker	  and	  McMichael,	  2012;	  Gadol	  et	  al,	  1994).	  This	  makes	  the	  results	  applicable	  to	  an	  in	  vivo	  setting.	  	  	  Although	  we	  have	  consistently	  seen	  that	  HCV	  transfer	  is	  boosted	  in	  the	  presence	  of	  HIV,	  it	  is	  not	  possible	  to	  tell	  exactly	  which	  cells	  are	  mediating	  this	  effect.	  Given	  that	  such	  small	  numbers	  of	  cells	  are	  infected	  with	  HIV,	  it	  is	  likely	  that	  uninfected	  T	  cells	  are	  also	  able	  to	  transfer	  HCV.	  Pathogenic	  infections	  of	  human	  CD4+	  T	  cells	  are	  characterised	  by	  generalised	  immune	  activation,	  including	  TNFα,	  IFNγ	  and	  IL-­‐6	  release	  (Rausell	  et	  al,	  2012)	  leading	  to	  progressive	  CD4	  T	  cell	  depletion	  (Sodora	  and	  Silvestri,	  2008).	  Therefore,	  mediators	  released	  into	  the	  supernatant	  from	  HIV	  infected	  cells	  are	  likely	  to	  act	  more	  widely.	  Studies	  of	  HIV-­‐exposed	  but	  not	  infected	  individuals	  have	  shown	  that	  HIV-­‐1	  specific	  T	  cells	  exist	  (Ritchie	  et	  al,	  2011β).	  Therefore	  it	  is	  likely	  that	  the	  presence	  of	  replicating	  HIV	  infection	  has	  effects	  on	  many	  cells	  within	  the	  culture.	  This	  requires	  further	  investigation.	  	  	  Interestingly,	  results	  show	  that	  co-­‐receptor	  engagement	  is	  not	  essential,	  but	  presence	  of	  replicating	  HIV	  is	  important	  for	  HIV	  boosted	  T	  cell	  transfer.	  A	  pseudoparticle	  system	  with	  pNL4.3	  genome	  and	  differing	  HIV	  envelopes	  (HIV	  R5,	  HIV	  X4)	  and	  non-­‐HIV	  (VSV)	  all	  boosted	  HCV	  transfer	  (Figure	  5.14),	  suggesting	  that	  replicating	  HIV	  is	  important,	  as	  VSVpp	  was	  associated	  with	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increased	  HCV	  trans-­‐infection.	  Further	  results	  show	  that	  ablating	  replication,	  within	  cells	  that	  had	  been	  infected	  with	  HIV	  and	  then	  cured,	  also	  reduced	  HCV	  transfer	  to	  a	  level	  of	  control	  (Figure	  5.17).	  Therefore	  HCV	  transfer	  requires	  replicating	  HIV.	  	   Lastly,	  we	  were	  able	  to	  show	  that	  T	  cells	  that	  have	  been	  exposed	  to	  HIV	  are	  associated	  with	  increased	  amounts	  of	  HCV	  RNA	  (Figure	  5.18).	  We	  did	  not	  investigate	  whether	  these	  cells	  had	  been	  infected	  with	  HCV,	  however	  previous	  studies	  have	  shown	  that	  lymphocytes	  are	  not	  amenable	  to	  infection	  (Marukian	  et	  al,	  2008).	  Therefore	  it	  is	  likely	  that	  HCV	  can	  associate	  with	  a	  T	  cell	  and	  is	  bound	  to	  the	  surface.	  Natarajan	  et	  al	  (2010)	  showed	  that	  HCV	  is	  carried	  on	  the	  surface	  of	  T	  cells,	  but	  also	  on	  NK	  cells,	  monocytes	  and	  B	  cells	  in	  co-­‐infected	  patients.	  Elucidating	  the	  mechanism	  would	  be	  the	  next	  step.	  Stamataki	  has	  shown	  that	  cell	  surface	  LDL	  receptor	  and	  CD81	  are	  important	  in	  HCV	  capture	  (unpublished	  data)	  and	  CD81	  expression	  on	  T	  cells	  is	  altered	  by	  HIV	  infection	  (Meroni	  et	  al,	  2007).	  Future	  work	  should	  include	  investigating	  the	  role	  of	  the	  tetraspanin	  CD81	  and	  LDL	  R	  in	  HCV	  capture	  in	  HIV	  infected	  T	  cells.	  	  	  In	  summary	  this	  chapter	  has	  described	  HCV	  trans-­‐infection	  mediated	  by	  CD4+	  T	  cells	  to	  a	  permissive	  hepatoma	  cell	  line.	  HCV	  transfer	  is	  boosted	  by	  HIV	  exposed	  T	  cells,	  and	  the	  presence	  of	  replicating	  HIV	  is	  important.	  However,	  there	  are	  significant	  limitations	  associated	  with	  this	  work	  so	  far.	  Much	  of	  the	  data	  is	  descriptive	  and	  requires	  more	  investigation	  to	  identify	  the	  mechanisms	  involved.	  The	  current	  inability	  to	  identify	  the	  exact	  cells	  that	  are	  HIV	  infected	  and	  then	  go	  on	  to	  transfer	  HCV	  on	  their	  surface	  makes	  investigating	  this	  particularly	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challenging.	  We	  have	  not	  characterized	  the	  T	  cells	  at	  all	  or	  looked	  at	  the	  signaling	  pathways	  set	  up	  within	  the	  cells	  on	  exposure	  to	  HIV/HCVcc.	  We	  have	  also	  not	  used	  patient	  derived	  virus	  or	  T	  cells	  isolated	  from	  HIV	  positive	  individuals	  to	  see	  whether	  the	  effect	  can	  still	  be	  demonstrated.	  It	  would	  also	  be	  interesting	  to	  show	  that	  HCV	  transfer	  can	  occur	  in	  the	  presence	  of	  anti-­‐HCV	  neutralising	  antibody.	  We	  would	  also	  like	  to	  further	  investigate	  the	  alterations	  in	  cellular	  signaling	  both	  within	  the	  T	  cell	  and	  the	  target	  cell	  when	  HCV	  is	  delivered	  in	  this	  way.	  Despite	  the	  shortcomings,	  we	  have	  robustly	  shown	  that	  T	  cells	  can	  transfer	  HCVcc	  and	  the	  presence	  of	  HIV	  impacts	  this	  significantly.	  	  	   These	  novel	  results	  provide	  a	  possible	  insight	  into	  HCV	  access	  to	  distant	  sites	  in	  vivo,	  a	  model	  that	  is	  used	  by	  other	  viruses,	  such	  as	  HIV	  (van	  Montfort,	  2007).	  Similarly,	  other	  cells	  bearing	  CD4	  on	  their	  cell	  surface,	  such	  as	  human	  placenta,	  may	  also	  be	  able	  to	  transfer	  HCV,	  offering	  insight	  into	  maternal	  to	  child	  transmission	  which	  is	  poorly	  understood,	  particularly	  in	  the	  context	  of	  co-­‐infection.	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6.1	  :	  General	  Discussion	  	  	   The	  data	  presented	  in	  this	  thesis	  describes	  the	  development	  of	  cell	  models	  for	  the	  study	  of	  HCV,	  viral	  host	  interactions	  and	  HCV/HIV	  co-­‐infection.	  	  	   We	  initially	  describe	  how	  the	  addition	  of	  DMSO	  to	  a	  human	  hepatoma	  cell	  line	  is	  able	  to	  drive	  the	  cell	  into	  a	  differentiated	  state.	  These	  cells	  are	  readily	  available	  and	  are	  easy	  to	  differentiate	  and	  maintain.	  The	  addition	  of	  DMSO	  to	  drive	  differentiation	  appears	  to	  effect	  multiple	  and	  broad	  ranging	  changes	  within	  the	  cell,	  many	  of	  which	  are	  known	  to	  interact	  with	  the	  HCV	  lifecycle.	  Huh-­‐7diff	  upregulate	  key	  hepatic	  enzymes	  in	  vivo,	  including	  enzymes	  involved	  in	  drug	  metabolism,	  and	  therefore	  provide	  a	  functional	  xenobiotic	  model.	  Despite	  slowed	  cell	  cycle	  progression	  they	  are	  not	  metabolically	  quiescent,	  showing	  evidence	  of	  altered	  glucose	  metabolism.	  Cells	  also	  show	  significant	  upregulation	  of	  candidate	  micro-­‐RNAs,	  which	  are	  likely	  to	  have	  complex	  interactions	  with	  virus	  and	  host.	  	  	  We	  went	  on	  to	  show	  that	  Huh-­‐7diff	  are	  able	  to	  support	  the	  entire	  HCV	  lifecycle,	  although	  are	  significantly	  less	  permissive	  than	  undifferentiated	  hepatoma	  cell	  lines.	  Unlike	  other	  available	  differentiated	  models	  for	  studying	  HCV	  replication,	  human	  hepatoma	  cells	  can	  support	  HCV	  entry,	  replication	  and	  egress,	  without	  the	  exogenous	  addition	  of	  key	  cellular	  factors.	  Differentiated	  cells,	  therefore,	  can	  give	  insight	  into	  the	  likely	  viral	  lifecycle	  within	  the	  human	  liver.	  Interestingly,	  the	  reduction	  in	  permissivity	  seen	  was	  a	  compound	  effect	  of	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reduced	  early	  viral	  replication	  and	  reduction	  of	  specific	  infectivity	  of	  the	  released	  viral	  particle.	  	  	  Despite	  identifying	  key	  steps	  in	  the	  viral	  lifecycle	  that	  were	  altered	  by	  differentiation	  we	  were	  not	  able	  to	  define	  the	  mechanism	  behind	  this.	  Candidate	  cellular	  factors	  that	  are	  known	  to	  alter	  viral	  infectivity,	  including	  miR122	  (Jopling	  et	  al,	  2005;	  Wu	  et	  al,	  2012)	  and	  SEC14L2	  expression	  (Saeed	  et	  al,	  2015)	  do	  not	  alter	  permissivity	  in	  differentiated	  hepatoma	  cells.	  Altered	  innate	  signaling	  pathways	  in	  hepatoma	  cells	  are	  key	  to	  the	  ability	  of	  these	  cells	  to	  support	  HCVcc	  (Sumpter	  et	  al,	  2005).	  We	  were	  able	  to	  show	  that	  differentiation	  induced	  the	  expression	  of	  TLR3	  and	  IL29	  in	  response	  to	  agonists	  and	  HCVcc.	  However,	  there	  was	  no	  detectable	  IL29	  protein	  and	  we	  could	  not	  robustly	  confirm	  that	  the	  altered	  innate	  pathways	  impacted	  viral	  replication.	  However,	  interestingly,	  these	  cells	  appear	  to	  respond	  to	  HCVcc	  and	  can	  provide	  a	  model	  for	  studying	  the	  host	  immune	  response.	  	  	  	  	  Cellular	   differentiation	   also	   reduced	   specific	   infectivity	   of	   the	   released	  viral	   particle.	   We	   confirmed	   these	   results	   functionally,	   however	   did	   not	  investigate	   the	   further	   mechanisms	   behind	   this.	   The	   HCV	   particle	   is	   closely	  associated	   with	   apolipoproteins,	   particularly	   apoE,	   apoB,	   apoA1	   and	   apoC	  (Catanese	  et	   al,	   2013;	  Chang	  et	   al,	   2007;	  Gastaminza	  et	   al,	   2008;	  Meunier	   et	   al,	  2008)	  and	  are	  particularly	  rich	  in	  ApoE	  (Merz	  et	  al,	  2011).	  ApoE	  is	  important	  for	  infectivity	  of	  the	  viral	  particle	  (Chang	  et	  al,	  2007).	  Hepatoma	  cells	  are	  known	  to	  have	   defective	   lipoprotein	   biogenesis	   (Jammart	   et	   al,	   2013)	   and	   this	   may	   be	  altered	   by	   cellular	   differentiation,	   since	   we	   have	   shown	   that	   other	   metabolic	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pathways	  can	  affected.	  Furthermore,	   the	  density	  of	  HCVcc	   in	  vitro	   is	   lower	   than	  that	  found	  in	  vivo,	   likely	  due	  to	  associations	  with	  lipoproteins	  (Lindenbach	  et	  al,	  2006).	  Viral	   assembly	  and	  egress	   is	   closely	   related	   to	   the	   lipoprotein	  metabolic	  pathways	   (Popescu	   et	   al,	   2014)	   and	  DMSO	   is	   known	   to	   affect	   cellular	   lipid	   and	  results	   in	   a	   reduction	   in	   lipid	   accumulation	   within	   hepatoma	   cells	   (Song	   et	   al,	  2014).	   Therefore	   investigating	   lipid	   metabolism	   and	   the	   lipid	   content	   of	   the	  released	   virion	   from	   differentiated	   cells	   would	   be	   important	   to	   consider.	   The	  VLDL	   pathway,	   despite	   being	   involved	   in	   the	   secretion	   of	   infectious	   viral	  particles,	  is	  interestingly	  redundant	  in	  cell-­‐cell	  spread	  in	  Huh-­‐7diff	  	  (Barretto	  et	  al,	  2014).	   It	   is	   therefore	   possible	   that	   alterations	   in	   the	   VLDL	   pathway	   in	  differentiated	   cells	   allow	   the	  virus	   to	   spread	  efficiently	   cell-­‐cell	   but	   inhibit	   cell-­‐free	  spread.	  	  	   	  The	   reduced	   permissivity	   of	   differentiated	   cells	   to	   support	   HCV	  replication	   is	   overcome	  when	   the	   virus	   is	   delivered	   cell-­‐to-­‐cell.	   Many	   viruses	  use	  cell-­‐to-­‐cell	  spread	  as	  it	  can	  be	  efficient	  way	  of	  infecting	  neighbouring	  cells,	  whilst	  protecting	   the	  virus	   from	   the	  host	   immune	   response	   (Sattentau,	  2105).	  Differentiated	   hepatoma	   cells	   would	   provide	   an	   excellent	   model	   for	   studying	  viral	   dissemination	   route	   and	   host	   responses.	   We	   went	   on	   to	   explore	   the	  possibility	  that	  HCV	  could	  be	  delivered	  to	  a	  human	  hepatoma	  cell	  via	  cell-­‐to-­‐cell	  transmission,	  mediated	  by	  another	  cell	  type	  such	  as	  a	  T	  cell.	  We	  showed	  that	  T	  cells	   could	   deliver	   HCV	   to	   permissive	   cells,	   although	   they	   were	   not	   able	   to	  overcome	  the	  restriction	  in	  Huh-­‐7diff	  suggesting	  that	  cell	  type	  is	  important	  in	  the	  mechanism	  of	  cell-­‐to-­‐cell	  delivery.	  CD4+	  T	  cells	  or	  T	  cell	  lines	  infected	  with	  HIV	  can	  transfer	  more	  HCV	  to	  a	  permissive	  cell	  line.	  This	  is	  independent	  of	  receptor	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engagement	  or	  soluble	  mediators,	  but	  requires	  replicating	  HIV.	  T	  cells	  appear	  to	  associate	  with	  more	  HCV	  on	   their	   surface	  when	  exposed	   to	  HIV,	  although	   it	   is	  not	  clear	  whether	  cells	  themselves	  need	  to	  be	  infected	  with	  HIV	  for	  this	  effect	  to	  occur.	   The	   mechanism	   behind	   this	   requires	   further	   investigation.	   Figure	   6.1	  provides	  a	  model	  of	  known	  and	  proposed	  modes	  of	  HCV	  transmission	  based	  on	  findings	  presented	  in	  this	  thesis.	  	  
	  	   The	   observation	   that	   virus	   can	   associate	   with	   immune	   cells	   is	  biologically	  relevant	  as	  it	  raises	  the	  possibility	  that	  HCV	  can	  use	  immune	  cells	  to	  spread	   to	   distal	   sites.	   One	   particular	   area	   of	   interest	   is	   in	   mother	   to	   child	  transmission.	   The	  mechanism	  behind	  HCV	  maternal	   to	   child	   transmission	   has	  not	   been	   clearly	   defined	   (Le	   Campion	   et	   al,	   2012)	   but	   HIV	   co-­‐infection	   is	  associated	   with	   significantly	   increased	   risk	   of	   HCV	   transmission	   (Gibb	   et	   al,	  2000;	  Marine-­‐Barjoan	  et	  al,	  2007).	  HCV	  itself	  is	  unable	  to	  infect	  trophoblasts	  (Le	  Campion	  et	  al,	  2012;	  Rajgor,	  personal	  communication),	  which	  are	  foetal	  derived	  cells	   that	   form	   the	   feto-­‐maternal	   interface.	   However,	   trafficking	   of	   maternal	  immune	   cells,	   including	   T	   cells,	   across	   the	   placenta	   has	   been	   well	   described	  (reviewed	  in	  Jeanty	  et	  al,	  2014).	  Association	  of	  HCV	  with	  cells	  that	  are	  directly	  transferred	   across	   the	   placenta	   from	   mother	   to	   child	   is	   a	   novel	   concept	   in	  vertical	  transmission.	  The	  finding	  that	  HIV	  co-­‐infection	  increases	  the	  quantity	  of	  HCV	   that	   is	   transferred	   is	   a	   biologically	   plausible	   mechanism	   and	   provides	  targets	  for	  therapeutic	  intervention.	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6.2:	  Future	  work	  	   This	  thesis	  has	  described	  the	  development	  of	  a	  differentiated	  cell	  system,	  that	  supports	  HCV	  infection	  but	  at	  lower	  levels	  than	  in	  standard	  hepatoma	  cells.	  There	  are	  restrictions	  in	  early	  viral	  replication	  and	  specific	  infectivity	  of	  the	  released	  viral	  particle,	  which	  can	  be	  overcome	  by	  cell-­‐to-­‐cell	  delivery.	  Despite	  changes	  in	  many	  key	  candidate	  cellular	  factors	  we	  have	  not	  been	  able	  to	  elucidate	  the	  exact	  mechanism	  behind	  this	  and	  therefore	  requires	  further	  investigation.	  	  	  Much	  of	  the	  work	  described	  is	  transcript	  data,	  and	  it	  would	  be	  pertinent	  to	  look	  at	  protein	  expression	  and	  location,	  particularly	  in	  relation	  to	  innate	  signaling.	  Much	  recent	  work	  has	  highlighted	  the	  importance	  of	  IL29	  in	  cellular	  response	  to	  HCV	  (reviewed	  in	  Breuning	  et	  al,	  2017).	  The	  expression	  of	  TLR3	  mRNA	  at	  detectable	  levels	  in	  differentiated	  cells,	  which	  are	  absent	  in	  hepatoma	  cells	  (Li	  et	  al,	  2005)	  is	  a	  potentially	  important	  finding.	  TLR3	  expression	  is	  central	  in	  viral	  recognition	  and	  downstream	  innate	  signaling.	  Therefore	  investigating	  protein	  levels	  and	  location	  in	  differentiated	  cells	  would	  be	  a	  useful	  additional	  step.	  Additionally	  there	  are	  candidate	  ISG’s,	  particularly	  ISG15	  (Kim	  et	  al,	  2000;	  Schneider	  et	  al,	  2014)	  that	  are	  known	  to	  directly	  inhibit	  HCV	  replication.	  Results	  so	  far	  would	  suggest	  that	  further	  understanding	  of	  innate	  signaling	  in	  Huh-­‐7diff	  would	  be	  important,	  not	  only	  in	  investigating	  HCV	  replication,	  but	  also	  in	  utilizing	  these	  cells	  as	  a	  model	  with	  intact	  innate	  signaling	  pathways.	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The	  effect	  of	  differentiation	  of	  the	  production	  of	  HCV	  lipoviral	  particle	  is	  also	  important,	  and	  has	  not	  yet	  been	  studied.	  Future	  work	  should	  include	  assessing	  the	  buoyant	  density	  of	  the	  released	  viral	  particle	  and	  the	  ability	  of	  the	  isolated	  released	  particle	  to	  then	  enter	  and	  replicate	  in	  differentiated	  cells.	  We	  have	  looked	  at	  the	  viral	  lifecycle	  of	  cell	  adapted	  HCVcc	  but	  not	  the	  virus	  once	  it	  has	  been	  released	  from	  differentiated	  cells.	  Given	  the	  importance	  of	  lipoproteins	  in	  viral	  entry	  (Popescu	  et	  al,	  2012;	  Jiang,	  et	  al	  2012)	  this	  would	  be	  important	  to	  consider.	  	  	  Much	  of	  the	  viral	  work	  so	  far	  has	  been	  using	  laboratory	  adapted	  SA13/JFH	  and	  should	  be	  expanded	  to	  include	  other	  viral	  strains,	  and	  patient	  derived	  virus.	  Differentiated	  cells	  express	  SEC14L2,	  which	  was	  recently	  identified	  as	  the	  missing	  cellular	  factor	  that	  allowed	  hepatoma	  cells	  to	  support	  HCV	  from	  patient	  sera	  (Saeed	  et	  al,	  2015).	  It	  would	  be	  interesting	  to	  look	  at	  whether	  differentiated	  cells	  were	  able	  to	  support	  patient	  derived	  virus.	  	  	  We	  have	  shown	  that	  Huh-­‐7diff	  are	  a	  good	  model	  for	  cell-­‐to-­‐cell	  viral	  transmission,	  which	  is	  an	  efficient	  mode	  of	  viral	  dissemination	  (Meredith	  et	  al,	  2013)	  and	  may	  represent	  the	  predominant	  route	  of	  viral	  spread	  in	  vivo	  (Carloni	  et	  al,	  2012).	  We	  used	  newly	  infected	  Huh-­‐7	  as	  ‘producer	  cells’;	  in	  order	  to	  better	  model	  the	  in	  vivo	  environment,	  chronically	  infected	  Huh-­‐7diff	  could	  be	  utilized	  as	  producer	  as	  well	  as	  target	  cells.	  We	  were	  able	  to	  show	  that	  virus	  can	  also	  be	  transmitted	  in	  association	  with	  other	  cell	  types,	  although	  the	  mechanism	  behind	  this	  is	  likely	  to	  be	  different;	  virus	  is	  delivered	  from	  the	  surface	  of	  a	  T	  cell	  rather	  than	  directly	  cell-­‐to-­‐cell.	  It	  would	  be	  interesting	  to	  investigate	  whether	  T	  cells	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are	  able	  to	  deliver	  virus	  in	  the	  presence	  of	  anti-­‐HCV	  neutralizing	  antibody,	  as	  cell-­‐to-­‐cell	  transmission	  in	  vivo	  is	  thought	  to	  evade	  this	  response.	  	  	  The	  mechanism	  by	  which	  HIV	  is	  able	  to	  increase	  HCV	  trans-­‐infection	  by	  CD4+	  T	  cells	  requires	  further	  investigation.	  Initial	  steps	  would	  be	  to	  look	  at	  LDLR	  and	  CD81	  expression	  on	  the	  surface	  of	  cells	  exposed	  to	  HIV.	  These	  have	  been	  shown	  to	  be	  important	  for	  HCV	  capture	  on	  lymphocytes	  (Stamataki,	  unpublished	  data).	  There	  is	  evidence	  that	  HIV	  can	  alter	  CD81	  expression	  on	  a	  T	  cell	  (Meroni	  et	  al,	  2007)	  and	  this	  is	  a	  plausible	  mechanism	  for	  HCV	  capture.	  We	  have	  showed	  that	  HIV	  only	  infects	  a	  small	  number	  of	  cells	  within	  the	  culture,	  which	  is	  likely	  representative	  of	  the	  number	  of	  cells	  infected	  in	  vivo(Pace	  et	  al,	  2012).	  However,	  we	  have	  not	  been	  able	  to	  confirm	  whether	  it	  is	  the	  cells	  that	  are	  infected	  that	  are	  able	  to	  mediate	  the	  effect.	  It	  is	  possible	  that	  HIV	  infection	  of	  a	  small	  number	  of	  cells	  alters	  the	  cellular	  micro-­‐environment	  allowing	  a	  larger	  number	  of	  cells	  to	  associate	  with	  HCV.	  We	  have	  shown	  that	  cell	  contacts	  are	  important,	  suggesting	  the	  cellular	  changes,	  rather	  than	  released	  soluble	  mediators	  are	  important	  for	  HCV	  capture.	  Clearly	  this	  is	  a	  huge	  area	  for	  future	  work,	  and	  focus	  initially	  would	  be	  on	  candidates	  for	  cell	  surface	  HCV	  capture.	  Understanding	  the	  T	  cell	  changes	  that	  are	  effected	  by	  HIV	  infection/exposure	  that	  interact	  with	  HCV	  capture	  and	  delivery	  would	  be	  important	  in	  going	  forward.	  	  	  Furthermore	  most	  of	  the	  work	  is	  with	  CXCR4	  tropic	  virus.	  It	  would	  be	  important	  to	  confirm	  the	  findings	  with	  a	  CCR5	  tropic	  virus.	  The	  shift	  from	  a	  CCR5	  to	  a	  CXCR4	  virus	  is	  associated	  with	  clinical	  decline	  and	  T	  cell	  depletion	  (Naif,	  2013),	  and	  therefore	  the	  finding	  of	  increases	  HCV	  capture	  may	  correlate	  with	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HIV	  viral	  tropism.	  Similarly,	  it	  would	  be	  interesting	  to	  see	  if	  T	  cells	  isolated	  from	  an	  HIV	  positive	  patient	  were	  also	  able	  to	  mediate	  the	  same	  effect.	  	  	  It	  is	  not	  clear	  whether	  T	  cells	  are	  the	  only	  cells	  able	  to	  transfer	  HCV	  to	  permissive	  cells.	  Dendritic	  cells	  are	  particularly	  important	  at	  mucosal	  surfaces	  for	  HIV	  capture	  and	  infection	  (Wu	  and	  KewalRemani,	  2006;	  Lambotin	  et	  al,	  2010).	  No	  work	  has	  been	  done	  with	  dendritic	  cells,	  or	  indeed	  other	  cells	  that	  support	  HIV	  infection	  and	  that	  could	  be	  used	  as	  a	  model	  for	  HCV	  trans-­‐infection.	  	  	   Exciting	  future	  work	  in	  this	  area	  would	  also	  include	  modelling	  T	  cell	  trans-­‐infection	  at	  sites	  distant	  to	  the	  liver,	  such	  as	  the	  human	  placenta,	  or	  blood/brain	  barrier.	  Placental	  models,	  such	  as	  BeWo	  cells	  or	  primary	  trophoblast	  cultures	  could	  be	  utilised	  for	  studies	  of	  HCV	  transmission.	  Initial	  steps	  would	  be	  to	  look	  at	  cell-­‐free	  and	  cell-­‐associated	  viral	  delivery	  to	  placental	  cells.	  	  We	  would	  then	  go	  on	  to	  look	  at	  whether	  T	  cells	  were	  able	  to	  cross	  the	  placental	  barrier	  and	  trans-­‐infect	  to	  permissive	  cells.	  	  	  In	  summary,	  we	  have	  described	  models	  that	  allow	  the	  study	  of	  viral	  host	  interactions	  and	  co-­‐infection.	  Future	  work	  based	  on	  these	  findings	  will	  allow	  progress	  in	  understanding	  HCV	  pathogenesis,	  dissemination	  and	  transmission,	  particularly	  in	  HIV	  co-­‐infected.	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